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Abstract  
i 
 
All viruses encode for at least one viral interferon (IFN) antagonist, which is 
used to subvert the cellular IFN response, a powerful antiviral innate immune response. 
Numerous in vitro and in vivo studies have demonstrated that IFN antagonism is crucial 
for virus survival, suggesting that viral IFN antagonists could represent promising 
therapeutic targets. This study focuses on Respiratory Syncytial Virus (RSV), an 
important human pathogen for which there is no vaccine or virus-specific antiviral drug. 
RSV encodes two IFN antagonists NS1 and NS2, which play a critical role in RSV 
replication and pathogenicity. We developed a high-throughput screening (HTS) assay 
to target NS2 via our A549.pr(ISRE)GFP-RSV/NS2 cell-line, which contains a GFP 
gene under the control of an IFN-stimulated response element (ISRE) to monitor IFN-
signalling pathway. NS2 inhibits the IFN-signalling pathway and hence GFP expression 
in the A549.pr(ISRE)GFP-RSV/NS2 cell-line by mediating STAT2 degradation. Using 
a HTS approach, we screened 16,000 compounds to identify small molecules that 
inhibit NS2 function and therefore relinquish the NS2 imposed block to IFN-signalling, 
leading to restoration of GFP expression. A total of twenty-eight hits were identified; 
elimination of false positives left eight hits, four of which (AV-14, -16, -18, -19) are the 
most promising. These four hit compounds have EC50 values in the single μM range and 
three of them (AV-14, -16, -18) represent a chemically related series with an indole 
structure. We demonstrated that the hit compounds specifically inhibit the STAT2 
degradation function of NS2, not the function of NS1 or unrelated viral IFN antagonists. 
At the current time, compounds do not restrict RSV replication in vitro, hence hit 
optimization is required to improve their potency. Nonetheless, these compounds could 
be used as chemical tools to determine the unknown mechanism by which NS2 
mediates STAT2 degradation and tackle fundamental questions about RSV biology.  
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Chapter 1: Introduction   
 
1.1 Introduction to the interferon system  
The early innate immune response to viral infections is characterized by the 
rapid production of interferons (IFNs), a group of widely expressed cytokines, which 
play key roles in mediating the antiviral response. Although IFNs are best known for 
their role in innate immunity, they also have other functions related to 
immunomodulation, proliferation (anti-growth) and the regulation of the adaptive 
immune response (González-Navajas et al., 2012; Caraglia et al., 2013; Hertzog 2012). 
Despite the fact that the majority of viruses have well-established mechanisms to 
circumvent the IFN system, the IFN response remains critical in slowing the progress of 
virus infections and thus, giving time for the development of an adaptive immune 
response. 
The IFN family consists of three main classes of related cytokines; type I, II and 
III IFNs. Type I IFNs are a diverse group of molecules, which was firstly described 
almost sixty years ago (Isaacs & Lindenmann 1957). These include IFN-α and IFN-β 
that are directly induced in response to viral infection, whereas other members of type I 
IFNs (IFN-ω, -ε, -κ, -δ) have a less defined role in antiviral response (Hertzog & 
Williams 2013). In humans, IFN-β is encoded by a single IFNB gene, whereas fourteen 
distinct genes encode for different subtypes of IFN-α (Ivashkiv & Donlin 2014). The 
type II IFN has a single member, IFN-γ, which despite having pleiotropic functions 
related to innate and adaptive responses, it is not secreted directly after viral infection, 
and therefore it has limited direct antiviral effects (Schroder et al., 2004). Type III IFNs, 
which is also known as the IFN-λ family, was discovered more recently, and consists of 
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four molecules (IFN-λ1, IFN-λ2, IFN-λ3 and IFN-λ4) (Kotenko et al., 2003; Egli et al., 
2014). Similar to type I IFNs, these molecules are secreted directly in response to viral 
infection and their induction appears to be regulated by common mechanisms as the 
IFN-α genes (Onoguchi et al, 2007; Lazear et al., 2015). Although type I and III IFNs 
share common regulatory pathways, several aspects of IFN-λ biology are different. For 
instance, the IFN-λ signalling controls frequent or persistent low-level infections at 
epithelial barriers, without creating severe inflammation, whereas IFN-α/β mediates a 
more inflammatory and systemic response, as it signals in almost all nucleated cells 
(Lazear et al., 2015; Wack et al., 2015). The type I IFNs, primarily the IFN-α/β 
response is the most powerful host defense against virus infections. Therefore, this 
study focuses on the IFN-α/β response, and particularly IFN-β, because the mechanism 
behind the virus-induced expression of IFN-β is better understood. The type I IFN 
response is divided into two pathways: the IFN-induction pathway and the IFN-
signalling pathway, which are described in detail below.  
 
1.1.1 Type I IFN-induction pathway  
The type I IFNs are produced mainly by innate immune cells, such as 
macrophages and dendritic cells (DCs), however, non-immune cells, such as fibroblasts 
and epithelial cells, are also capable of producing IFNs, more predominantly IFN-β 
(Ivashkiv & Donlin 2014). The activation of the type I IFN-induction pathway requires 
the recognition of pathogen-associated molecular patterns (PAMPs), which are 
molecules generated by viruses during their replication cycle. These viral components 
are usually parts of the viral genome, such as single-stranded RNA (ssRNA), double-
stranded RNA (dsRNA), genomic DNA, or viral proteins (reviewed in Iwasaki 2012). 
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The PAMPs can be recognized as ‘non-self’ signatures by pattern-recognition receptors 
(PRRs) that trigger the activation of the downstream IFN-induction pathways. Two 
main classes of PRRs have been described; (i) cytoplasmic sensors, including the 
retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), the nucleotide 
oligomerization domain (NOD)-like receptors (NLRs), and an increasing range of 
newly described cytosolic nucleic acid sensors (e.g. cGAS), and (ii) membrane bound 
receptors, such as Toll-like receptors (TLRs) (Broz & Monack 2013). This study 
focuses on Respiratory Syncytial Virus (RSV), which is a negative sense single 
stranded RNA (-ssRNA) virus. Cytoplasmic and endosomal recognition of RNA viruses 
is predominantly mediated by RLR and TLR receptors, thus the rest of this section will 
focus on the RLR- and TLR-dependent activation of the IFN-β induction pathway, 
which is summarized in Figure 1.1.  
 
1.1.1/1 RLR-dependent activation of type I IFNs 
Two well-characterized RLRs are the retinoic acid inducible gene I (RIG-I) and 
the melanoma differentiation-associated gene-5 (mda-5). These are two widely 
expressed RNA helicases that can sense virus-derived nucleic acids generated in 
cytoplasm (reviewed in Goubau et al., 2013). Specifically, RIG-I is capable of 
recognizing blunt short double-stranded 5’-triphosphorylated RNA, whereas mda-5 is 
found to recognize long dsRNA (Kato et al., 2008). Following binding to their 
appropriate ligands, both RIG-I and mda-5 undergo conformational changes that expose 
their caspase recruitment domains (CARDs), which can subsequently interact with the 
mitochondrial antiviral-signalling protein (MAVS) adaptor, also known as 
Cardif/VISA/IPS-1 (Figure 1.1) (Kawai et al., 2005). 
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Figure 1.1 IFN-induction pathway The RLR- and TLR3-dependent activation of the type I 
IFN (IFN-β) induction pathway is illustrated. Cytoplasmic dsRNA and 5’-triphospoRNA are 
recognized by mda-5 and RIG-I, respectively. The TLR3-dependent signalling is activated in 
response to extracellular dsRNA and dsRNA present in phagosomes or endosomes. Both 
pathways lead to the phosphorylation and nuclear translocation of IRF3 and NF-κB 
transcription factors, where they bind the IFN-β promoter and initiate transcription of IFN-β. 
Modified from Randall and Goodbourn (2008). 
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The engagement with the adaptor activates a number of downstream kinases, 
which are essential for activating IFN regulatory factor-3 (IRF3) and the nuclear factor 
kappa B (NF-κB), respectively (Figure 1.1). The RLR-mediated activation of IRF3 
requires recruitment of an E3 ubiquitin ligase, the TNF-receptor associated factor 3 
(TRAF3), which associates with the adaptor protein MAVS (Paz et al., 2011). 
Downstream of TRAF3, TBK1 (TRAF family member-associated NF-κB activator 
(TANK)-binding kinase 1) and the inducible IκB kinase (IKKε), are activated in an 
uncharacterized manner, and directly phosphorylate IRF3 (Goubau et al.,  2013). 
Following its phosphorylation, IRF3 dimerizes, and translocates into the nucleus, where 
it combines with its co-activator CBP/P300 to induce transcription of the IFN-β 
promoter (Figure 1.1) (Perry et al., 2005). The activation of the IFN-β promoter can be 
also amplified by a positive feedback loop, in which the early produced IFN-α/β trigger 
the transcription of IRF7; IRF7 is successively activated by TBK1 and IKKε in a 
similar manner to IRF3 (Trinchieri 2010). 
Activation of NF-κB obligates its dissociation from its inhibitor IκB molecules.  
This involves activation of IκB molecules by two kinases, IKKα and IKKβ, which 
subsequently allows the polyubiquitination of the IκB molecules and their destruction 
by the proteasome (Zandi et al., 1997). The IKKα and IKKβ molecules bind to a 
regulatory subunit, the NF-κB essential modulator (NEMO) to form the IKK-complex, 
which is a core element of the NF-κB cascade (Randall & Goodbourn 2008).  The IKK-
complex interacts with upstream signalling molecules, including RING type E3 ligases 
(e.g. TRAF6) and kinases (e.g. RIP1), which act as an activation platform (Figure 1.1) 
(Hoesel & Schmid 2013). Although, the exact mechanism by which IKKα and IKKβ 
become activated remains obscure, it is clear that their activation requires 
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phosphorylation on two serine residues; Ser177 and Ser181 for IKKβ, and Ser176 and 
Ser180 for IKKα (Israël 2010). It was shown that phosphorylation of IKKβ is mediated 
by the TGF-β activating kinase 1 (TAK1), which in turn phosphorylates IκΒα (Wang et 
al. 2001). Notably, phosphorylation of IKKα is not necessary for activating the 
canonical pathway, though it is required for activation of the alternative NF-κB pathway 
(Israël 2010). Activation of the IκΒ molecules and their subsequent proteasomal 
degradation leads to the liberation of NF-κB, which makes the nuclear localization 
signal (NLS) of the p65 subunit of NF-κB accessible (Hoesel & Schmid 2013). 
Subsequently, NF-κB translocates to the nucleus where it serves as an enhanceosome 
component for the activation of the IFN-β promoter (Figure 1.1). 
The IFNB gene promoter contains four positive regulatory domains (PRDs I to 
IV), which serve as binding sites for the transcription factors described above (Figure 
1.1). In particular, IRF3/IRF7 associates with PRD I/III, ATF-2/c-Jun heterodimers 
interact with PRD IV, and NF-κB binds to PRD II (Basagoudanavar et al., 2011). 
Optimal induction of the IFNB gene requires binding of the transcription factors IRF3 
and NF-κB together with the ATF-2/c-Jun dimers to the IFN-β promoter (Randall & 
Goodbourn 2008) (Figure 1.1).  
 
1.1.1/2 TLR-dependent activation of type I IFNs 
The TLR family also plays an instructive role in innate immune responses 
against viral infections, as members of the TLR family (e.g. TLR2. TLR3, TLR6, TLR7 
and TLR9) trigger intracellular signalling pathways that lead to production of IFN-β 
(Iwasaki 2012). More precisely, TLR3 receptors can recognize extracellular dsRNA, 
dsRNA delivered through the endosomes and dsRNA presented in phagosomes (Figure 
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1.1) (Alexopoulou et al., 2001; Schulz et al. 2005). Although most of TLRs signal 
through an adaptor called myeloid differentiation factor 88 (MyD88), activation of the 
TLR3-dependent pathway requires TRIF (Toll-interleukin (IL)-1-resistannce (TIR) 
domain-containing adaptor inducing IFN-β) (Goubau et al., 2013; Takeda & Akira 
2004). Engagement of TLR3 by dsRNA leads to TLR3 dimerization and its tyrosine 
phosphorylation that causes TRIF recruitment. TRIF recruitment leads to activation of 
both IRF3 and NF-κB ‘arms’ of the type I IFN induction pathway, in almost the same 
way that MAVS adaptor does during the RIG-I/mda-5 activation pathway (Figure 1.1) 
(Goubau et al., 2013). 
In addition to the TLR3-dependent pathway, TLR7 and TLR9 receptors can also 
trigger activation of the IFN-β induction pathway (Iwasaki 2012). The TLR7- and 
TLR9-dependent pathways are activated by ssRNA and DNA, respectively, which is 
delivered through the endosomes (Heil et al., 2004; Tabeta et al., 2004). In brief, TRL7 
and TLR9 recruit the MyD88 adaptor, which causes the phosphorylation and the 
translocation of both IRF7 and NF-κB to the nucleus, where they can bind and activate 
the IFN-β promoter (Randall & Goodbourn 2008; Takeuchi & Akira 2009).  Unlike the 
TLRs discussed above, the TLR4 receptor responds entirely to an extracellular signal 
and it activates the IFN-induction pathway primarily in response to bacteria pathogens 
and lipopolysaccharide (LPS) (Kawai & Akira 2006). The TLR4 receptor signals 
through both the TRIF-dependent pathway (like TLR3) and the MyD88-dependent 
pathway (like TLR7 and TLR9) to activate IRF3 and NF-κB, respectively (Yamamoto 
et al., 2002). Whilst the role of TLR4 activation against virus infection remains unclear, 
there is evidence that RSV and VSV envelope proteins (F and G, respectively) can 
induce type I IFNs through a TLR4-dependent pathway (Marr & Turvey 2012; Georgel 
 Chapter 1:  
Introduction  
8 
 
et al., 2007). Moreover, TLR2 is expressed on the surface of immune cells in 
association with TLR1 or TLR6 and signals though both MyD88 and Tirap (toll-
interleukin 1 receptor domain containing adaptor protein) (Takeda & Akira 2004). 
TLR2 and TLR6 complexes are known for their ability to activate early innate 
immunity in response to bacterial motifs, as well as viruses, including Hepatitis C virus 
and Dengue virus (Chang et al., 2007; Chen et al., 2015).  
Recognition of ‘foreign’ cytoplasmic DNA in some mammalian cells, especially 
macrophages and DCs can also trigger the activation of the IFN-induction pathway 
(Ishii et al., 2006). More recently, numerous cytoplasmic viral DNA sensors have been 
identified, including cGAMP synthase (cGAS) (Sun et al., 2013), DDX41 helicase 
(Zhang et al., 2011) and IFIT16 (Unterholzner et al., 2010). These sensors induce type I 
IFNs through a central signalling cascade involving a molecule called stimulator of IFN 
genes (STING), which serves as a scaffold for the phosphorylation of IRF3 by the 
kinase TBK1 (Tanaka & Chen 2012). In addition to virus stimuli, type I IFNs can be 
induced by host factors and cytokines such as tumor necrosis factor (TNF), which signal 
via IRF1 rather than via IRF3 and IRF7 (Yarilina et al., 2008). In conclusion, type I 
IFNs are rapidly induced in response to virus stimuli through a number of different 
pathways, which are predominantly activated by RLR and TLR sensor molecules either 
in the cytoplasm or endosomes. Regardless the mechanism behind the activation of the 
IFN-β promoter, following its induction, IFN-β is secreted from infected cells, and 
binds to its receptor on the surface of infected or uninfected cells, in order to mediate 
activation of the IFN-signalling pathway, which is reviewed in the following 
subsection.  
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1.1.2 Type I IFN-signalling pathway 
1.1.2/1 Signalling responses to IFN-α/β  
The biological activities of IFN-α/β are initiated after the activation of the JAK 
(Janus activated kinase) /STAT (signal transducers and activators of transcription) 
signalling pathway, which is also known as the type I IFN-signalling pathway (Figure 
1.2). All the type I IFNs signal through a common heterodimeric receptor, which is 
composed by two distinct subunits, namely IFNAR1 and IFNAR2 (Kim et al., 1997). 
Each of these receptor subunits interacts with a member of the Janus activated kinase 
(JAK) family; the IFNAR1 subunit is constitutively associated with tyrosine kinase 2 
(Tyk2), whereas IFNAR2 is associated with JAK1 (Ivashkiv & Donlin 2014). In 
addition to JAK1, STAT1 and STAT2 also bind to the cytoplasmic domain of the 
IFNAR2 subunit in untreated cells, however, STAT1 can only bind when STAT2 is 
present (Li et al., 1997). Furthermore, it is also demonstrated that STAT1 and STAT2 
weakly associate with each other in the cytoplasm prior to cytokine stimulation 
(Stancato et al., 1996).  
The ligand-induced dimerization of the receptor causes a conformational 
change, such that JAK1 phosphorylates and activates Tyk2, which then cross-
phosphorylates JAK1 to activate it further (Gauzzi et al., 1996). Tyk2 phosphorylates 
tyrosine 466 on IFNAR1 and tyrosine 690 on STAT2, whereas STAT1 is 
phosphorylated by JAK1 on tyrosine 701 (Stark et al., 1998). In particular, when Y466 
of IFNAR1 is phosphorylated, it creates a docking site, where the Src homology 2 
(SH2) domain of STAT2 can bind to, allowing the tyrosine phosphorylation of STATs 
(Yan et al., 1996). Transcriptional activation by STAT1, whether activated by type I or 
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II IFN, also requires phosphorylation on serine 727, which is catalyzed by several 
cellular kinases (Uddin et al., 2002).  
 
 
 
 
Figure 1.2 The IFN-signalling pathway. The JAK/STAT pathway is activated after the 
binding of IFN-α/β to IFNAR receptor. Phosphorylated STAT1 and STAT2 localize into the 
nucleus, where they bind IRF9 to form the ISGF3 complex. The ISGF3 transcription factor 
binds to the ISRE sequences, which are present in the promoters of ISGs (e.g. MxA) to initiate 
their transcription, and establish an antiviral state in the virus-infected cell. Modified from 
Platanias (2005). 
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The phosphorylation of both STATs is followed by their dissociation from the 
receptor, which allows the phosphorylated STAT1–STAT2 heterodimer to translocate 
into the nucleus (Stark et al., 1998; Yan et al., 1996). In the nucleus, the STAT1–
STAT2 heterodimers interact with the DNA binding protein IRF9 to form the STAT1–
STAT2–IRF9 complex, which is known as the interferon-stimulated factor gene 3 
(ISGF3) (Figure 1.2) (Ivashkiv & Donlin 2014). ISGF3 is the major transcription factor 
formed in response to type I IFNs, as it stimulates the activation of the IFN-stimulated 
response element (ISRE), which initiates transcription of hundreds of genes, the IFN-
stimulated genes (ISGs), many of which have antiviral activity (Schoggins & Rice 
2011) . 
The antiviral mechanisms of some ISGs have been studied extensively and 
reviewed comprehensively, including the ds-RNA dependent protein kinase (PKR) 
(Nakayama et al. 2010), the 2’5’-oligoadenylate synthetase (OAS) (Silverman 2007), 
the Mx family of genes (Haller & Kochs 2011), IFN-induced proteins with 
tetratricopeptide repeats (IFITs) and IFN-induced transmembrane proteins (IFITMs). 
(Lenschow 2010; Diamond & Farzan 2013), the promyelocytic leukemia (PML) nuclear 
bodies (Everett & Chelbi-Alix 2007), the tripartite motif (TRIMs) family (Yap & Stoye 
2012), and viperin (Helbig & Beard 2014). One remarkable property of ISG-mediated 
antiviral activity is the magnitude with which a single IFN effector can restrict virus 
replication. For instance, IFIT1/ISG56 is primarily responsible for the IFN-induced 
inhibition of parainfluenza type 5 virus (PIV5) by selectively inhibiting the translation 
of PIV5 mRNAs (Andrejeva et al., 2013). Nonetheless, it is known that ISGs have a 
plethora of other functions. Some of them, including PKR, are involved in the 
establishment of a pro-apoptotic state in target cells (Maher et al., 2007; Nakayama et 
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al., 2010), whereas others, such as the cyclin-dependent kinase (CDK) inhibitor p21 
(also known as pWAF, CIP) are profoundly cytostatic, triggering a growth arrest at the 
G1/S transition point in many cell types (Ferrantini et al., 2007). Moreover, other ISGs 
have a major role in promoting the transition from innate to adaptive immune responses, 
and one key example is the class I major histocompatibility complex (MHC) (Le Bon & 
Tough 2002).  
 
1.1.2/2 Crosstalk between IFN-signalling pathways  
Whilst the activation of the STAT1–STAT2–IRF9 heterodimer is the canonical 
mode of ISRE activation, IFNAR activation induces the formation of other STAT 
complexes; it activates STAT1 and STAT3 homodimers and heterodimers in most cell 
types and STAT4, STAT5 and STAT6 in certain cell types (Torpey et al., 2004; Gomez 
& Reich 2003; Gupta et al., 1999; van Boxel-Dezaire et al., 2006). These complexes 
can either bind to the ISRE or to another type of element, known as an IFN-γ-activated 
site (GAS) element, which can be also present in the promoter of ISGs (Brierley et al., 
2006). Signalling in response to type III IFNs (IFN-λ family) follows a very similar 
pattern to that in response to type I IFNs, as it also leads to the formation of the 
STAT1–STAT2–IRF9 heterodimer, despite signalling through a different receptor 
(IFNLR) (Lazear et al., 2015). In contrast, type II IFN (IFN-γ) signals through the 
IFNGR receptor, and leads to the formation of STAT1-STAT1 homodimers, which bind 
to GAS elements in the nucleus and activate transcription of ISGs (Randall & 
Goodbourn 2008). Although not a part of the canonical type I signalling responses, 
STAT1 homodimers could be also activated through the IFN-α/β signalling, indicating 
that crosstalk exists between the two pathways (Decker et al., 1991). Interestingly, 
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IKKε is important for regulating the balance between type I and type II IFN response, 
as the IKKε-mediated phosphorylation of STAT1 suppresses STAT1 homodimer 
formation, and thereby facilitates ISGF3 formation, augmenting type I antiviral 
responses (Ng et al., 2011). In addition, many ISGs show either sustained induction in 
response to IFNs or biphasic induction kinetics, which are usually related to IRF1. In 
particular, IRF1 binds to most, if not all ISREs, and it is induced by both IFN-α/β and 
IFN-γ, but it is more responsive to IFN-γ (Randall & Goodbourn 2008). Although, IRF1 
plays a central role in the regulation of ISGs expression, it still remains unclear how 
IRF1 regulates gene expression between type I and II IFNs. Interestingly, each of these 
IFNs induces a unique and partially overlapping set of ISGs, whereas some other ISGs, 
such as PKR and OAS, can be activated directly by viral dsRNA in the absence of IFN 
(Lemaire et al., 2008; Ibsen et al., 2015). Taken together, the induction of ISGs is 
mediated through various mechanisms that could be intersecting and often self-
reinforcing. 
In conclusion, type I IFN-signalling pathway is an extremely powerful antiviral 
defense mechanism, which mediates an autocrine loop and induces the expression of 
ISGs in response to virus replication. ISGs establish an antiviral state within infected 
cells or neighboring uninfected cells, which provides protection from virus infections in 
the absence of adaptive immunity. 
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1.2 Viral IFN antagonism  
The survival of almost all mammalian viruses, regardless of genome type and 
complexity, is based on their ability to outrun innate immunity before the development 
of adaptive immune responses (Versteeg & Garcia-Sastre 2010). Viruses have evolved 
an astounding variety of IFN antagonistic strategies targeting virtually all parts of the 
IFN system, often in a highly specific manner (Weber & Haller 2007). Over 170 
different viral IFN antagonists from 93 distinct viruses have been described to date, and 
nearly 50% of them antagonize multiple steps of the cellular IFN system (Versteeg & 
Garcia-Sastre 2010). Although every viral IFN antagonist is unique in its own right, 
they counteract the cellular IFN response by using common strategies, including: (i) 
global inhibition of cellular gene expression, (ii) sequestration, cleavage or degradation 
of IFN effector molecules, and (iii) acquisition of replication strategies that are 
insensitive to IFNs (Randall & Goodbourn 2008; Versteeg & Garcia-Sastre 2010).   
 
1.2.1 The pleiotropic nature of viral IFN antagonists 
The multifunctionality of viral IFN antagonists is reliant to the nature of virus 
genome. For instance, the relatively limited genome capacity of RNA viruses favors 
high degree of multifunctionality and restricts the variability of accessory proteins. 
Hence, RNA viruses do not have genes that exclusively encode for IFN antagonists, as 
in the case of large DNA viruses, but instead IFN antagonists are highly multifunctional 
and sometimes conserved within related RNA viruses (Versteeg & Garcia-Sastre 2010). 
A key example of a multifunctional IFN antagonist is the NS1 protein of Influenza A 
and B viruses (Family Orthomyxoviridae), which despite its small size (26 kDa) 
antagonizes the host immune responses in a species-specific manner using a plethora of 
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different strategies (Kochs et al., 2007; Hale et al., 2008). Although multifunctionality 
is a common characteristic for RNA viruses, small DNA viruses also encode for 
multifunctional proteins. For instance, the E6 and E7 proteins of Human Papilloma 
Virus (HPV) are well known for their oncogenic properties, but they also have a 
numerous functions against the cellular IFN response (Cordano et al., 2008). In 
contrast, some other DNA viruses have larger genomes and sometimes encode for 
proteins with functions limited to IFN antagonism. For example, poxviruses encode for 
proteins called ‘viroceptors’, which can be either secreted or localized to the surfaces of 
infected cells and compete with the cellular IFN receptor for its ligand (Seet et al., 
2003).  
The nature of the virus genome and the genomic replication tactics differ 
between families, hence the IFN inhibitory strategies vary with some of them having a 
higher prevalence in certain virus classes (Katze et al., 2002). More precisely, negative-
sense single-stranded RNA (-ssRNA) viruses are more susceptible to detection by the 
IFN sensory molecules, compared to +ssRNA or DNA viruses. Therefore, interfering 
with the RLR-mediated pathways is a common feature between -ssRNA viruses, and it 
has been extensively reported in a number of different -ssRNA families, such as 
Paramyxoviridae and Orthomyxoviridae (Andrejeva et al., 2004; Gack et al., 2009). 
Defending the host cell innate immunity is crucial for successful viral infections, 
therefore viruses have evolved a plethora of mechanisms to circumvent the cellular IFN 
response and establish infections, which are often highly pathogenic and virulent.
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1.2.2 The plethora of IFN evasion tactics evolved by Paramyxoviruses  
The current study focuses on RSV, which is the prototype species of Genus 
Pneumovirus; Subfamily Pneumovirinae; Family Paramyxoviridae; Order 
Mononegavirales (Collins et al., 2013). The Paramyxoviridae family has two 
subfamilies: (i) Paramyxovirinae subfamily, which includes important human and 
animal pathogens such as mumps, measles virus, the human parainflluenza viruses 
(HPIVs), and (ii) Pneumovirinae subfamily, which consists of two genera, the 
Pneumoviruses and the Metapneumoviruses. The Genus Pneumonovirus consists of 
RSV and its animal relatives, such as the bovine RSV (BRSV), ovine RSV (ORSV) and 
pneumonia virus of mice (PVM), and the Genus Metapneumovirus consists of human 
and avian metapneumonovirus (Collins et al., 2013). RSV is considered to be one of the 
most complex members of Paramyxoviridae family, because it encodes additional 
proteins, namely NS1, NS2, SH, M2-1, M2-2, that are not present in any other virus of 
the family (Chambers & Takimoto 2009).  
 
1.2.2/1 Viral IFN antagonists of Paramyxovirinae 
Viral IFN antagonism has been extensively studied within the Paramyxoviridae 
family, which is the largest virus family with pleiotropic and also conserved IFN 
antagonists. The paramyxoviruses that belong to the Paramyxovirinae subfamily encode 
accessory proteins (V/C/W), which abrogate various facets of the cellular type I IFN 
response (Audsley & Moseley 2013). The V, C and W proteins are encoded by the same 
gene that encodes for the P protein; V/W proteins are produced through RNA editing, 
and an overlapping open reading frame (ORF) encodes for the C protein (Chambers & 
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Takimoto 2009). Therefore, P/V/W proteins share N-terminal sequences, but they have 
different C-termini, which usually have unique functions.  
Although paramyxoviruses exhibit a commonality in their viral IFN antagonists, 
the manner with which they inhibit the cellular IFN response varies within the 
subfamily and it is highly dependent on the accessory proteins expressed by each virus 
(Parks & Alexander-Miller 2013). Specifically, the majority of paramyxoviruses utilize 
the same strategy to subvert the IFN-induction pathway, which involves the highly 
conserved cysteine-rich C-terminal domain (CTD) of their V proteins. This domain 
binds to mda-5, and prevents downstream activation of the IFN-β promoter (Andrejeva 
et al., 2004). Furthermore, most paramyxoviruses are resistant to the antiviral responses 
induced by IFNs, as their V proteins also have the ability to inhibit STATs (Goodbourn 
& Randall 2009). Although almost all V proteins act against the JAK/STAT pathway, 
they inhibit STATs using different molecular mechanisms, ranging from cytoplasmic 
sequestration to proteasomal degradation (Figure 1.3) (Audsley & Moseley 2013). For 
instance, PIV5 V protein targets STAT1 for proteasome-mediated degradation (Didcock 
et al., 1999), whereas Nipah virus V protein sequesters STAT1 and STAT2 in the 
cytoplasm and prevents their nuclear localization, which impedes them from binding to 
the ISRE sequences (Rodriguez et al., 2002).   
In addition to the inhibition strategies imposed by V proteins, the C and W 
proteins also have imperative functions against the cellular IFN response. For example, 
the V protein of Sendai virus (SeV) has no effect on the IFN-signalling pathway (Gotoh 
et al., 1999) but instead SeV encodes for a set of four C proteins, the larger of which is 
mainly responsible for STAT1 inhibition though degradation (Garcin et al., 2002). The 
PIV3 C protein also targets STAT1 but not through degradation, as it was shown to 
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inhibit its phosphorylation (Malur et al., 2005). Furthermore, other paramyxoviruses 
encode for W proteins, which are also potent antagonist of the IFN-signalling pathway. 
For instance, Nipah virus W protein sequesters STAT1 in the nucleus, and thereby 
blocks transcription of the IFN-induced effector molecules (Shaw et al., 2005).  
 
 
Figure 1.3 Paramyxovirus inhibition of the IFN-signalling pathway. A remarkable variety 
of different type I IFN evasion strategies have been reported within family Paramyxoviridae. 
Paramyxoviruses encode viral IFN antagonists (V, C, W, NS1 and NS2), which circumvent all 
different steps of the IFN-signalling pathway, including phosphorylation, nuclear translocation 
of STATs and ISGF3-mediated activation of the ISRE sequences of ISGs. hMPV interacts with 
JAK kinases and inhibits phosphorylation of STAT1, however it remains unknown, which viral 
protein(s) is responsible for these functions.   
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1.2.2/1 Viral IFN antagonists of Pneumovirinae 
Adding to the variation observed within the Paramyxoviridae family, the 
paramyxoviruses that belong to the Pneumovirinae subfamily do not express any of the 
V, C or W accessory proteins, and instead some encode for two non-structural proteins 
(NS), NS1 and NS2, which impose similar functions to V, C or W proteins (Figure 1.3). 
RSV NS1 and NS2 proteins work either independently or co-operatively to inhibit the 
early innate immunity by circumventing multiple steps of the IFN induction and 
signalling pathways (Barik 2013), as will be discussed in detail in Section 1.4. Although 
RSV does not express any of the accessory proteins found in other paramyxoviruses, it 
antagonizes the IFN-signalling pathway using similar strategies. RSV NS1 and NS2 
mediate proteasomal degradation of STAT2 (Spann et al., 2004; Lo et al., 2005; 
Goswami et al., 2013), a function also observed by the V protein of PIV2 
(Paramyxovirinae subfamily) (Parisien et al., 2001). In contrast, BRSV NS1 and NS2 
have not been reported to antagonize STAT2, though NS1 and NS2 proteins of both 
human and bovine RSV use a common strategy to suppress the IFN-induction pathway, 
which involves inhibition of IRF3 (Schlender et al., 2000; Spann et al., 2004). 
Furthermore, human metapneumovirus (hMPV) (Genus Metapneumovirus) lacks NS1 
and NS2, nonetheless hMPV modulates cellular innate immune response by down 
regulating Jak1 and Tyk2, and subsequently inhibiting STAT1 phosphorylation using a 
yet unknown mechanism (Dinwiddie & Harrod 2008; Junping Ren et al., 2011).  
In conclusion, paramyxoviruses outrun the cellular IFN response using an 
astonishing array of strategies that are attributed to their multifunctional and in some 
cases conserved IFN antagonists. Escaping early innate immunity is crucial for virus 
infection, therefore targeting IFN antagonism/antagonists appears to be a promising 
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strategy for developing new therapeutic approaches. This study focuses on RSV, and 
particularly on its two IFN antagonists, NS1 and NS2. Hence, the following section 
introduces RSV, and discuses the intricate strategies of its two IFN antagonists NS1 and 
NS2 against the cellular IFN response. 
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1.3 Introduction to Respiratory Syncytial Virus (RSV) 
1.3.1 RSV epidemiology and pathogenicity 
RSV was first isolated from nasal secretions of young chimpanzees in 1955, and 
was initially named ‘chimpanzee coryza agent’ (Blount et al. 1956). A year after, it was 
also isolated from two human infants, one with bronchiolitis and one with pneumonia 
(Chanock et al. 1956). Since then, RSV is recognized as the leading cause of acute 
lower respiratory tract illness (ALRI) in infants and young children worldwide (Hall et 
al., 2009). RSV is also a significant cause of morbidity and mortality among 
immunocompromised individuals and the elderly (Falsey et al., 2000). The clinical 
severity of RSV infections can vary from mild upper respiratory tract infection to severe 
bronchiolitis; approximately 40% of all primary RSV infections in infancy result in 
ALRI (Simoes et al., 2003; Paes et al., 2011). Interestingly, RSV re-infections occur 
throughout life and they do not depend on antigenic differences. First or second 
infections mostly lead to ALRI but there is a substantial reduction in disease severity in 
following infections that presumably reflects increasing protective immunity (Collins & 
Melero 2011). It still remains controversial whether there is a relationship between the 
clinical severity and RSV subtype (A and B) (Wright & Piedimonte 2011), which  can 
circulate independently from each other or also co-circulate during one epidemic 
(Kneyber et al., 1998; Anderson et al., 1985).  
It has been estimated that, in 2005, RSV caused 34 million cases of ALRI in 
children younger than five years old globally, 3.4 million of which required 
hospitalization (Nair et al., 2010). Moreover, 66,000 to 199,000 children younger than 5 
years old died from RSV-associated ALRI in 2005, with 99% of these deaths occurring 
in developing countries (Nair et al., 2010). RSV morbidity and mortality rates are 
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considerably higher in premature-born infants (<35 weeks gestational age) and in 
infants with chronic lung disease (such as bronchopulmonary dysplasia and cystic 
fibrosis) or hemodynamically significant congenital heart disease (CHD) (Venkatesh & 
Weisman 2006; Wright & Piedimonte 2011). Similar to other respiratory viruses, RSV 
can also trigger exacerbations of asthma and chronic obstructive pulmonary disease 
(COPD), which are two common inflammatory diseases of the airways, however the 
link between RSV and these diseases is not well understood yet (Kurai et al., 2013; 
Mehta et al., 2013).  
In vivo, RSV is largely restricted to the superficial cells of the respiratory 
epithelium and shedding occurs at the apical membrane of airway epithelial cells 
(AECs), suggesting that polarized epithelium is the preferred cellular target (Zhang et 
al., 2002). RSV infection causes airway obstruction due to peribroncheal mononuclear 
cell infiltration, mucus secretion, and sometimes syncytia formation in the lungs (Van 
Drunen Littel-Van Den Hurk & Watkiss 2012). In vitro models suggested that RSV is 
not inherently a highly cytopathic virus, as during an infection of several weeks, RSV 
triggered little visible damage to lung tissue but it caused impairment of the ciliary 
beating (Zhang et al., 2002). This suggests that the RSV-induced effects on ciliary 
function presumably facilitate the airway obstruction that is characteristic of RSV 
disease. Severe RSV infections are also associated with the activation of inflammatory 
cytokines and activated granulocytes in the airways of infants and children with ARLI 
(Collins & Melero 2011). Neutrophils are the most abundant immune cell activated 
during severe RSV infection in infants (Abu-Harb et al., 1999), however activation of 
the DC8+ T lymphocytes (Graham et al., 1991) and Th2 biased stimulation of the CD4+ 
T lymphocytes have been also suggested to mediate RSV disease (Adkins et al., 2004; 
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Collins & Melero 2011). Although immune and inflammatory responses can enhance 
RSV disease, viral load is also correlated with RSV disease severity in infants 
(DeVincenzo et al., 2010; Houben et al., 2010). The mechanisms behind RSV 
pathogenicity are not fully understood, however viral (e.g. viral load), environmental 
(e.g. smoking) and host factors (e.g. prematurity), all contribute to the severity of RSV 
disease (Van Drunen Littel-Van Den Hurk & Watkiss 2012).  
 
1.3.2 RSV current treatment  
Despite extensive efforts, development of an anti-RSV vaccine has proven to be 
particularly challenging and complicated, especially after the disastrous vaccination 
trials with a formalin-inactivated RSV vaccine (FI-RSV) in 1969 (Kim et al., 1969). FI-
RSV not only failed to provide immunity to RSV but 80% of the immunized children 
required hospitalization when naturally infected with the wild-type virus, because 
natural exposure resulted in immune-mediated enhancement of disease (Collins & 
Melero 2011; Kim et al., 1969). Since then, prophylactic options are limited to passive 
immunization with a humanized RSV-neutralizing, fusion (F)-specific monoclonal 
antibody, the Palivizumab (Synagis
TM
; MedImmune), which provides 55% reduction in 
RSV-associated hospitalization (Anon 2006). A second generation monoclonal 
antibody, the motavizumab (MedImmune), was shown to bind to RSV F protein 70-fold 
better than palivizumab, and it exhibits about a 20-fold improvement in neutralization of 
RSV in vitro (Wu et al., 2007).  Despite its better efficacy in vitro, there was 
questionable evidence that motavizumab had additional benefit in comparison to 
palivizumab in vivo, and administration of motavizumab significantly increased adverse 
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effects in infants, therefore the US FDA committee never approved its use in the clinic 
(Wright & Piedimonte 2011).   
For therapeutic intervention, the nucleoside analogue ribavirin is the only drug 
licensed for RSV treatment in humans, but its use is limited due to the lack of proven 
efficacy, the difficulty of administration (usually aerosolic), and concerns of toxicity 
(Anon 2006; Collins & Melero 2011). A number of different therapeutic agents such as 
bronchodilators, corticosteroids, β-agonists, epinephrine and montelukast (used for the 
maintenance treatment of asthma) have been suggested for RSV treatment, but clinical 
trials have not demonstrated conclusive clinical benefit, (Wright & Piedimonte 2011; 
Krilov 2011). In conclusion, current treatment of acute RSV infections mainly involves 
supportive care, which highlights the lack of effective therapeutic options, and the need 
for new antiviral drugs for RSV treatment.  
 
1.3.3 Overview of RSV genome and replication cycle 
RSV virions are pleomorphic spherical or filamentous particles, which consist of 
a nucleocapsid packaged in a lipid envelope derived from the host cell plasma 
membrane (Figure 1.4/A) (Collins et al., 2013). RSV entry requires attachment to 
cellular glycosaminoglycans (GAGs), which is followed by fusion with the plasma 
membrane, allowing the release of the viral genome in the cytoplasm (Figure 1.5) 
(Hallak et al., 2000). RSV envelope contains three proteins: the fusion (F), the 
glycoprotein (G) and the small hydrophobic protein (SH) (Figure 1.4/A). The F protein 
directs viral penetration and syncytium formation. Similar to its counterparts in 
Paramyxoviridae, the RSV F protein is synthesized as a precursor F0 and it is activated 
by furin-like host protease to yield two disulfide-linked subunits, F1 and F2 (González-
Reyes et al., 2001). 
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Figure 1.4 Structure and genome organization of RSV (A) RSV virion particle 
(approximately 200nm). RSV envelope consists of F, G, and SH. M is present between the outer 
envelope and the inner RNP. From Bawage et al., (2013) (B) RSV gene map. The map shows 
the negative sense RNA genome of RSV, which has a 3’ end leader (Le) and a 5’end trailer (Tr) 
region. The overlapping M2-1 and M2-2 ORFs are shown over the gene. The numbers below 
the map indicate the size of each RSV protein in amino acids (aa). The viral proteins are as 
follows: NS1, nonstructural protein 1; NS2, nonstructural protein 2; N, nucleoprotein; P, 
phosphoprotein; M, matrix protein; SH, small hydrophobic glycoprotein; G, attachment 
glycoprotein; F, fusion glycoprotein; M2-1, product of the first ORF in the M2 mRNA; M2-2; 
product of the second ORF in the M2 RNA; L, large polymerase protein. 
 
 
 
A 
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F cleavage liberates a hydrophobic stretch of amino acids called the fusion peptide, 
which is inserted into the target cell membrane and leads to the creation of a stable 
helical bundle that forms as the viral and cell membranes are apposed (Collins et al., 
1984; McLellan et al., 2011). The G protein plays a major but not exclusive role in 
attachment and it was found to bind cell-surface GAGs, including heparan sulfate 
(Hallak et al. 2007).  The F and G proteins are the only virus neutralization antigens and 
are the two major protective antigens (Collins & Crowe 2007).  In contrast to F and G, 
the SH protein has no apparent contribution to viral entry. Instead, SH is a short 
transmembrane glycoprotein with similar structural features to viporins, which are a 
small class of proteins that can modify membrane permeability, and can affect budding 
and apoptosis (Gonzalez & Carrasco 2003; Collins et al., 2013).  
RSV has a non-segmented, negative-sense RNA genome of 15.2 kb long, which 
encodes 10 transcription units in the order 3’-NS1-NS2-N-P-M-SH-G-F-M2-L-5’ 
(Figure 1.4/B) (Collins 1991). The RSV genome replicates in cytoplasmic inclusion 
bodies, where the negative-sense viral genomic RNA serves as a template for the 
production of mRNAs by viral RNA-dependent RNA polymerase complexes (Figure 
1.5) (Harrison et al., 2010).  Similar to the rest of Mononegavirales, subgenomic RSV 
mRNAs are produced in a polar gradient, in which transcription decreases along the 
gene order, as the polymerase detaches from the genome template at various gene 
junctions (Figure 1.5) (Collins et al., 2013). Each mRNA encodes for a single 
polypeptide, except M2 mRNA that has an upstream and a downstream ORFs, which 
partially overlap and encode for the M2-1 and M2-2 proteins, respectively (Figure 
1.4/B). Later in the infectious cycle, the viral polymerase ignores transcription signals 
and produces positive-sense replicative intermediate called the antigenome, which 
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serves as a template for the production of progeny negative-sense genomes (Figure 1.5) 
(Collins & Melero 2011). 
The phosphoprotein (P) protein is also important for virus replication as it is an 
essential co-factor of the viral polymerase (Collins & Crowe 2007). It also acts as an 
adaptor that binds to N and M2-1 proteins to mediate interactions in the nucleocapsid 
and polymerase complex (Asenjo et al., 2006; Khattar et al., 2001; García-Barreno et 
al., 1996). M2-1 protein is an essential transcription processivity factor that is important 
for the efficient synthesis of full-length mRNAs (Fearns & Collins 1999), and it is also 
a transcriptional anti-terminator factor that enhances the ability of the viral polymerase 
to read-through intergenic junctions (Hardy & Wertz 1998). The other product of M2 
gene, the M2-2 protein is not essential for viral viability, but it appears to be important 
in modulating the balance between transcription and RNA replication (Bermingham & 
Collins 1999). The matrix (M) protein lines the inner envelope surface and is important 
in virion morphogenesis and virus assembly as it is required for the transport of 
nucleocapsids from viral inclusion bodies to plasma membrane (Mitra et al., 2012). 
Although RSV genome replication takes place entirely in the cytoplasm, M protein was 
also found in the nucleus, where it interacts with the host cell transcription machinery 
(Figure 1.5) (Ghildyal et al., 2003).  
RSV assembly and budding occur at the plasma membrane and the minimum 
protein requirements for infectious virus particles are the F, M, N and P proteins (Teng 
& Collins 1998). RSV buds preferentially from the apical surface of infected polarized 
epithelial cells by hijacking the cellular apical recycling endosome (Figure 1.5) (Brock 
et al., 2003). In addition to structural proteins and proteins involved in genome 
replication, RSV encodes for two NS  proteins,  NS1 and NS2,  which are the two major 
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Figure 1.5 RSV replication cycle (1) RSV enters by direct fusion at the plasma membrane, 
releasing the encapsidated genome RNA and RNA-dependent RNA polymerase (yellow) into 
the cytoplasm, where viral mRNA synthesis occurs mainly at inclusion bodies. (2) Minimal unit 
for RNA transcription and replication requires L, N and P proteins of the RNP complex, and 
likely M2-1, M2-2 and M. (3) The polymerase uses the genome as a template to produce capped 
and polyadenylated mRNAs, which are transcribed in a polar gradient, and then translated into 
viral proteins. Early during infection NS1 and NS2 antagonize the innate immune response to 
allow virus replication in the cytoplasm. (4-5) The polymerase uses the genomic RNA to 
produce a positive sense antigenome RNA, which serves as a template for the production of 
progeny negative-sense genomes 6-7. The M protein migrates to the nucleus, possibly to block 
the transcription of host genes, and later it is suggested that it returns to the cytoplasm, and 
recruits the nucleocapsid at the assembly point. The encapsidated genomes are assembled with 
other viral proteins (F, G, SH, N, P and M) and bud from the plasma membrane to produce 
progeny virus particles from the apical surface. (F; light blue, G; green, SH; black, N; red, L; 
yellow, P; blue, M; brown, M2-1; orange, M2-2; light pink, NS1; pink, NS2; purple) 
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IFN antagonists encoded by RSV. These proteins are the main focus of this study, as we 
are interested in targeting them to identify small molecules that suppress their function 
against the cellular IFN system. RSV NS1 and NS2 proteins and their functions are 
described below.  
 
1.3.3/1 RSV NS1 and NS2 proteins   
RSV NS1 and NS2 are two small proteins (139 and 124 amino acid residues 
long, respectively), which are expressed early after RSV infection (Collins & Crowe  
2007). Although NS proteins have several functions associated with virus replication 
and viral pathogenesis, they are primarily known because of their ability to antagonize 
the cellular IFN response, which allows a more robust virus replication (Barik 2013). 
Since RSV genome transcription has a polar gradient, NS1 and NS2 are the most 
abundant RSV proteins, as they are the most promoter-proximal genes (Figure 1.5 and 
1.6) (Collins et al., 2013).  
NS1 and NS2 proteins are unique to RSV, without sequence homologs in any 
other virus or eukaryotic genomes, except their NS1 and NS2 counterparts of other RSV 
stains, such as BRSV (Bossert et al., 2003; Schlender et al., 2000). The molecular 
structure of RSV NS1 and NS2 has not been solved yet, therefore there is limited 
knowledge regarding NS1 and NS2 functional domains (Figure 1.6). NS1 and NS2 
exhibit no discernible sequence similarity with each other, since the longest common 
peptide sequence between them is the DNLP tetrapeptide at their C-terminus (Figure 
1.6), the function of which is not completely understood yet. It has been previously 
shown that NS1 and NS2 protein co-precipitate, suggesting that they have the ability to 
heterodimerize and form complexes (Swedan et al., 2009). The DNLP tetrapeptide is 
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not essential for heterodimer formation, however it is indispensable for other 
interactions that are related to IFN antagonism (Swedan et al., 2011), which are 
addressed in the following section. Evidence suggests that both NS1 and NS2 form 
homodimers, which might allow them to accomplish more complex and dynamic 
regulation of host signalling cascades (Swedan et al., 2009; Swedan et al., 2011). 
Unfortunately, the lack of structural information, together with the unstable nature of 
these proteins, impedes us from revealing NS1 and NS2 interactions, which would 
allow us to further elucidate their functions in IFN antagonism and understand their 
extended roles in RSV replication. 
 
Figure 1.6 Main functional domains of RSV NS1 and NS2 proteins. The boundaries of each 
domain are drawn based on the published work of Swedan et al., (2011), and they indicate the 
domain required for each interaction. The C-terminal tetrapeptide DNLP is the only common 
sequence between NS1 and NS2. RSV genome is described in Figure 1.3.  
 
.
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Of the eleven RSV proteins, NS1 and NS2 exhibit an intermediate to high 
degree of sequence conservation (65-82% amino-acid identity) between the two human 
RSV antigenic subgroups A and B (RSVA and RSVB) and ovine or bovine RSV, as 
they were found to be more highly conserved than the SH or G proteins but were less 
well conserved than any of the other proteins (Alansari & Potgieter 1994; Pastey & 
Samal 1995). Sequence comparisons between human RSVA and RSVB have shown 
that NS1 and NS2 were highly conserved at the amino-acid level, as they shared 92% 
and 87% sequence similarity, respectively (Johnson & Collins 1989). An evolutionary 
analysis of human RSVA and RSVB genomes collected from 1998 to 2010 showed that 
for all coding sequences (CDSs), there was more variation in RSVA than RSVB 
sequences, however the number of non-synonymous mutations was higher in some of 
the RSVB CDSs (Rebuffo-Scheer et al., 2011). Although NS1 and NS2 CDSs had a 
high number of non-synonymous mutations, the CDSs with the highest non-
synonymous mutations were those for the G, M2-2, and SH. Specifically, the average of 
the non-synonymous versus synonymous mutation ratio (dN/dS) for RSVB NS1 and 
NS2 CDSs was 0.092 and 0.052, whereas G, M2-2, and SH CDSs had higher dS/dN 
ratio, which was equal to 0.376, 0.155, 0.173, respectively (Rebuffo-Scheer et al., 
2011). Moreover, a recent study have investigated the local evolutionary patterns of 
RSVA and RSVB in Kilifi, Kenya, over a 10-year period, and showed that NS1 had a 
lower evolutionary rate (substitution/site/year) than NS2, the CDS of which was the 
second more variable after the G CDS (Agoti et al., 2015). NS2 showed an elevated 
level of evolutionary rate, consistent with a protein interacting with polymorphic host 
target proteins, including host-immune factors (Spann et al., 2005; Swedan et al., 2011) 
and perhaps cytoskeleton (Liesman et al., 2014).  
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1.4 RSV evasion strategies against the type I IFN system   
1.4.1 PRRs activation in response to RSV infection 
Cytopathic effects of RSV in human airways have been observed in histological 
studies of lung tissue from fatal cases of RSV infection, indicating that the primary 
target cells for RSV replication are human bronchial, bronchiolar and alveolar epithelial 
cells (Welliver et al., 2007; Lay et al., 2013). Consequently, the first site of encounter 
between RSV and the host is the respiratory epithelium, which induces early innate 
immune response at the site of infection (Lay et al., 2013).  
The precise innate immune responses to RSV infection are not well understood, 
though evidence suggests that RSV activates different types of PRRs. Specifically, RSV 
infections rapidly induce RIG-I, a RLR receptor, the activation of which is associated 
with induction of type I but also type III IFNs (Bitko et al., 2008). Consistent with this 
finding, other studies have shown that RSV is a potent inducer of IFN-α/β and IFN-λ 
during in vitro infections of AECs and A549 basal epithelial cells (Spann et al., 2004; 
Ramaswamy et al., 2006). Interestingly, RSV infection of nasal epithelial cells (NECs) 
was shown to trigger the induction of only IFN-λ, suggesting that IFN-λ, but not IFN-
α/β, is perhaps the first line of defense against RSV infection in the upper respiratory 
tract (Okabayashi et al., 2011). However, the crosstalk between the two pathways 
makes it difficult to uncover the series of innate immune events that are activated in 
response to RSV in the respiratory epithelium.  
Among all TLRs, TLR3 receptors are the most abundant in AECs, however 
TLR3s can only recognize dsRNA in endocytic compartments and currently, there is no 
evidence to support that RSV generates TLR3-activating dsRNA species during its 
replication. In contrast, RSV infection in mice was found to trigger activation of TLR2 
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and TLR6 receptors in leukocytes, which activate innate immunity against RSV by 
promoting TNF, interleukin-6 (IL-6), CCL2 (Chemokine (C-C motif) ligand 5), and 
CCL5 (also known as RANTES) (Murawski et al., 2009). An interesting study showed 
that purified RSV F protein binds to TLR4 and/or its co-receptor CD14 (Marr & Turvey 
2012). However, the significance of this observation remains unresolved, since RSV 
infection does not block the LPS-induced activation of TLR4, indicating that TLR4 
receptor complex does not seem to play a biological role in RSV pathogenesis (Marr & 
Turvey 2012). Taken together, these studies provide evidence that TLR-dependent 
signalling is important for activating early innate responses to RSV, however the role of 
TRLs in controlling RSV infections needs to be further explored.  
A member of the NLR family, the nucleotide-binding oligomerization domain 
containing 2 (NOD2) was also shown to be rapidly induced after RSV infection but the 
relative importance of the pathway in regards to RSV detection in comparison to the 
RLR and TLR pathway still remains to be explicated (Vissers et al., 2012; Barik 2013). 
Hence, the rest of this section will focus on RSV evasion strategies against the RLR- 
and TLR-mediated activation of type I IFNs, which have well defined roles in 
controlling virus infections.  
 
1.4.2 The importance of RSV NS1 and NS2 for IFN antagonism  
The success of RSV in establishing infections in AECs relies on its capacity to 
suppress the innate and acquired immune responses. As discussed earlier in Section 1.2, 
one of the main differences between RSV and other members of Paramyxoviridae 
family is that RSV does not express any of the V/C/W proteins, which confer IFN 
resistance to other paramyxoviruses, but instead RSV expresses two putative NS 
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proteins; NS1 and NS2 (Parks & Alexander-Miller 2013). Recombinant RSVs (rRSVs) 
in which the NS1 and/or NS2 genes have been deleted singly or in combination 
(RSV.ΔNS1, RSV.ΔNS2 and RSV.ΔNS1/2) are IFN-sensitive and replicate 
inefficiently in vitro, indicating important defects in virus-host interplay (Jin et al., 
2000; Schlender et al., 2000; Spann et al., 2003; Spann et al., 2004). Specifically, the 
replication of the RSV.ΔNS1/2 in A549 cells was severely reduced (>100-fold reduced) 
compared to wild type RSV (wtRSV), whereas RSV.ΔNS1 and RSV.ΔNS2 were 
moderately attenuated (20- to 45-fold reduced) (Spann et al., 2004). These viruses also 
form pinpoint plaques in HEp-2 cells; plaques were up to 95% reduced in size for the 
RSV.ΔNS1/2 mutant, and 90% and 80% for RSV.ΔNS1 and RSV.ΔNS2, respectively 
(Spann et al., 2003; Jin et al., 2000). In IFN-incompetent cells, the replication of the 
RSV.ΔNS2 was comparable to wtRSV, whereas the RSV.ΔNS1 and RSV.ΔNS1/2 
mutants replicated less efficiently (20-fold decrease) (Teng & Collins 1998; Spann et 
al., 2004; Jin et al., 2000; Young et al., 2003). This indicates that the replication 
deficiency of these viruses is primarily due to enhanced IFN responses, emphasizing the 
importance of NS1 and NS2 for IFN antagonism.  
The replication kinetics of RSV.ΔNS1 and RSV.ΔNS2 have also been studied in 
vivo. Studies on the recombinant virus that lacks NS1 showed that the replication of 
RSV.ΔNS1 was more than 2000-fold reduced in the upper respiratory tract and more 
than 17,000-fold reduced in the lower, when compared to the wtRSV infection in 
chimpanzees (Teng et al., 2000). Likewise, the replication levels of the recombinant 
virus that lacks NS2 were also quantified in chimpanzees; RSV.ΔNS2 was found to 
replicate to moderate levels in the upper respiratory tract but it showed 10,000-fold 
reduction in replication in the lower respiratory tract compared to the wtRSV 
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(Whitehead et al., 1999). In conclusion, in vivo studies suggest that the functions of 
NS1 and NS2 are more important for the establishment of lower respiratory tract 
infections, which are more pathogenic and often lead to severe respiratory defects. The 
restriction of viral replication observed for the RSV NS deletion viruses is presumably 
due to augmented IFN responses, which allow the development of a more powerful 
innate and adaptive immunity to RSV infection (Karron et al., 2013).  
 
1.4.3 RSV NS1 and NS2 functions against type I IFNs  
1.4.3/1 NS1 and NS2 functions against the IFN-induction pathway  
The vast majority of RSV anti-IFN properties are attributed to NS1 and NS2, 
which have joint, as well as, independent functions against the cellular IFN response. 
The molecular mechanisms by which NS1 and NS2 suppress IFN-induction pathway 
are currently under intense investigation and the existing experimental data is still 
inconclusive. NS1 and NS2 have been reported to interact with multiple steps of the 
RLR-mediated pathway but all of these interactions have yet to be elucidated (Figure 
1.7). The first studies to report NS-mediated IFN antagonism were performed using 
BRSV (Schlender et al., 2000; Bossert et al., 2003). BRSV NS1 and NS2 have been 
found to interact with the IFN-induction pathway by blocking phosphorylation of IRF3 
(Bossert et al., 2003). Given that human and bovine RSV share 71% similarity, 
regarding the amino acid sequences of their individual proteins, it is not surprising that 
NS1 and NS2 of human RSV have been reported to have a similar function against the 
IFN-induction pathway. Specifically, it has been shown that NS2 inhibits the nuclear 
accumulation of both IRF3 and NF-κB (Ling et al., 2009; Spann et al., 2004). However, 
the level of inhibition was significantly greater when both NS1 and NS2 were present, 
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suggesting that NS1 and NS2 act cooperatively to suppress activation and nuclear 
localization of both IRF3 and NF-κB (Spann et al., 2005). A more recent study 
suggested a different mechanism for IRF3 inhibition, according to which NS1 interferes 
with the interaction of IRF3 with its cofactor CBP, and subsequently inhibits IRF3 
binding to the IFN-β promoter to suppress IFN-β induction (Ren et al., 2011). 
In addition to the interactions with IRF3 and NF-κB, evidence suggests that NS1 
and NS2 mediate a decrease in the expression levels of TRAF3, whereas NS1 also 
mediates a decrease in IKKε and IRF7 (Figure 1.7) (Swedan et al., 2009; Goswami et 
al., 2013). It is suggested that NS1 and NS2 reduce TRAF3 levels through a novel non-
proteasomal mechanism, for which their common C-terminal tetrapeptides are not 
required, however the C terminus of NS1 is involved in lowering IKKε levels by a 
nonproteasomal mechanism (Figure 1.7) (Swedan et al., 2011; Swedan et al., 2009). 
Interestingly, NS2 appears to antagonize the early activation of the RIG-I 
signalling cascade by binding to the N-terminal CARD of RIG-I, and thus inhibiting its 
interaction with the downstream component MAVS (Figure 1.7) (Ling et al., 2009).  It 
is also speculated that the inhibition of the RIG-I pathway is caused by an interaction 
between NS1 and NS2 with MAVS in mitochondria. Specifically, intracellular 
localization studies have shown that NS2 and NS1-NS2 complexes localize in 
mitochondria, whereas singular expression of NS1 results in nuclear localization, 
suggesting that NS1-NS2 complex might directly interact with mitochondrial MAVS to 
block RIG-I mediated signalling (Swedan et al., 2011). In addition to the interaction of 
NS2 with RIG-I, NS1 was shown to degrade RIG-1 when constitutively expressed in 
A549 cells (Goswami et al., 2013), however the prevalence of these interactions during 
RSV infection remains to be elucidated. In conclusion, RSV NS1 and NS2 have 
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evolved a plethora of mechanisms with which they circumvent key steps of the IFN-
induction signalling cascade, including early events like RIG-I activation, and latter 
events like IRF3 and NF-κB nuclear translocation. 
 
 
 
 
 
Figure 1.7 RSV NS1 and NS2 interactions with the IFN-induction pathway. RSV NS1 and 
NS2 have been reported to interact with several effector molecules of the IFN-induction pathway 
to suppress the activation of the IFN-β promoter, and block the IFN response to RSV infection. 
There are a noteworthy number of interactions in the literature, most of which seem to target the 
RIG-I dependent IFN induction pathway. 
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1.4.3/2 NS1 and NS2 functions against the IFN-signalling pathway  
RSV NS1 and NS2 proteins also counteract the IFN-signalling pathway and 
subsequently suppress the activation of the ISRE elements, which are present within the 
promoters of ISGs (Ramaswamy et al., 2004). The majority of studies that focus on the 
RSV-mediated IFN antagonism unanimously suggest that RSV infections and 
expression of recombinant NS1 and NS2 in epithelial cells causes an evident decrease in 
STAT2 levels, which outruns the downstream events of the IFN-α/β response. 
However, there is controversy regarding the molecular mechanism that RSV uses to 
mediate a decrease in STAT2 levels. In particular, the majority of evidence supports 
that STAT2 decrease is mainly driven by NS2 with NS1 having some effect (Spann et 
al., 2004; Lo et al., 2005; Swedan et al., 2011; Goswami et al., 2013), whereas other 
evidence suggests that STAT2 degradation requires only NS2 (Ramaswamy et al., 
2006). In contrast, Elliott et al., (2007) proposed a NS2-independent mechanism and 
suggested that NS1 has an E3 ligase activity that is crucial for STAT2 degradation.  It is 
possible that the exact stoichiometry of the NS1, NS2 and NS1-NS2 heterodimer varies 
between these studies and that may account for some of the differences reporter in the 
literature, which are discussed in detail below.  
One of the earliest studies to support NS-mediated STAT2 antagonism was 
published by Lo et al., (2005), who showed that constitutive expression of NS2 is 
related to a significant reduction in STAT2, whereas NS1 expression had a less 
significant impact on STAT2 levels. Interestingly, co-expression of NS1 and NS2 
suppressed STAT2 below baseline levels, suggesting that NS1 and NS2 work together 
to achieve robust inhibition of STAT2 (Lo et al., 2005). Furthermore, it was shown that 
NS2 interacts with the host microtubule-associated protein 1B (MAP1B) through its C-
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terminus DNLP tetrapeptide (Figure 1.5), and this interaction was found to be essential 
for the STAT2-decreasing activity of NS2 (Swedan et al., 2011). In fact, it is suggested 
that MAPIB could be part of the NS1-NS2 complex, hence it might be important for the 
synergistic functions of NS1 and NS2 (Swedan et al., 2011).  
Shedding more light on the mechanism behind STAT2 decrease, other studies 
demonstrated that STAT2 antagonism is caused by a NS2-mediated proteasomal 
degradation (Ramaswamy et al., 2006; Ramaswamy et al., 2004).  In general, 
proteasome-mediated degradation of proteins usually occurs after protein ubiquitylation. 
The process of protein ubiquitylation is catalyzed by coordinated enzymatic reactions 
that are mediated by enzymes known as E1 (ubiquitin-activating enzyme), E2 
(ubiquitin-conjugating enzyme) and E3 (ubiquitin ligase) (Da Fonseca et al., 2012; 
Jiang & Chen 2011).  E3 ligases are responsible for targeting ubiquitylation to specific 
substrate proteins, by covalently attaching ubiquitin to lysine side chains of the 
substrate protein (Jiang & Chen 2011). Some of the E3 ubiquitin ligases belong to the 
suppressor of cytokine signalling (SOCS) family of proteins, which are involved in 
inhibiting the JAK/STAT pathway (Yoshimura et al., 2007). Interestingly, RSV-
induced STAT2 degradation was prevented by knocking down expression of 
endogenous E3 ligase components like Cul2 and Rbx1 (Elliott et al., 2007). The same 
study has also shown that NS1 associates with Cul2, suggesting that NS1 can assemble 
ubiquitin ligase enzymes to target STAT2 to the proteasome (Elliott et al., 2007). 
Notably, internal sequences of NS1 and NS2 shared distant homology to the consensus 
sequence for elongin C and cullin 2 binding motif (BC box), which occurs in E3 ligases 
such as SOCS, proposing that this motif might be responsible for the E3 ligase activity 
of NS1 and NS2 that permits STAT2 degradation (Elliott et al., 2007; Swedan et al., 
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2009). However, the role of this motif still remains unclear, since mutations within the 
BC box motif did not inhibit STAT2 degradation or any other function of either NS1 or 
NS2 protein (Swedan et al., 2011). Interestingly, a more recent study have demonstrated 
that RSV NS1 protein upregulates SOCS1 mRNA independently of the RLR signalling 
pathway, suggesting that SOCS1 might be important for the degradation activity of NS1 
against STAT2 or other innate immune proteins (Xu et al., 2014).   
The first model to describe the NS-degradasome has recently been proposed by 
Goswami et al., (2013), who suggested that NS proteins assemble a heterogeneous 
degradation complex (~300 – 750 kDa in size), which translocates to mitochondria upon 
RSV infection. Their controversial findings suggest that optimal RSV suppression of 
cellular interferon response requires mitochondrial MAVS to be part of the NS-
degradasome, hence MAVS facilitates the NS-mediated RIG-1 inhibition, and STAT2 
degradation (Goswami et al., 2013).  To date, no other studies have been reported that 
either support or refute this observation, however a few studies have reported 
association of RSV NS1 and NS2 with mitochondria. Specifically, proteomic analyses 
of the RSV NS1 interactome indicated that NS1 is associated with a number of 
mitochondrial proteins (Wu et al., 2012). Consistent with these findings, Boyapalle et 
al., (2012) have demonstrated that RSV NS1 directly binds to mitochondrial MAVS, 
however the domains of interaction have not been mapped. Interestingly, another recent 
study has shown that during RSV infection proteins involved in innate antiviral immune 
response (e.g.Tom70) accumulate on mitochondria, supporting the hypothesis that 
mitochondria are likely to be hijacked by NS1 and NS2 for the assemblage of the NS-
degradasome (Munday et al., 2015). The role of mitochondria in RSV infection remains 
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to be further elucidated, however current evidence unanimously suggests that they have 
important implications for RSV biology, and perhaps IFN antagonism. 
Although the function of RSV NS1 and NS2 against STAT2 is well 
documented, the precise mechanism behind STAT2 degradation is undetermined. Our 
up-to-date knowledge suggests that STAT2 degradation is a synergistic event that 
requires both NS1 and NS2, and remarkably, this function still remains the only 
documented interaction of RSV NS1 and NS2 with the type I IFN signalling cascade.  
 
1.4.3/3 NS1 and NS2 interactions with antiviral ISGs  
Current investigations suggest that RSV NS1 and NS2 can also directly suppress 
ISGs. For instance, NS1 and NS2 were shown to antagonize the RSV-mediated 
upregulation of the let-7i and miR-30b miRNAs, which have an antiviral effect and are 
induced by an IFN- or NF-κB-dependent mechanism, respectively (Thornburg et al., 
2012). More recently, another study have shown that NS1 can suppress the function of 
an IFN-induced antiviral protein, namely 2'-5'-oligoadenylate synthetase-like 
(OASL) by mediating proteasomal degradation of specific OASL isoforms (Dhar et al., 
2015). RSV infection also activates several ISGs of the IFIT family, namely ISG56, 
ISG54 and ISG60 (Hastie et al., 2012; Janssen et al., 2007), however it is still unclear 
whether RSV interferes directly with these IFITs, the antiviral role of which is also not 
clear yet.  
 
1.4.4 NS-independent functions of RSV against type I IFN system 
In addition to the RSV NS1 and NS2 functions against the cellular IFN 
response, other RSV proteins have been reported to interact directly or indirectly with 
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several factors of the cellular IFN pathway. RSV G contains a conserved CX3C 
chemokine-like motif, which binds to the CX3C receptor (CX3CR1) on various 
immune cells and airway epithelial cells, and thereby inhibits innate immune responses 
to RSV infection (Chirkova et al., 2013). RSV G protein was also shown to modulate 
the expression of two SOCS proteins, SOCS1 and SOCS3, to inhibit type I IFNs and 
ISG15 expression very early, as well as late in infection (Oshansky et al., 2009). The 
RSV N protein also has a role in antagonizing host innate immunity by interacting with 
dsRNA-regulated protein kinase PKR, which induces early innate immunity responses 
to RSV infection (Minor et al., 2010). Specifically, it has been reported that N binds to 
PKR, and prevents it from phosphorylating eIF-2a and inhibiting protein synthesis 
(Groskreutz et al., 2010). Another interesting study has shown that the N protein co-
localizes with mda-5 and MAVS, suggesting that N protein localizes these molecules 
within the viral inclusion bodies to attenuate the downstream signalling cascade that 
activates the IFN-β promoter (Lifland et al., 2012). In summary, although RSV IFN 
evasion strategies are primarily executed by NS1 and NS2, a few recent studies have 
illustrated that other RSV proteins might also contribute to IFN antagonism perhaps at 
different stages during the replication process.  
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1.5 RSV NS1 and NS2 functions beyond IFN antagonism  
One of the earliest studies to evaluate the effect of NS1 and NS2 on virus 
replication was Jin et al., (2000), who quantified the replication kinetics of recombinant 
RSV viruses lacking NS1 and NS2 (RSV.ΔNS1 and RSV.ΔNS2, respectively). As 
discussed earlier, RSV.ΔNS2 grew poorly only on IFN-competent cells, whereas 
RSV.ΔNS1 was equally attenuated in cells that were either proficient or incompetent to 
IFN, indicating that NS1 protein has functions in virus replication beyond IFN 
antagonism (Jin et al., 2000). A similar study showed that replacement of RSV NS1 and 
NS2 by PIV5 V protein partially restored some of the IFN-inhibitory functions but did 
not fully restore virus replication, also suggesting that RSV NS1 and NS2 have other 
functions related to virus replication (Tran et al.,2007). Consistent with these findings, 
RSV NS1 protein was found to be a potent inhibitor of RSV polymerase-mediated 
transcription and RNA replication in a minireplicon assay, indicating that NS1 could 
play a role as a negative regulatory protein (Atreya et al., 1998). Beside the expected 
interactions of RSV P protein with itself and N protein, it has been demonstrated that P 
can also bind to NS1, indicating a direct role of NS1 in the replication complex (Hengst 
& Kiefer 2000). It has been also shown that NS1 co-precipitates with M protein during 
virus infection, however no interaction was detected between NS2 and RSV structural 
proteins (Evans et al., 1996).  
Furthermore, previous studies have demonstrated that RSV induces a G1-phase 
arrest in the cell-cycle (Gibbs et al., 2009; Smith et al., 2011). Interestingly, 
recombinant RSV lacking NS1 lost its ability to modulate the cell cycle, indicating that 
RSV NS1 is indispensable for this function (Wu et al., 2012). More specifically, NS1 
was found to interact with complexes, which contain proteins that are involved in the 
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regulation of cell cycle, such as ATR (ataxia telangiectasia- and Rad3-related protein) 
and MED29 (mediator complex subunit 29), suggesting that these interactions are 
important for the NS1 function against the cell cycle (Wu et al., 2012). 
NS1 and NS2 also appear to have a crucial role in suppressing premature 
apoptosis, allowing the virus time to replicate. Specifically, they were found to activate 
anti-apoptotic genes through a phosphatidylinositol 3-kinase (PI3K)- and NF-κΒ-
dependent but IFN-independent mechanisms (Bitko et al., 2008). Likewise, 
bioinformatic and proteomic analyses of the NS1 interactome indicated that NS1 
interacts with a number of cellular proteins, most of which were related to the inhibition 
of apoptosis and also the regulation of transcription of host cell mRNAs (Wu et al., 
2012). Despite that there is less known about the role of RSV NS2 in virus replication 
apart from IFN antagonism, an interesting study has recently shown that NS2 is a 
contributing factor for the exacerbation RSV airway disease by promoting cell shedding 
of the airway epithelial cells, which facilitates viral release but also contributes to the 
obstruction of the distal airways (Liesman et al., 2014).  
In conclusion, NS1 and NS2 have a plethora of anti-IFN functions but also have 
functions beyond IFN antagonism, which are related to virus replication and 
pathogenicity. All evidence suggests that NS1 and NS2 can work synergistically, 
sharing subunits, activities and cellular locales to inhibit IFN response but in addition, 
being different proteins allows them to perform specific individual roles related to virus 
replication and virus pathogenicity (Barik 2013). This highlights the multifunctional 
nature of NS1 and NS2, and also intensifies the importance of NS1 and NS2 for RSV 
infection. 
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1.6 Advances in RSV antivirals  
With the lack of effective antiviral treatments, supportive therapy remains the 
mainstay of care for patients hospitalised with RSV infection and it is often combined 
with oxygen and mechanical ventilation as well as pharmacotherapy with ribavirin, 
intravenous immunoglobulin (Palivizumab), bronchodilators and corticosteroids 
(Wright & Piedimonte 2011; Chu & Englund 2013). The currently available antiviral 
approaches have debatable cost-effectiveness, therefore treatment of RSV is usually 
reserved for patients with ALRI, or to prevent progression from upper respiratory to 
lower respiratory tract infection in high-risk individuals, such as preterm infants, the 
elderly and those suffering from cardiovascular diseases and immunosuppression (Chu 
& Englund 2013).  
The lack of RSV vaccine and virus-specific antivirals highlights the clinical 
need for new anti-RSV therapies. There is an extensive ongoing research that aims the 
development of better RSV therapeutics, and although a number of promising new 
antiviral agents are under development by multiple pharmaceutical and biotechnology 
companies, none of them has been approved for clinical use yet. These include small 
molecule fusion inhibitors, attachment inhibitors, inhibitors of RNA synthesis, and 
small interfering RNA particles (siRNA) (Table 1.1). Screening compound libraries in 
cellular antiviral assays led to the discovery of small-molecule RSV inhibitors that 
target the F protein, few of which are currently in clinical trials (Meanwell et al., 2011). 
One of the F inhibitors, TMC-353121, and an inhibitor of the polymerase, YM-53404, 
are still at the preclinical stage of development (Sudo et al. 2005; Roymans et al. 2010; 
Chu & Englund 2013). The effectiveness of the recently discovered oral RSV F 
inhibitor GS-5806 also generates a level of optimism, showing that small molecule 
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antiviral agents can control RSV infection in vivo (Wright 2014; DeVincenzo et al., 
2014).  Clinical trials demonstrated that RSV infected individuals had lower virus load 
and lower total mucus weight, when administrated 50 mg of GS-5806 (DeVincenzo et 
al., 2014). The evaluation of the GS-5806 is at an early stage, hence the usefulness and 
the effectiveness of this drug still needs to be confirmed against natural RSV infections 
in infants. In addition to chemical compounds, other types of molecules have been 
shown to inhibit RSV infectivity in vitro, including peptides and small-interfering 
RNAs (siRNAs) (Krilov 2011). In particular, cocktails of intranasal antiviral siRNAs 
have been proposed for RSV therapy but their efficacy remains unverified (Barik & Lu 
2015).   
 
Table 1.1 RSV drug candidates  
 
Drug Name 
Viral Antigen 
Target 
 
Stage of Development 
 
Reference 
Small molecule inhibitors 
BMS-433771 F protein  Animal models (Cianci et al., 2004; 
Meanwell et al., 2011) 
TMC-353121 F protein  Preclinical  (Roymans et al., 2010) 
BTA-9881 F protein Phase I  (Chu & Englund 2013) 
MDT-637 F protein Phase I  (Chu & Englund 2013) 
GS-5806 F protein  Phase II (DeVincenzo et al., 2014) 
YM-53404 L protein  Preclinical  (Sudo et al., 2005) 
RSV-604 N protein  Phase II (Chapman et al., 2007) 
Other inhibitors 
siRNAs NS1 protein Animal models (Zhang et al., 2005) 
siRNAs P protein Animal models  (Bitko et al., 2005) 
siRNAs N protein Phase II (DeVincenzo et al., 2010) 
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The majority of RSV drug candidates target RSV F protein and traditional drug 
targets (e.g. virus-encoded enzymes), and there are no drug candidates in the literature 
that target either NS1 or NS2 proteins. More than ten years ago, a study showed that 
siRNA nanoparticles targeting NS1 resulted in attenuated RSV infection and infection-
induced pulmonary pathology in mice (Zhang et al., 2005), however the efficacy of the 
intranasal siNS1 was never tested in clinical studies. 
It is widely accepted that the major obstacle in antiviral therapies (especially 
against RNA viruses) is the generation of drug-resistant virus strains; it has been 
estimated that virus’ mutation rates (substitutions per nucleotide per cell infection 
(s/n/c)) range from 10
-8
 to10
-6
 s/n/c for DNA viruses to 10
−6
 to 10
−4
 s/n/c for RNA 
viruses, which is much higher than the 10
-10 
s/n/c observed for bacterial and lower 
eukaryotes (Sanjuán et al., 2010; Gago et al., 2009). Therefore, it is very doubtful that a 
single molecule could ever prevent RSV infection without the acquisition of drug 
resistance virus strains. The existing antiviral therapies against other RNA viruses, 
including HIV and HCV, indicate that combinational therapy using different 
mechanistic classes of antiviral drugs can be the future for the establishment of an 
effective anti-RSV therapy. Current investigations are heavily leaning towards the 
identification of entry inhibitors, nonetheless NS1 and NS2 inhibitors have the potential 
to be valuable antiviral drugs for RSV control and prevention.  
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1.7 The importance of HTS in drug discovery  
Over the past two decades, HTS has emerged and matured as a platform of early 
drug discovery in both the pharmaceutical industry and the academia (Zang et al., 
2012). In early 1990s, biochemical HTS assays became a central area of drug discovery, 
however recent efforts have been dedicated to the development of cell-based HTS 
platforms, which provide better predictability of clinical efficacy, and thus reduce the 
number of animal tests and accelerate the drug discovery process (Carnero 2006). 
Considering that the first article on HTS was published in 1991, and that it takes 
on average 13.5 years from target identification to drug approval (Paul et al., 2010), it is 
still early to evaluate the success of HTS in drug discovery. Nonetheless, it has been 
estimated that among 58 drugs that were approved between 1991 and 2008, 19 were 
attributed to HTS (Perola 2010). The first two approved drugs with origins in HTS hits 
were tyrosine-kinases with anti-cancer properties, namely Gefitinib (Iressa; 
AstraZeneca) and Erlotinib (Tarceva; Roche), which received approval by FDA in 2003 
and 2004, respectively (Fry et al., 1994). Another successful example of cell-based HTS 
in drug discovery is the commercialization of Eltrombopag (Promacta/Revolade; 
GlaxoSmithKline), a thrombopoietin (TPO) receptor agonist, which was approved by 
the FDA in 2008, for treating chronic idiopathic thrombocytopenic purpura (Duffy et 
al., 2001). The approved drugs with origins in HTS hits have a wide range of targets 
and act against different diseases, including cancer, diabetes and other diseases, like 
pulmonary hypertension and hypernatremia (Zang et al., 2012; Macarron et al., 2011). 
HTS assays have been widely utilized for the identification of antiviral 
therapeutics. In particular, the discoveries made from HTS have considerably 
contributed to HIV treatment, since three of the anti-retroviral agents that are currently 
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used in the highly active antiretroviral therapy (HAART) were originally identified 
using HTS assays (Macarron et al., 2011). HAART is the most effective currently 
available antiviral therapy, and it consists of several classes of drugs that act on 
different stages of the HIV life cycle. HTS led to the discovery of an HIV-1 entry 
inhibitor, namely Maraviroc (Selzentry; Pfizer) (MacArthur & Novak 2008), a protease 
inhibitor, called Tipranavir (Aptivus; Boehringer Ingelheim) (Temesgen & Feinberg 
2007) and Etravirine (Intelence; Tibotec Pharmaceuticals), which is a reverse 
transcriptase inhibitor (De Corte 2005).  
In conclusion, HTS represents an effective method for discovering novel 
antiviral agents or repurposing existing molecules. The success of a HTS approach 
requires carefulness and precision and relies on several screening steps such as reagent 
preparation, assay development and most importantly, target identification and 
screening library.  
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1.8 Research Objectives  
The overall aim of this study was to develop a modular screening platform, 
which would allow viral IFN antagonists to be subjected to HTS for the identification of 
novel small molecules that inhibit their function(s). This project sought to determine 
whether a novel class of virus-specific antiviral drugs that work by inhibiting viral IFN 
antagonists’ function could be developed. Small molecules that inhibit targeted viral 
IFN antagonists would allow us to validate this vital class of viral proteins as 
therapeutic targets, and could also represent useful research tools for revealing the 
pleiotropic functions of viral IFN antagonists. The current study aims to (i) develop a 
cell-based HTS assay that allows identification of small molecules that inhibit viral IFN 
antagonists, (ii) utilize this screening approach to target RSV IFN antagonists NS1 or 
NS2 to identify small molecules that inhibit their function(s) against the cellular IFN 
response, (iii) validate the ability of hit compounds to inhibit RSV NS1 or NS2 
function(s), (iv) investigate the specificity of the hit compounds to reveal their 
mechanism of action, (v) characterize hit compounds in regards to their ability to 
restrict RSV replication in vitro.  
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Chapter 2: Materials and Methods 
 
2.1 Cells, viruses and antibodies  
2.1.1 Mammalian cell-lines  
 
293T:  Human embryonic kidney cell-line  (provided by Professor Richard Iggo, 
University of Bordeaux) 
A549:  Human carcinomic alveolar basal epithelial cell-line  (European 
Collection of Cell Cultures (ECACC)) 
HEp2:  Hela derivatives, human cervix carcinoma epithelial cell-line (ECACC) 
Fibroblasts: Human dermal fibroblasts (provided by Professor Sophie Hambleton, 
University of Newcastle) 
 
 
In addition to the basic cell-lines mentioned above, the following A549 and Hep2 
derivatives (generated by others) were also used in this study: 
 
A549.pr(IFN-β)GFP: A549 cell-line stably expressing the green fluorescence (GFP) 
gene under the control of the IFN-β promoter (Chen et al., 2010). This cell-line has 
inducible resistance to puromycin as expression of puromycin N-acetyl-transferase 
(PAC) is also under the control of the IFN-β promoter.  
 
A549.pr(IFN-β)GFP-BVDV/Npro: A549.pr(IFN-β)GFP cell-line stably expressing the 
N-terminal protease (Npro) of Bovine Viral Diarrhea Virus (BVDV) with an N-terminal 
V5 tag (Chen et al., 2010). This cell-line encodes for encodes for PAC. 
 
Chapter 2:  
Materials and Methods  
52 
 
A549.pr(IFN-β)GFP-HCV/NS3.4A(1b): A549.pr(IFN-β)GFP cell-line stably expressing 
the NS3.4A protease of HCV genotype 1b with a C-terminal V5 tag (produced by Dr 
Catherine Adamson). This cell-line encodes for encodes for PAC. 
 
A549.pr(ISRE)GFP : A549 cells producing GFP under the control of the ISRE (MxA) 
element (produced by Dr Claudia Haas and Mrs Zoe Gage). This cell-line has inducible 
resistance to puromycin as expression of PAC is also under the control of the ISRE 
promoter. 
 
 Hep2-BVDV/Npro: Hep2 cells stably expressing BVDV N pro (Carlos et al., 2007). 
This cell-line encodes for encodes for PAC. 
 
Hep2-PIV2/V: Hep2 cells stably expressing PIV2 V protein (produced by Mr Dan 
Young). This cell-line encodes for encodes for PAC. 
 
 
In addition to the cell-lines mentioned above, the following permanent cell-lines were 
generated (Section 2.3) and used as part of this study: 
 
 
A549.pr(IFN-β)GFP derivatives:  
 
A549.pr(IFN-β)GFP-RSV/hNS1: A549.pr(IFN-β)GFP cell-line stably expressing 
‘humanized’ codon-optimized NS1 (hNS1) protein of RSV with an N-terminal V5 tag. 
This cell-line encodes for blasticidin-S deaminase, which confers resistance to 
blasticidin.  
 
A549.pr(IFN-β)GFP-RSV/hNS2: A549.pr(IFN-β)GFP cell-line stably expressing hNS2 
protein of RSV with an N-terminal myc-tag. This cell-line encodes for encodes for 
PAC. 
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A549.pr(IFN-β)GFP-RSV/hNS1.hNS2: A549.pr(IFN-β)GFP cell-line stably expressing 
hNS1 and hNS2 proteins of RSV with an N-terminal V5 tag or myc-tag, respectively. 
This cell-line encodes for encodes for both blasticidin-S deaminase and PAC. 
 
 
A549.pr(ISRE)GFP derivatives:  
 
A549.pr(ISRE)GFP-RSV/hNS1: A549.pr(ISRE)GFP cell-line stably expressing hNS1 
protein of RSV with an N-terminal V5 tag. This cell-line encodes for blasticidin-S 
deaminase. 
 
A549.pr(ISRE)GFP-RSV/hNS2: A549.pr(IFN-β)GFP cell-line stably expressing hNS2 
protein of RSV with an N-terminal myc-tag. This cell-line encodes for encodes for 
PAC. 
 
A549.pr(IFN-β)GFP-RSV/hNS1.hNS2: A549.pr(IFN-β)GFP cell-line stably expressing 
hNS1 and hNS2 proteins of RSV with an N-terminal V5 tag or myc-tag, respectively. 
This cell-line encodes for encodes for both blasticidin-S deaminase and PAC. 
 
A549.pr(ISRE)GFP-RBV/P: A549.pr(ISRE)GFP cell-line stably expressing P protein of 
Rabies virus(RBV) with an N-terminal V5 tag. This cell-line encodes for encodes for 
PAC. 
 
A549.pr(ISRE)GFP-PIV5/V: A549.pr(ISRE)GFP cell-line stably expressing V protein 
of PIV5. This cell-line encodes for encodes for PAC. 
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2.1.2 Viruses  
PIV5 VΔC (vM2): A strain of PIV5, which has the C-terminal of its V protein deleted, 
therefore it cannot circumvent the IFN induction (He et al., 2002). The PIV5 VΔC 
(vM2) stock is a defective-interfering (DI) rich preparation of the PIV5 VΔC strain, 
which was generated by Mr Dan Young (Chen et al., 2010). 
 
wtRSV: A wild-type A2 strain of RSV, which was kindly provided by Professor Peter 
Collins (NIAID, USA). The full-length cDNA sequence of the wtRSV(A2) was 
published by Collins et al., (1987) (GeneBank Accession No. M74568).  
 
RSV.ΔNS1 and RSV.ΔNS2: Recombinant RSV A2 viruses that have the NS1 or the 
NS2 gene deleted, respectively (Collins & Murphy 2002). These viruses were also 
provided by Professor Peter Collins (NIAID, USA).  
 
rRSV: A recombinant ‘wild-type’ Long strain RSV virus (Rameix-Welti et al., 2014), 
which was kindly provided by Jean-François Eléouët (Unité de Virologie et 
Immunologie Moleculaires, France). 
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2.1.3 Antibodies   
All the primary and secondary antibodies used in this study are listed on Table 2.1, 
except the mouse anti-RSV fusion antibody (1:250) (AbD Serotec), which was used for 
visualising RSV plaques with immunostaining.   
 
Table 2.1 List of antibodies. Primary and secondary antibodies used for western blotting (WB) 
and/or immunostaining (IF) 
Antibody Company Ab 
dilution 
for WB  
Time  
WB/IF 
Ab 
dilution 
for IF 
Primary Antibodies  
mouse anti-V5 (336/SV5-Pk1) AbD Serotec® 1:2000 1 h/ 1h  1:400 
mouse anti-myc (4A6) Merck Millipore, 1:1000 O/N/1 
hour 
1:200 
rabbit anti-Mx1/2/3 (H-285)  Santa Cruz Biotechnology 1:750 O/N/1h  1:50 
rabbit anti-STAT2 (C-20) Santa Cruz Biotechnology  1:1000 O/N/1h  1:200 
mouse anti-β-actin  Sigma-Aldrich  1:10000 1 h/- - 
goat anti-RSV  Abcam® 1:1500 O/N/- 1:200 
Secondary Antibodies 
rabbit anti mouse (HRP
1
)-
conjugated  
Sigma-Aldrich 1:2000 1 h/-  - 
goat anti rabbit (HRP
1
)-
conjugated  
Sigma-Aldrich, 1:2000 1 h/-  - 
donkey anti goat (HRP
1
)-
conjugated  
Santa Cruz Biotechnology 1:2000 1 h/-  - 
IRDye®80°°W goat anti-
mouse 
LI-COR 1:10000 1 h/-  - 
IRDye®680RD donkey anti-
goat  
LI-COR, 1:10000 1 h/-  - 
IRDye®680RD goat anti-
rabbit  
LI-COR 1:10000 1 h/-  - 
goat anti-mouse TR
2 AbD Serotec® - - /1h  1:400 
donkey anti-goat TR
2 
Santa Cruz Biotechnology - - /1h 1:400 
goat anti-rabbit TR
2 AbD Serotec®, - - /1h  1:400 
goat anti-mouse FITC
3 
Southern Biotech - - /1h  1:400 
donkey anti-goat FITC
3 Abcam® - - /1h  1:400 
goat anti-rabbit FITC
3 
Sigma-Aldrich  - /1h  1:400 
1
 Horseradish peroxidase (HRP),  
2 
Texas Red (TR),  
3
 Fluorescein isothiocyanate (FITC) 
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2.2 Cell culture  
2.2.1 Cell maintenance  
Cell monolayers were cultured in 25cm
2
, 75cm
2
 or 175 cm
2
 tissue culture flasks 
(Greiner Bio-One) in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% [v/v] fetal bovine serum (FBS; ThermoScientific) and 1% [v/v] penicillin and 
streptomycin (pen/strep), and incubated at 37°C/5% CO2. Cells were routinely 
trypsinised (Trypsin/ ethylenediaminetetraacetic acid (EDTA)) when approximately 
90% confluent.  
 
2.2.2 Cryopreserving and resuscitation of cells. 
Cells were tested for mycoplasma, using the PCR Mycoplasma Test Kit II, 
following manufacture’s instructions (PromoKine) and only mycoplasma-negative cells 
were stored in our liquid nitrogen collection. Cells were trypsinized, resuspended in 
10% [v/v] FBS/DMEM, and pelleted at 1500 rpm for 5 min at room temperature (RT). 
Cells were then resuspended in freezing medium (DMEM supplemented with 30% [v/v] 
FBS and 10% [v/v] DMSO), aliquoted into cryovials and frozen at -80°C, before long-
term storage in liquid nitrogen. For resuscitation of cells, cryovials were rapidly thawed 
at 37°C, before centrifugation at 1500 rpm for 5 min at RT. Cells were then 
resuspended and grown in normal growth medium at 37°C/5% CO2. The following day, 
medium was replaced in order to remove traces of DMSO. The appropriate antibiotic 
selection markers (e.g. puromycin or blasticidin) were added once cells formed 50% 
healthy monolayers.  
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2.3 Generation of A549.pr(IFN-β)GFP and 
A549.pr(ISRE)GFP derivatives that stably express viral IFN 
antagonists  
 
2.3.1 Gene Sequences   
Codon-optimized, ‘humanized’ versions of the RSV/Long genes for NS1 
(hNS1) and NS2 (hNS2) were published by Lo et al., 2005 (GenBank accession no. 
AY904040.1 and AY904041.1, respectively). The rabies virus P (RV/P) gene sequence 
derived from the challenge virus standard (CVS) strain 11 (GenBank accession no. 
ADJ29909.1). The published sequences were synthesized by Dundee Cell Products, and 
therefore the desired peptide tags were added to the sequences (Appendix 1). The 
RSV/hNS1 and RV/P sequence had a N-terminus V5-tag (GKPIPNPLLGLDST) 
(Randall et al., 1987), whereas hNS2 had a N-terminus myc-tag (EQKLISEEDL). The 
PIV5/V sequence derived from PIV5 W3 strain (GenBank accession no. JQ743318.1).  
 
2.3.2 Generation of lentivirus transfer vectors  
 For the development of reporter cell-lines that express viral IFN antagonists, we 
used second-generation lentivirus system, which consists of three lentiviral plasmids.  
The transfer vectors supply the minimum cis-acting genetic sequences (e,g LTRs, 
packaging () site, the rev response element (RRE), the central polypurine tract (cPPT) 
and SFFV promoter) necessary for the vector to transduce the target cell and deliver a 
gene of interest. In order to create an infectious lentivirus, two packaging plasmids are 
required; i) the CMV-R plasmid, which encodes the gag structural proteins and pol and 
(ii) the VSV-G plasmid, which encodes the envelope glycoprotein of vesicular stomatis 
virus (VSG) for the generation of pseudotyped virus particles that can be transduced to 
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a broad range of host cell types.  
Two lentiviral transfer vectors were used for the generation of the A549 reporter 
cell-line derivatives. These were the pdl’SV5V’IB vector, which encodes for 
blasticidin-S deaminase to confer resistance to blasticidin, and the pdlNotI’IRES.puro 
vector, which encodes for puromycin N-acetyl-transferase (PAC), and hence confers 
resistance to puromycin (Appendix 2). RSV hNS2 and Rabies P genes were cloned 
directly into the pdlNotI’IRES.puro vector, because they were synthesized with 
compatible restriction sites at their 5’ and 3’ ends (BamH1 and NotI, respectively). This 
led to the generation of the pdl.RSV.hNS2/NotI’IRES.puro and 
pdl.RBV.P/NotI’IRES.puro lentiviral transfer vectors. In order to clone RSV hNS1 into 
the pdl’SV5V’IB vector, the right restrictions sites were added at the 5’ and 3’ ends of 
the gene sequence  (BamH1 and NdeI, respectively) using polymerase chain reaction 
(PCR). The gene was cloned into an intermediate cloning vector, the pGEM®-T Easy 
vector (Promega), and then sub-cloned into the pdl’SV5V’IB vector to generate the 
pdl’RSV/hNS1’IB transfer vector. The lentiviral vector which encodes for PIV5/V 
(pdl.PIV5/V.puro) was previously generated by Dr Marian Killip, and it was used for 
the generation of the A549.pr(ISRE)GFP-PIV5/V reporter cell-line.   
 
2.3.2/1 Polymerase Chain Reaction (PCR)  
All PCR reactions were carried out using the KOD hot start DNA polymerase 
(Merck Millipore). PCR reactions were carried out in 200 μl PCR tubes; the reaction 
mix had a total volume of 50 μl, and typically comprised of the following: 5 μl 10X 
polymerase buffer (1X final conc.), 3 μl 25 mM MgSO4 (1.5 mM final conc.), 5 μl 2 
mM dNTPs (0.2 mM final conc.), 1.5 μl of 10 mM appropriate forward and reverse 
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primers (0.3 μM final conc.), 1 μl of plasmid DNA template (10 ng final conc.), and 1 
μl KOD hot start DNA polymerase (0.02 U/ μl final conc.). Table 2.2 shows the primers 
designed for this study. PCR reactions were carried out in a thermocycler (Biometra
®
, 
T-gradient), using the cycling conditions shown in Table 2.3.  
 
Table 2.2 Primer sequences.  
For generating the pdl’SV5V’IB.RSV.hNS1.blast vector 
Primer Name  Sequence (5’ to 3’ end)   
Forward: BamH1_RSV.hNS1 GGCGGATCCATGGGAAAGCCGATCCCAAAC 
Reverse: NotI_RSV.hNS1 GGCCATATGCTTAAGGGTTG 
Note:  
BamH1 restriction site, NdeI restriction site 
 
 
 
Table 2.3 Cycling conditions for KOD Hot Start DNA polymerase 
Step Duration Temperature 
1. Polymerase activation  2 min 95
°
C 
2. Denature  20 s 95
°
C 
3. Annealing  10 s lowest Tm 
°
C - 5
°
C 
4. Extension    if target size      
<500 bp  
                       if target size 
500-1000 bp 
10 s / kb 70
 °
C 
15 s / kb 70
°
C 
 
 
2.3.2/2 DNA gel electrophoresis 
PCR reactions were analysed on a 0.7 % [w/v] agarose gel (Sigma-Aldrich) in 
TBE buffer (1M Tris base, 1M Boric acid and 0.02 M EDTA). The samples were mixed 
with the appropriate volume of DNA loading buffer (Promega), prior to DNA 
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electrophoresis. Samples were run at 90V in TBE buffer (containing 1 μg/ml ethidium 
bromide), until bands were clearly resolved. Along with the samples, known DNA size 
markers were also run (1kb and 100 bp ladders; Promega). Resolved DNA bands of 
interest were excised under UV light, and purified using the QIAquick PCR purification 
kit (following manufacturer’s instructions; QIAGEN®).  
 
2.3.2/3 Cloning into pGEM®-T Easy vector 
Before cloning into the lentiviral transfer vector, the amplified inserts were 
cloned into the commercially available pGEM®-T Easy vector (Promega). The 
pGEM®-T Easy vector has T-overhangs at the insertion site, therefore cloning into the 
pGEM®-T Easy vector requires the generation of poly-A tailed inserts. For the A-
tailing reaction, 7 μl of purified PCR product were incubated with 1 μl of GoTaq® 
DNA polymerase (5 units) (Promega), 1 μl of 10X polymerase buffer (1X final conc.) 
and 1 μl of dATPs (0.2 mM final conc.). The total 10-μl reaction was incubated at 70°C 
for 30 minutes. The poly-A tailed inserts were ligated into pGEM®-T Easy vector using 
T4 DNA ligase (Promega). A standard ligation reaction comprised of 1 μl pGEM®-T 
Easy vector (50 ng), 5 μl of 2X rapid ligation buffer, 1 μl of T4 DNA ligase (3 Weiss 
Units/ μl) and lastly, 3 μl of the purified PCR product. The ligation reactions were 
performed overnight at 4°C.  
The following day, the ligation mixture was transformed into 100 μl of ultra-
competent E. coli cells (JM109) prepared using the Z-Competent™ E. coli 
Transformation Kit  (following manufacture’s instructions: ZYMO Research). 
Transformants were plated on ampicillin/X-Gal plates overnight at 37°C to allow blue-
white colony screening. Briefly, the pGEM®-T Easy vector contains the lacZ gene, 
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which encodes for β-galactosidase enzyme, an enzyme occurring in E.coli that cleaves 
lactose into glucose and galactose. In principle, functional β-galactosidase enzyme is 
produced due to α-complementation, a process that is disrupted in clones containing 
recombinant DNA. Functional β-galactosidase induces the hydration of X-gal (Thermo 
Fisher Scientific), which then produces an insoluble blue pigment called 5,5’-dibromo-
4,4’-dichloro-indigo, therefore successfully transformed clones that carry the gene of 
interest are the ones that form white colonies (Whitehouse 2014).  
Transformed white colonies were inoculated into 5 ml of Luria-Bertani (LB) 
broth supplemented with 5 μl ampicillin (50 mg/ml) (Sigma) and incubated overnight at 
37°C in an orbital shaker (225 rpm). The plasmids were extracted with QIAprep Spin 
Miniprep Kit (following manufacture’s instructions; QIAGEN®). Successfully cloned 
plasmids were confirmed with dye-terminator sequencing analysis performed by 
Dundee Sequencing Services.  
 
2.3.2/4 UV spectrophotometry 
The concentration of purified plasmid DNA was quantified by measuring 
Absorbance at 260 nm (A260) using NanoDrop 1000 UV spectrophotometer 
(ThermoScientific). The purity of DNA preparation (i.e. protein or ethanol 
contamination) was indicated by the A260/A280 ratio (ratios  > 1.8 were considered 
acceptable) 
 
2.3.2/5 Cloning into lentiviral transfer vectors  
The pdl’RSV/hNS1’IB lentiviral transfer vector was generated by extracting the 
RSV/hNS1 gene from pGEM®-T Easy vector and ligating it into the pdl’SV5V’IB 
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vector using the BamH1-NdeI restriction sites. The pdl.RSV.hNS2/NotI’IRES.puro and 
pdl.RBV.P/NotI’IRES.puro vectors were generated by cloning the RSV hNS2 and 
Rabies P gene sequences into the pdlNotI’IRESpuro vector using the BamH1-NotI 
restriction sites, which are present on the vector’s multiple cloning site (MCS). Typical 
restriction digest reactions were carried out following manufacturer’s instructions 
(Promega). The reactions were run on a 0.7 % [w/v] agarose gel, and the DNA bands 
that corresponded to the vector and insert molecular weight were excised from the gel, 
and purified using QIAquick Gel extraction kit (following manufacturer’s instructions; 
QIAGEN®). The concentration of the purified DNA fragments was measured using UV 
spectrophotometry. Ligations were carried out using T4 DNA ligase (Promega). A 
standard ligation reaction contained 100 ng of vector DNA, 1 μl of T4 DNA ligase, 1 μl 
10X ligase buffer, and the appropriate concentration of insert DNA was calculated using 
the following formula;  
 
 ng of insert =  [((ng of vector) x (kb size of insert)) / (kb size of vector)] x ( molar ratio 
of (insert/ vector))  
 
Deionized water was added to a final reaction volume of 10 μl. The reactions were 
incubated overnight at 4°C, and plasmid DNA was amplified, purified and sequenced, 
as previously described. For higher DNA concentrations, the lentivirus transfer vectors 
were extracted with the QIAGEN Plasmid Plus Maxi Kit (following manufacturer’s 
instructions; QIAGEN®), before using them for generating lentiviruses. 
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2.3.3 Lentivirus-mediated generation of A549.pr(IFN-β)GFP and 
A549.pr(ISRE)GFP derivatives that stably express viral IFN 
antagonists 
 
2.3.3/1 Transfection of 293T cells for lentivirus production  
 To generate lentivirus stocks, Lipofectamine® 2000 (Invitrogen) was used to 
transfect T75 flasks of 70% confluent Human Embryonic Kidney 293T cells with 10 μg 
of transfer vector, together with 6 μg of the CMV-R and 6 μg of the VSV-G packaging 
plasmids (following manufacturer’sinstructions; Invitrogen). The cells were incubated 
at 37°C for 5 hours with the transfection mix, and then the transfection mix was 
replaced with 10 ml of DMEM (10% [v/v] FBS). At 48h post-transfection the 
supernatant was collected, then clarified by centrifugation (3000 rpm, 15 mins) and 
filtration (45 μm filters). Lentivirus stocks were stored in 1 ml aliquots at -80°C.   
 
2.3.3/2 Lentiviral transductions of A549 reporter cells 
 The lentivirus stocks were used to generate reporter cell-lines expressing the gene 
of interest.  Therefore, T25 flasks of 50% confluent A549 reporter cells were transduced 
with 1 ml of lentivirus, 1ml of DMEM (serum free, antibiotic free) and polybrene (final 
conc. 8 μg/ml). The cells were incubated at 37°C for 2.5 hours, before adding 2 ml of 
DMEM (10% [v/v] FBS), and incubating at 37°C for 2 days. Selections with the 
appropriate antibiotic followed; selection with puromycin (2 μg/ml) lasts 2 days, 
whereas selections with blasticidin (10 μg/ml) lasts 4-6 days. The generated A549 
reporter cell-line derivatives were maintained under antibiotic selection until used for 
further experiments.   
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2.4 Characterization of reporter cell-line derivatives that 
stably express viral IFN antagonists 
 
2.4.1 SDS-PAGE gel electrophoresis  
One of the approaches used to evaluate the expression of the viral IFN 
antagonists in the reporter cell lines was western blot analysis. Before western blot 
analysis, proteins were separated by SDS-PAGE (sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE)). Specifically, cells were grown in 6-well 
plates until 90-100 % confluent monolayer, washed twice in phosphate buffered saline 
(PBS), and then lysed in 200 μl of disruption buffer (10M Urea, 20% [w/v] SDS, 15% 
[v/v], β-mercaptoethanol, 0.004 [w/v] bromophenol blue). Afterwards, cell lysates were 
sonicated in short 5 second pulses for 3-5 cycles and then heated for 10 minutes at 95°C 
to ensure the proteins are denatured.  The samples were loaded on 12% hand-cast 
polyacrylamide gels (30% Protogel), the recipe of which is shown in Table 2.4. Gels 
were run with 1X TGS running buffer (25mM Tris, 192mM glycine, 0.1% [w/v] SDS 
pH 8.3) at 110V for approximately 2 hours in Bio-Rad electrophoresis tanks. 
   Table 2.4 SDS-PAGE resolving and casting gel recipes  
Reagent 12 % 
Resolving Gel 
4% 
Stacking Gel 
30% Acrylamide (ProtoGel) 10 ml 1.3 ml 
Resolving Gel Buffer (0.375 M Tris-HCl, 
0.1% SDS, pH 8.8) OR 
Stacking buffer (0.125 M Tris-HCl, 0.1% 
SDS, pH 6.8 
6.25 ml 2.5 ml 
10% [w/v] Ammonium persulfate (APS) 250 μl 100 μl 
TEMED (Tetramethylethylenediamine) 25 μl 10 μl 
Water 8.475 ml 6.09 ml 
Total Volume (for four gels) 25 ml 10 ml 
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2.4.2 Western blot analysis  
After SDS-PAGE electrophoresis, the proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes using the Bio-Rad Trans-blot Turbo 
Transfer system with 1X NuPage transfer buffer (500 mM Bicine, 500 mM, Bis-Tris, 
20.5 mM EDTA). PVDF membranes were activated in 100% methanol prior to transfer. 
Following transfer, membranes were blocked for 1 hour at RT in PBS containing 5% 
[w/v] skimmed milk powder and 0.1% [v/v] Tween-20. The membranes were 
subsequently incubated with the appropriate primary antibody, which are all listed in 
Table 2.5. All the antibodies were diluted in blocking buffer. Afterwards, the 
membranes were washed 6 times for 5 minutes in PBS plus 0.1% [v/v] Tween-20 to 
remove any unbound primary antibody. For chemiluminescence, the membranes were 
incubated with secondary antibodies conjugated to horseradish peroxidase (HRP). 
Following a second round of washing with PBS 0.1% [v/v] Tween-20, enhanced 
chemilumescent (ECL) Pierce
TM
 western blotting substrate (LifeTechnologies) was 
added to the membranes for 5 minutes for the detection of horseradish peroxidase 
(HRP) enzyme activity. Finally, the membranes were exposed to X-ray film and 
developed using the KODAK X-OMAT 1000 processor. When Odyssey CLx has been 
used instead of chemiluminescence, the HRP-conjugated secondary antibodies were 
replaced with the LiCOR’s IRDye secondary antibodies. Membranes were imaged and 
bands quantified using the Odyssey CLx Imaging Suite (Image Studio) program.  
2.4.3 Immunofluorescence  
The expression of the viral IFN antagonist has been also evaluated by 
immunofluorescence. For immunofluorescence, the cells were grown on circular glass 
coverslips (1 mm thick).  Firstly, cells were rinsed thrice with 1 ml PBS (2% [v/v] FBS) 
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and then fixed with 1 ml of 5% [v/v] formaldehyde/PBS for 30 minutes. Then, the fixed 
cells were washed thrice with 1 ml PBS supplemented with 2% [v/v] FBS. The 
permeabilisation of the cell membranes was achieved by incubating the cover slips in 1 
ml of 0.1 % [v/v] Triton X/PBS for 20 minutes. Following another round of washing 
with 2% [v/v] FBS/PBS, 30 μl of primary antibody dilution in 2% [v/v] FBS/PBS was 
added onto the coverslips and left in darkness, at RT, for 1 hour. Following primary 
antibody incubation, the slides were washed thrice with 2% [v/v] FBS/PBS and then 30 
μl of secondary antibody dilution in 2% [v/v] FBS/PBS was added onto the cover slips 
and left in darkness, at RT, for 1 hour. DAPI (4', 6-diamidino-2-phenylindole) dye was 
added to the cells together with the secondary antibody diluted 1:1000. The slides were 
again washed twice with 2% [v/v] FBS/PBS and finally, drops of citifluor mounting 
buffer (Citifluor Ltd) were placed onto microscope glass slides and coverslips were 
gently inverted above them. The slides were observed with a Nikon Microphot-FXA 
immunofluorescence microscope and kept at 4°C after observation. All 
immunofluorescent pictures have been taken at 20X magnification, unless otherwise 
indicated.  
2.4.4 Induction of the IFN-β promoter or ISRE element 
In order to activate the IFN-β promoter, the A549.pr(IFN-β)GFP cell-line and its 
derivatives were infected with PIV5.VΔC (vM2) virus (2x108 Pfu/ml) at a MOI of 7 
(diluted 1:100 in DMEM (10% [v/v] FBS)) . Then, the cells were incubated for 24 
hours at 37°C, before measuring GFP expression. To activate the ISRE element, the 
A549.pr(ISRE)GFP cell-line and its derivatives were treated with 10
4
 U/ml of purified 
IFN- (Roferon, NHS) in DMEM (10%[v/v] FBS), and incubated for 48 hours at 37°C, 
before measuring GFP expression 
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The GFP expression was either observed with fluorescent microscopy or 
quantified using TECAN infinite® 200 plate reader. For visualizing GFP expression, 
cells were grown on coverslips until confluent monolayers, and then the appropriate 
inducer was added (PIV5-VC or IFN-). The induced cells were fixed with 5% [v/v] 
formaldehyde/PBS, and GFP expression was observed with a Nikon Microphot-FXA 
immunofluorescence microscope. All fluorescent pictures have been taken at 20X 
magnification, unless otherwise indicated. Furthermore, our cell-based reporter assay is 
adapted to a 96-well plate format, which allowed automated detection of GFP 
expression using the TECAN plate reader. In order to measure GFP fluorescent units, 
3x10
4
 cells were seeded in 100 μl DMEM (10 % [v/v] FBS) per well. The next day 
confluent monolayers were treated with the appropriate inducer, so that there were at 
least 3 repeats for each treatment. To measure GFP the excitation was set at 488 nm and 
emission at 518 nm, and the data was analyzed using the Magellan data analysis 
software. 
 
2.5 siRNA transfections for knocking out gene expression 
In order to knock out hNS2 expression in the A549.pr(ISRE)GFP-RSV/hNS2 
cell-line, siRNAs were designed against the mRNA sequence of RSV hNS2 protein 
(Table 2.5). For this experiments, we used a non-targeting siRNA (siNT), as a negative 
control (ON-TARGETplus Non-targeting siRNA, Dharmacon). The siRNAs were 
shipped as dried pellets of 20 nmol. The dried pellets were resuspended in 1ml of 1X 
siRNA buffer (ThermoScientific). The final concentration of the master stock was 20 
μM (pmol/μl), which was used to generate 100 nM working stocks in 1X siRNA buffer.  
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Table 2.5 siRNAs designed for knocking out expression of RSV hNS2 (Dharmacon/Thermo 
Fisher Scientific) 
Name siRNA sequence 
sihNS2  
Sense                5’ GCACCAAGUACAAGAAGUAUU 3 
Antisense  5’ UACUUCUUGUACUUGGUGCUU 3’ 
 
2.5.1 siRNA transfections using Lipofectamine® RNAiMax 
For siRNA transfections we used Lipofectamine® RNAiMax (Life 
Technologies). The RNA-lipid complexes were prepared first, and then the appropriate 
concentration of cells was added to the complexes. The following protocol is optimized 
for siRNA transfections in a 12-well plate. To generate the RNA-lipid complexes, 100 
μl of 100 nM siRNA (10 nM final conc.) was added to 100 μl of 1:100 lipofectamine 
RNAiMax (1:1000 final dilution) in serum free Opti-MEM® (Life Technologies). The 
plate containing the mixture was centrifuged for 1 min at 1000 rpm at RT to ensure 
solutions are at the bottom of each well and well mixed. The mixture was incubated for 
30 min at RT to allow time for RNA-lipid complexes to form. Afterwards, 800 μl of 
6x10
4
 cell/ml were added to the RNA-lipid complexes, and mixed well by pipetting up 
and down several times. The plates were incubated at 37°C/5% CO2 for 1-3 days, and 
the level of knock down was observed with western blot analysis.  
 
2.5.2 IFN treatment following siRNA transfections  
To assess restoration of GFP expression upon NS2 siRNA knockdown, cells 
were transfected with sihNS2, and then treated with IFN-α. The transfection procedure 
was the same as described above, however the assay volumes were adjusted to a 96-well 
plate. In particular, 10 μl of 500 nM siRNA was added to 10 μl of 1:100 lipofectamine® 
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RNAiMax in serum free Opti-MEM® (Life Technologies). In addition, we used higher 
concentration of cells, 3x10
5 
cell/ml instead of 6x10
4
 cell/ml to have the same cell 
density as our standard assay. Following siRNA transfections cells were incubated for 
24 hours at 37°C/5% CO2, and then treated with 10 μl of 1:10 (final conc. 9090.90 
U/ml) IFN-α (Roferon, NHS) for further 48 hours. The GFP expression levels were 
measured using TECAN plate reader, as described earlier, and fluorescent images were 
taken using IncuCyte cell imager at 10X maginification.  
 
2.6 Preparation of RSV stocks  
2.6.1 Virus propagation – Supernatant  
Multiple T175 cm
2
 flasks were infected for each virus stock and combined 
together at the final step for concentrating the virus. T175 cm
2
 flasks with 80-90% 
confluent Hep2-BVDV/Npro cells were infected with 20 ml of virus inoculum, which 
contained low MOI virus (MOI 0.01) diluted in 2% [v/v] FBS/DMEM containing 
pen/strep. The flasks were tightly closed and left rocking at 37°C without replacing the 
inoculum with fresh media. Flasks were checked under the microscope every day for 
cytopathic effect (CPE), and usually viruses were harvested three days after infection. 
For wtRSV, extensive cell death and syncytia were formed three days after infection. 
Similarly, RSV.ΔNS1 and RSV.ΔNS2 caused extensive cell death by the third day but 
the size of the syncytia was much smaller, when compared to the wild type (Figure 2.1). 
The procedure for harvesting the supernatant and concentrating the virus was 
conducted strictly at 4°C or on ice. Firstly, the 20 ml of media was collected from each 
flask and the attached cells were scraped into 10 ml of PBS. The scraped cells 
underwent two rounds of sonication (30 seconds each) using an ultrasonic bath 
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sonicator to release the virus particles that were attached to the cell surface, and 
therefore have not been released to the media. The sonicated cells were added to the 
harvested virus and centrifuged at 1200 rpm for 7 min to spin out the cell debris. The 
pelleted cell debris was discarded and the clarified supernatant was concentrated using 
polyethylene glycol (PEG) 6000. 
 
Figure 2.1 CPE of RSV infections three days after infection. wtRSV infection causes fusion 
of cells to from large syncytia, whereas RSV.ΔNS1 and RSV.ΔNS2 infections mostly result in 
cell death and rounded up cells.  
 
 
2.6.2 Virus propagation – PEG-6000 concentration  
To concentrate the virus, 50% [w/v] PEG-6000 was added to the supernatant to 
a final concentration of 10% [w/v] and stirred at 4°C for 1 hour. Then, the supernatant 
(+PEG-6000) was centrifuged at 4000xg for 30 min, and the pelleted virus was 
suspended in serum-free media (1ml per each flask). The concentrated virus sample was 
vortexed to ensure virions were evenly distributed throughout aliquot period. Virus 
stocks were aliquoted in 100 μl aliquots, which were snap-frozen with liquid nitrogen 
and stored immediately in -80°C freezer. The titers of the stocks were determined with 
plaque assays.  
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2.7 RSV plaque assays 
Hep2 naïve or Hep2-BVDV/Npro cells were seeded at a density of 2x105 
cells/ml in 12-well plates, 24 hours prior to infection to achieve 90-100% confluent 
monolayers. The RSV virus stocks were serially diluted (30 μl of virus stock in 270 μl 
serum-free DMEM) in dilutions ranging from 10
-1 
to 10
-7
. The dilution series were 
prepared in duplicate in 96-well plates. Growth media was removed and 100 μl of each 
virus dilution was added to the cells, starting from the highest to the lowest dilution.  
Plates were incubated for 1 hour at 37°C/5% CO2, and gently shaken every ten minutes 
to ensure coverage. Then, the virus inoculum was aspirated and 1 ml of methylcellulose 
overlay was added to each well (0.5% [v/v] methylcellulose, 2% [v/v] FBS DMEM 
containing pen/strep). Plates were incubated at 37°C/5% CO2 with as little movement as 
possible for 4-7 days or until syncytia were visible. The cells were fixed by adding 1 ml 
of 10% [v/v] formaldehyde/PBS at the top of the overlay. After 1 hour incubation at RT, 
the fixative was poured off and replaced with PBS.  At this step, plates were stored at 
4°C, if they were not directly used for immunostaining.  
 
2.7.1 HRP-based Immunostaining  
Prior immunostaining, cells were washed with PBS three times to remove all 
traces of overlay and fixative. Then, 250 μl of blocking buffer (5% [w/v] dried skimmed 
milk in PBS) was applied on each well and the plate was incubated with rocking for 30 
min to 1 hour at RT or overnight at 4°C. Blocking buffer was removed and 200 μl of a 
mouse anti RSV fusion antibody (AbD Serotec) diluted 1:250 in blocking buffer was 
added to each well, and the plate was incubated with rocking for 1 hour at RT. Then, 
primary antibody was removed and wells were washed three times with PBS before 
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adding 200 μl per well of anti-mouse HRP antibody (Sigma-Aldrich) diluted 1:1000 in 
blocking buffer. Plates were incubated with rocking for 1 hourat RT, and then 
secondary antibody was removed and PBS washes were repeated. The secondary 
antibody was detected with the 4 CN peroxidase substrate system (KPL), which was 
prepared just before use by combining equal volumes of 4 CN Peroxidase Substrate and 
Peroxidase Substrate Solution B (1:1 solution). Then, 200 μl of the peroxidase substrate 
solution was added in each well, and the plate was incubated with rocking at RT until 
purple plaques become visible, usually 10 min after substrate addition.  Plaques were 
counted using microscope to ensure accurate counting of the plaques. Then, virus titers 
(PFU/ml) were calculated using the following formula:  
 
Virus titer (Pfu/ml) = (number of plaques) / ((dilution factor) x (volume of diluted virus 
added to the well)) 
 
2.8 RSV infections  
Monolayers of cells were infected with virus suspended in 2% [v/v] 
FBS/DMEM at an appropriate MOI. Monolayers were washed prior to infection in PBS 
to remove all traces of serum. During the adsorption period, low-volume virus inoculum 
(50 μl/ well, for a 24-well plate) was added to the cells for 1h on a rocking platform at 
37°C, and then 2% [v/v] FBS/DMEM was added to a maximum volume of 400 μl/well 
(for a 24-well plate), without removing the inoculum. Cells were incubated at 37°C/5% 
CO2 until harvested.  
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2.9 Performance of a HTS approach to target RSV NS2  
2.9.1 Assay Development  
The quality and robustness of our assay has been validated at a 96-well plate 
format, and then it was further miniaturized to a 384-well plate format (Figure 2.2), 
using in-house screening equipment. The protocol of the 96-well and 384-well plate 
assay is shown in Table 2.6. These experiments did not require addition of any chemical 
compounds; hence the low signal controls were as indicated in Figure 2.2, whereas the 
rest of the wells were all treated with interferon for 48 hours to assess the variation in 
GFP signal along the plate. For the 96-well plate assay, 3x10
5
 cells/ml were seeded in 
100 μl DMEM (10 % [v/v] FBS) per well, in clear 96-well microplates (Greiner Bio-
one), using a microplate dispenser (WellMate, Thermo Scientific). The next day, 10 μl 
of 1:10 IFN-α (Roferon, NHS) diluted in 10 % [v/v] FBS/DMEM (final dilution 1:110) 
was added to the columns 2-11 using the WellMate cell dispenser. Plates were spun 
down at 1200 rpm at RT for 30 seconds, and then incubated at 37°C/5% CO2 for 48 
hours. On the last day of the assay, the cells were fixed with 100 μl of 10 % [v/v] 
formaldehyde/PBS (5 % [v/v] final conc.) for 20 minutes, washed under running water, 
and dried on paper towels. Then, 100 μl PBS added in each well, and GFP fluorescent 
units were measured using the TECAN plate reader. Once GFP readings were taken, all 
the wells were stained with 50 μl 0.15% [w/v] crystal violet for 30 minutes, and the 
absorbance (A650 nm) was measured using TECAN plate reader. The dispensing of 
formaldehyde, PBS and crystal violet was carried out using the WellMate cell 
dispenser.  
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Figure 2.2 Schematic presentation of the 96-well (top plate) and 384-well (bottom plate) 
format of our HTS assay. Columns 1 (96-well plate)/Columns 1 and 2 (384-well plate): (+) 
IFN controls, these wells were treated with IFN only (high signal controls). Columns 2-11(96-
well plate) / Columns 3-22 (384-well plate): Testing wells, these wells were treated with 11.42 
μΜ of compound for 2 hours and then treated with IFN for 48 hours. Column 12 (96-well plate) 
/ Columns 23 and 24 (384-well plate): Low signal controls, these wells had no treatment. 
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The exact same procedure was followed for the 384-well plate assay, however 
the concentration and volumes of the reagents were adjusted to a lower density format, 
as shown on Table 2.6.  
Table 2.6 Protocol of 96-well and 384-well plate formats of the A549 reporter assay 
Day Description 96-well format 384-well format 
 
Day 1 
Cell plating  3 x 10
4 
cells/well  
Total Volume in each 
well: 100 μl 
1.12 x 10
4 
cells/well  
Total Volume in each 
well: 50 μl 
 
Day 2 
IFN treatment for 48 hours 
(Roferon A/NHS, 1x10
6
 
units /ml) 
10 μl of 1:10 dilution / 
well (final conc. 
9090.90 U/ml ~10
4 
U/ml
 
) 
20 μl of 1:40 dilution / 
well (final conc. 
7142.85 U/ml) 
 
 
Day 4 
Fix plates for 20 min 100 μl of 10% [v/v] 
formaldehyde/PBS 
fixing buffer  
23 μl of 20% [v/v] 
formaldehyde/PBS 
fixing buffer 
Wash and read plates  Washes with water, 
read in 100 μl PBS 
Washes with water, 
read in 20 μl PBS 
Crystal Violet Staining for 
20 min to assess cell 
viability  
50 l 0.15% [v/v] 
crystal violet stain  
15 l 0.15% [v/v] 
crystal violet stain 
 
2.9.1/1 Statistical Validation/ Data analysis 
The performance of our HTS assay was quantified with three statistical parameters: 
(i) the signal to background ratio (S/B), which it is also known as fold increase in 
signal, (ii) the signal variability as indicated by the percentage of coefficient of variation 
(%CV), (iii) the Z’ factor, which is a measure of statistical effect size that takes into 
consideration both signal window and signal variability of negative and positive 
controls. Statistical parameters were calculated using the following formulas;  
 
i) Fold increase (S/B) = μ (experimental FU value) / μ (background FU value),  
where FU stands for fluorescent units, μ stands for mean 
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ii) % CV = % (σ / μ),  
where μ stands for mean, and σ for standard deviation.  
 
iii)       Z’ factor = 1 – [(3 (σp + σn)) / | μp – μn|],  
where μ stands for mean, σ for standard deviation, p for positive control and n for 
negative control.  
 
The quantitative assessment of assay quality was based on the Dundee’s Drug 
Discovery Unit (DDU) quality control (QC) guidelines, according to which an excellent 
and robust cell-based HTS assay should have S/B ratio > 2.5, %CV < 10% and Z’ factor 
> 0.5. The Z’ factor is a dimensionless statistical parameter that has a range of 0 to 1. 
For an assay to be considered appropriately robust for compound screening, the Z’ 
factor has to be greater than 0.5 (Zhang 1999; Hughes et al., 2011). 
 
2.9.2 In-house HTS to identify inhibitors of RSV NS2 IFN antagonist  
To identify small molecule inhibitors of the RSV NS2 protein, the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line was subjected to HTS using an in-house 
chemical library, the Maybridge 16,000 compound library, which was kindly provided 
by Professor Nick Westwood (University of St Andrews, UK). The compound library 
consisted of fifty 384-well plates, hence the screen was carried out into five batches of 
ten plates to minimize handling error. The protocol of our screen is summarized in 
Table 2.7. HTS requires large number of cells, therefore A549.pr(ISRE)GFP-
RSV/hNS2 cells were grown into T175 cm
2
 tissue culture flasks. On the first day of the 
assay, cells were split using 0.48 mM EDTA to avoid over-trypsinizing the interferon 
receptors on cell surface.  Then, cells were seeded in barcoded black 384-well cell bind 
plates (Greiner Bio-one) at a density of 1.12 x 10
5
 cells/ml in 50 μl 10 % [v/v] 
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FBS/DMEM per well. Throughout the assay, plates were incubated in stacks of three in 
an incubator used only for HTS to minimize the probability of getting incubator related 
plate patterns, such as edge effects. The next day, 80 nl of compound was added to each 
well (final screening concentration 11.42 μΜ) using an automated liquid-handling robot 
(MiniTrak
TM
). The compounds were added to columns 3-22 of each plate, whereas 
columns 1-2 and 23-24 were the no compound controls (Figure 2.2). Plates were 
incubated at 37°C/5% CO2 for 2h and then, 20 μl of 1:40 IFN-α ((final conc. 7142 U/ml)) 
was added to the columns 1-22 using a microplate dispenser (WellMate, Thermo 
Scientific). To make sure that the reagents were well mixed, the plates were spun down 
at 1200 rpm for 30 seconds at RT, and then incubated at 37°C/5% CO2 for 48 hours. 
Afterwards, cells were fixed with 20 μl of 20% [v/v] formaldehyde/PBS (5% [v/v] final 
conc.) using the WellMate dispenser. Plates were left at RT for 20 min and then, the 
fixative was removed and plates were washed under running water. Water residues were 
removed by drying plates on tissue paper. Then, 50 μl of PBS were added in every well 
using the WellMate dispenser. GFP expression levels were measured using the TECAN 
microplate reader, and analyzed using the Magellan data analysis software. Cell 
viability was assessed after staining the wells with 20 μl of 0.15 % [w/w] crystal violet 
for 30 min. Plates were washed with water, and let to dry on tissue paper, before 
measuring the crystal violet absorbance (A6500 nm) using the TECAN microplate 
reader.  
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Table 2.7 Protocol of a 384-well format cell-based HTS assay 
Step Parameter  Value  Description  
1 Plate cells  50 μl  A549.pr(ISRE)GFP-RSV/hNS2
 
Incubation time  18 h 37°C / 5% CO2 
2 Compound Addition  80 nl  1: 875 dilution 
Centrifugation  30 sec  1200 rpm at RT 
Incubation time  2 hours 37°C / 5% CO2 
3 Interferon treatment  20 nl  1: 40 dilution 
Centrifugation  30 sec  1200 rpm  
Incubation time  48 h 37°C / 5% CO2 
4 Fix plates  23 μl  40% Formaldehyde/PBS 
Incubation time  20 min RT  
5 Assay readout – GFP 
signal  
 
488 nm / 
518 nm 
TECAN plate reader  
6 Cell viability assay  15 μl 0.15% Crystal violet stain  
Incubation time  20 min RT  
Assay readout – 
Absorbance  
650 nm  TECAN plate reader 
Step Notes 
1 Cell seeded at a density of 1.12x10
5 
cells/ml in Greiner Bio-one black 384-well 
cell bind plate. 
2 Library concentration was 10 mM and screen was conducted at 11.42 μΜ. 
Compounds were added to the columns 3-22, using the MiniTrak Robot.  
3 IFN-α (Roferon, NHS) has a concentration of 10
6 
U/ml and it was added to the 
cells at a final dilution of 1:140, which is equal to 7142.85 U/ml. IFN-α 
(Roferon, NHS) was added to the columns 1-22.  
4, 5 After fixing, plates were washed with water and GFP readings were taken in 20 
μl of PBS. 
6 Plates were left to dry overnight before A650 readings were taken.  
1, 3,4,6 All liquid transfers were carried out using the WellMate microplate dispenser 
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2.9.2/1 Statistical validation of primary screen  
The statistical validation of the HTS assay was performed using the three 
statistical parameters described in the Section 2.9.1/1, and hit selection was performed 
on the plates that passed the QC criteria. Hit compounds that had a percentage (%) 
effect in fluorescent signal 50% above the assay control were selected. In addition to the 
% effect, hits were designated as molecules that restored GFP expression ≥3 standard 
deviations (SD) (Z-Score= 3) above the sample signal mean, which was calculated 
using the following formula;  
 Z-Score = (X-μ)/σ  
where X is the raw signal, μ is the mean GFP signal of all the compound-containing 
wells of one plate, and σ is the standard deviation of all compound containing wells of 
one plate. 
 
2.9.2/2 Hit validation  
2.9.2/2.1 Dose-response analysis 
After running a primary screen, the selected hits were tested at various 
concentrations and plotted against the GFP signal to test whether they form good dose-
response curves.  For those hits that had a sigmoidal function, the half maximal 
effective concentration (EC50) was calculated using the Hill equation, which is a four-
parameter logistic equation;  
Y= B + [(T-B) / (1 +  (EC50 / X)
h
] 
A standard dose-response curve is defined by four parameters, namely B: baseline 
response (bottom asymptote), T: maximum response (top asymptote), h: slope (hill 
slope or hill coefficient), and the EC50 value, which is the drug concentration that 
Chapter 2:  
Material and Methods  
80 
 
provokes a response halfway between baseline and maximum (Goktug et al., 2013). In 
this study, the EC50 values were calculated using Prism Software (GraphPad).  
 
2.9.2/2.2 Testing the stability of the compounds’ activity  
To assess the activity of hit compounds over time, 10 μΜ of compound or 
0.05% [v/v] DMSO was added to T25 cm
2
 flasks containing either 50-60% confluent 
A549 naïve cells in 8 ml of 10 % [v/v] FBS/DMEM or plain growth media. A 400-μl 
sample was collected from each flask every day for a week and stored at -80°C. On the 
eighth day of the experiment, 100 μl of each sample was added into 96-well plates (3 
wells for each condition) containing A549.pr(ISRE)GFP-RSV/hNS2 cells. The 
compounds were incubated with the cells for 2 hours, and then cells were treated with 
IFN-α (Roferon, NHS), as described in Section 2.4.4. The activity of the compounds 
was assessed in regards to their ability to restore the GFP expression levels in the 
A549.pr(ISRE)GFP-RSV/hNS2 cells. The GFP restoration mediated by fresh 
compound (10 μΜ) was set as the maximum restoration activity for each compound. 
After GFP fluorescent units were measured, the cell density in each well was observed 
with crystal violet (A650 nm) and GFP expression was normalized based on cell 
density.  
 
2.9.2/2.3 Testing the compounds’ toxicity  
The compounds’ toxicity was tested using AlamarBlueTM cell viability assay 
(following manufacture’s instructions; ThermoScientic). This assay quantitatively 
measures the viability of mammalian cell-lines, based on their ability to metabolically 
process the oxidized form of AlamarBlue reagent (non-fluorescent blue) to the reduced 
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form of AlamarBlue reagent (fluorescent red). The oxidized AlamarBlue reagent is 
100% reduced in metabolically active healthy cells. The AlamarBlue assay was 
performed in a 96-well plate format. In particular, A549.naïve cells and 
A549.pr(ISRE)GFP-RSV/hNS2 cells were seeded at a density of 3x10
4
 cells/well 
(100μl total volume / well) leaving column 12 empty. Column 12 was left for the 100% 
reduced and the 0% reduced controls, which were added in triplicate at the end of the 
assay. The 100% reduced AlamarBlue control was prepared after autoclaving 10 % 
[v/v] AlamarBlue/ 10% [v/v] FBS/DMEM, whereas the 0% [v/v] reduced AlamarBlue 
control was non-autoclaved 10% [v/v] AlamarBlue/ 10% [v/v] FBS/DMEM. A negative 
control of only medium without cells was also added to determine background signal 
(column 11). To construct dose-response curves, compounds were serially diluted (2-
fold dilutions starting at 50 μM) on the cells and incubated for 48 hours (columns 2-10). 
After incubation, oxidized AlamarBlue reagent was added at the top of each well to a 
final concentration of 10 % [v/v]. The AlamarBlue reagent was incubated with the cells 
for 4 hours at 37°C, and fluorescent units were measured with excitation wavelength at 
545 nm and emission wavelength at 590 nm, using the TECAN plate reader. The % 
reduction of AlamarBlue was calculated using the following formula;  
 
% Reduction of AlamarBlue reagent = 100 X [(Experimental FU value – Negative 
control FU value) / (100% reduced positive control FU value - Negative control FU 
value)],  
 
where FU stands for fluorescent units 
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2.9.2/2.4 Testing hit compounds activity in regards to their impact on RSV growth  
The compounds’ impact on RSV growth was tested using plaque assays and 
growth curves. The plaque assays were carried out as described in Section 2.7. In order 
to assess the effect of the compounds on RSV plaque size and number, 10 μΜ of the 
tested compound was added into the 0.5% [v/v] methylcellulose overlay. In addition, 
RSV growth kinetics were performed in A549 naïve cells in the absence or the presence 
of the hit compounds, as described before by Stewart et al., (2014). In particular, A549 
naïve cells were seeded in T25 flasks, so that they were 80-90% confluent on the next 
day. Flasks were infected with 1 ml of RSV (A2 or Long strain) at a MOI of 0.01 in 2% 
[v/v] FBS/DMEM. The flasks were tightly closed, and gently shaken for 3 hours at 
37°C to facilitate virus spread and attachment. Afterwards, the inoculum was removed, 
and the cells were washed 5 times with PBS to ensure that non-attached virus particles 
were removed. Once cells were washed, they were treated with 5 ml of 10% [v/v] 
FBS/DMEM containing 10 μl of the tested compounds or equivalent volume of DMSO 
(0.05% [v/v]). At various times post infection the amount of infectious virus in the 
culture medium was estimated (Pfu/ml) by plaque assays on Hep2-BVDV/Npro cells, as 
described in Section 2.7.  
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Chapter 3: Development of a modular cell-based 
HTS assay to target viral IFN antagonists for 
drug discovery  
 
3.1 Introduction  
All viruses, studied to date, encode at least one viral IFN antagonist, which is 
used to counteract the cellular IFN system, a powerful antiviral innate immune 
response. Viral IFN antagonists circumvent the IFN response using an astonishing 
repertoire of functions. Numerous genetic studies, both in cell culture and animal 
models, have demonstrated that knockout of viral IFN antagonist function is a critical 
determinant of viral replication, virulence and pathogenicity. Inhibition of viral IFN 
antagonist function impedes a virus’ ability to counteract the cellular IFN response, 
predisposing infection outcome in favor of the host and consequently viral clearance. 
Hence, this vital class of viral proteins represents a diverse plethora of novel 
therapeutics targets that are not generally targeted by traditional antiviral approaches. 
 
3.1.1 Overview of assay concept  
We have embarked on a project to develop a cell-based HTS platform that will 
allow us to identify inhibitors of specific targeted viral IFN antagonists of choice. Prior 
to this study, two A549 reporter cell-lines have been developed by members of the 
Randall/Adamson group, which represent the foundation of our screening platform. The 
A549 reporter cell-lines have a fluorescent reporter gene (GFP) under the control of the 
IFN-β promoter or the ISRE element, and are named; A549.pr(IFN-β)GFP (Chen et al., 
2010) and A549.pr(ISRE)GFP, respectively. Therefore, the A549.pr(IFN-β)GFP and 
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A549.pr(ISRE)GFP reporter cell-lines provide a straightforward method to monitor 
activation or inhibition of either the IFN-induction or IFN-signalling pathway by 
measuring GFP expression (Figure 3.1).  
 
 
Figure 3.1 Schematic overview of the assay concept in three basic steps. Step 1: 
Development of GFP reporter cell-lines that allow monitoring of the IFN-induction or IFN-
signalling pathways (A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP). Step 2: Expression of a 
viral IFN antagonist (X) will suppress the cellular IFN induction and/or signalling, and hence 
block the GFP expression in the A549.pr(IFN-β)GFP and/or A549.pr(ISRE)GFP reporter cell-
line. Step 3: A small molecule inhibitor will block the function of the viral IFN antagonist (X) 
against the cellular IFN induction or/and signalling and will eventually restore GFP expression 
in the reporter assay. 
 
 In this study, we further developed these reporter cell-lines by generating 
derivatives that expressed viral IFN antagonists of clinically important viruses for which 
there is a need for new antiviral drugs (Figure 3.1). We hypothesized that the ability of a 
reporter cell to produce GFP would be reduced when a viral IFN antagonist is 
expressed, because viral IFN antagonists block cells’ ability to produce and/or respond 
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to IFNs. A small molecule that inhibits the viral IFN antagonist would suppress the 
antagonist’s function against the cellular IFN system and would increase GFP 
expression in the reporter cell-line. Therefore, reporter cell-lines that express viral IFN 
antagonists would facilitate the identification of small molecules that inhibit viral IFN 
antagonists and subsequently restore GFP expression (Figure 3.1). Any small molecule 
inhibitors identified would allow us to validate viral IFN antagonists as suitable drug 
targets and could represent starting molecules for future antiviral drug development. 
Furthermore, inhibitors of viral IFN antagonists could also be utilized as research tools 
to better understand the function of these critical viral proteins and explore their role in 
virus replication. 
 
3.2 Results  
3.2.1 Verification of A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP 
reporter cell-lines 
 
In order to verify the A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP reporter cell-
lines, we quantified the ability of the reporter cell-lines to produce GFP fluorescent 
signal following addition of the appropriate inducer (Figure 3.2). The IFN-β promoter 
was activated using a genetically modified PIV5 virus, which expresses a truncated 
form (deletion of C terminus) of the V protein (PIV5.VΔC) and therefore has lost its 
ability to counteract the IFN-induction pathway (Chen et al., 2010). As expected, 
PIV5.VΔC infection led to activation of the IFN-β promoter and subsequently induced 
GFP expression in the A549.pr(IFN-β)GFP cell-line, whereas the uninfected cells did 
not produce GFP, as observed by fluorescent microscopy (Figure 3.2/A). The average 
background fluorescent signal in the A549.pr(IFN-β)GFP cell-line was 7821 fluorescent 
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units, which was increased to 13929 following PIV5.VΔC infections, resutling in a fold 
increase in GFP expression equal to 1.8 (Figure 3.2/B).  
 
 
Figure 3.2 Verification of A549.pr(IFN-β)GFP (A-B) and A549.pr(ISRE)GFP reporter 
cell-lines (C-D). The A549.pr(IFN-β)GFP cell-line was infected with PIV5.VΔC virus (~MOI 
7) for 24 hours for activating the IFN-β promoter. The A549.pr(ISRE)GFP was treated with 
purified IFN-α (104 U/ml) for 48 hours to activate the ISRE element. Following induction of the 
IFN-β promoter or ISRE element, GFP fluorescent units were observed with fluorescent 
microscopy (A and C) or quantified using TECAN plate reader (B and D). Graphs present mean 
values (n=8) with standard deviations (SD). Statistical analysis was performed using unpaired t-
test, ****p<0.0001 (Prism/GraphPad). 
 
The IFN-signalling pathway was activated following 48-hour incubation with 
IFN-/, which signals through the IFNAR receptor to activate the ISRE element. 
Similar to the A549.pr(IFN-β)GFP cell-line, fluorescent microscopy showed that the 
   
A          B 
 
 
 
 
 
           
 
C          D 
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A549.pr(ISRE)GFP cell-line produced high GFP expression in response to IFN-/ 
treatment, whereas the untreated cells did not produced GFP (Figure 3.2/C). 
Quantification of GFP fluorescent signal showed a significant increase in GFP 
expression when A549.pr(ISRE)GFP was treated with IFN-/ (Figure 3.2/D). 
Specifically, the average background signal in A549.pr(ISRE)GFP was 8268 
fluorescent units, and following IFN-/ treatment the fluorescent signal was increased 
to 27796, corresponding to a fold increase in GFP expression equal to 3.4 (Figure 
3.2/D). In conclusion, both A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP produced high 
GFP expression following addition of the appropritate inducer, confirming that these 
reporter cell-lines represent a powerful method for monitoring activation of IFN-
induction and IFN-signalling pathways.  
 
3.2.2 Verification of assay controls; A549.pr(IFN-β)GFP and 
A549.pr(ISRE)GFP derivatives that constitutively express BVDV/Npro 
or PIV5/V  
 
The aim of this study was to generate derivatives of A549 reporter cell-lines that 
express viral IFN antagonists of clinically important viruses and further utilized them 
for HTS to identify small molecule inhibitors that suppress their function. We reasoned 
that expression of viral IFN antagonists would reduce GFP expression in the 
A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP cell-lines. To assess this, we used 
genetically modified reporter cell-lines that stably expressed viral IFN antagonists with 
well-documented anti-IFN properties. These were the BVDV Npro and the PIV5 V 
proteins, which were used as controls in our study. A variant of the A549.pr(IFN-β)GFP 
reporter cell line that stably expressed BVDV/Npro has been generated and verified 
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prior to this project by members of the Randall group  (Chen et al., 2010). In brief, 
BVDV/Npro is the N-terminal protease (Npro) encoded by the BVDV polyprotein, 
which targets IRF3 for proteasomal degradation (Hilton et al., 2006). Thus, when 
BVDV/Npro is expressed, the activation of the IRF3 downstream immune effectors is 
blocked. Expression of BVDV/Npro was detected using the V5 epitope tag, which is 
fused to its N-terminus (Figure 3.3/A). The effect of BVDV/Npro on the activation of 
IFN-β promoter was measured with regards to GFP expression (Figure 3.3/B and 
3.3/C). Specifically, A549.pr(IFN-β)GFP-BVDV/Npro reporter cell-line did not 
produce GFP following PIV5.VΔC infections, indicating that BVDV/Npro suppressed 
the PIV5.VΔC-induced activation of the IFN-β promoter in the A549.pr(IFN-β)GFP-
BVDV/Npro reporter cell-line (Figure 3.3/B). Quantification of GFP fluorescent units 
showed that GFP production was dramatically inhibited (95% reduction) in 
A549.pr(IFN-β)GFP-BVDV/Npro compared to the  naïve A549.pr(IFN-β)GFP reporter 
cell-line (Figure 3.3/C).  
In order to generate a similar control variant of the IFN-signalling cell-line, we 
created a derivative of A549.pr(ISRE)GFP that constitutively expressed PIV5 V protein 
(Figure 3.3/B). Broadly, PIV5 V protein antagonizes the IFN-signalling by targeting 
STAT1 for proteasome-mediated degradation, and subsequently blocks the ISRE-
induced transcription of ISGs (Didcock et al., 1999). Similar to the BVDV/Npro-
expressing cell-line, expression of PIV5 V completely blocked GFP expression in the 
A549.pr(ISRE)GFP-PIV5/V cell-line, as none of the cells produce GFP in response to 
IFN-α treatment (Figure 3.3/E). Quantification of the GFP fluorescent signal showed 
that PIV5 V completely blocked activation of the ISRE element in the 
A549.pr(ISRE)GFP-PIV5/V  cell-line,   resulting   into   complete   inhibition   of   GFP  
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fluorescent signal (100% reduction) compared to the naïve A549.pr(ISRE)GFP reporter   
cell-line   (Figure 3.3/F). Overall, GFP fluorescent levels were totally blocked by 
BVDV/Npro  and  PIV5/V  expression,  indicating  sufficient  inhibition of  both   IFN-
induction and IFN-signalling pathways in our reporter assay. 
To further characterize the A549.pr(ISRE)GFP-PIV5/V cell-line, the 
functionality of PIV5 V was tested based on its ability to reduce MxA expression 
(Figure 3.4). In brief, ISRE elements are present within the promoters of ISGs, and 
thereby ISRE activation regulates their transcription. The ISRE element used for 
generating the A549.pr(ISRE)GFP reporter cell-line is part of the promoter of MxA, 
which is an IFN-induced GTPase with reported antiviral activity against a wide range of 
viruses (Haller & Kochs 2011). Thus, MxA and GFP expression are under the control of 
the same promoter in the A549.pr(ISRE)GFP reporter cell-line. MxA expression was 
highly upregulated in the A549.pr(ISRE)GFP cell-line following IFN-α treatment, 
whereas, similar to GFP expression, MxA expression was completely blocked in the 
A549.pr(ISRE)GFP-PIV5/V cell-line (Figure 3.4). Taken together, this data suggests 
that we successfully developed a control variant of A549.pr(ISRE)GFP that stably 
expresses PIV5 V protein, which completely suppresses activation of the IFN-
signalling, as determined by measuring GFP signal and MxA expression.  
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Figure 3.3 Characterization of A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP derivatives 
that constitutively express BVDV/Npro and PIV5/V. (A-B) Western blot analysis shows 
expression of BVDV/Npro and PIV5/V in the A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP 
reporter cell-lines, respectively. (C-D) GFP expression in A549.pr(IFN-β)GFP-BVDV/Npro 
cell-line following infections with PIV5.VΔC (1:100 dilution) for 24 hours was observed using 
fluorescent microscopy and quantified using TECAN plate reader. (E-F) GFP expression in the 
A549.pr(ISRE)GFP-PIV5/V cell-line following treatment with purified IFN-α (104 U/ml) for 48 
hours was observed using fluorescent microscopy and quantified using TECAN. Graphs are 
presented as percentage (%) of GFP expression relative to A549.pr(IFN-β)GFP and 
A549.pr(ISRE)GFP, which were set as 100% controls, respectively. Bars represent mean values 
(n=4) and error bars show SD. Statistical analysis was performed using unpaired t-test, *p<0.05, 
**p<0.001 (Prism/GraphPad). 
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Figure 3.4 Effect of PIV5 V on MxA expression upon activation of the IFN-signalling 
pathway. MxA expression was observed using Odyssey CLx imager, following 16-hour 
treatment with purified IFN-α (2000 U/ml).  Expression of PIV5 V protein was detected using 
anti-V5 antibody.  
 
 
3.2.3 Proof-of-principle data demonstrating that our cell-based assay is 
suitable for identifying small molecules that inhibit the function of 
targeted viral IFN antagonist.  
 
To generate proof-of-principle data, we exploited HCV NS3.4A protease 
inhibitors (PIs), the only clinically approved drug class that target a viral IFN 
antagonist. NS3.4A is essential for HCV replication as it mediates cleavage of the viral 
polyprotein; it also antagonizes the IFN-induction pathway by cleaving the signalling 
adaptors MAVS and TRIF at Cys-508 and Cys-372 residues, respectively (Meylan et 
al., 2005; Lin et al., 2006; Li et al., 2005). In order to test our hypothesis that inhibitors 
of viral IFN antagonists can be identified via GFP restoration, we utilized an 
A549.pr(IFN-β)GFP derivative that constitutively expresses HCV NS3.4A protease of 
genotype 1b (A549.pr(IFN-β)GFP-HCV/NS3.4A(1b)), which was previously made by 
Dr Catherine Adamson (Figure 3.5).  
Chapter 3:  
Development of a modular cell-based HTS assay to target viral IFN antagonists for drug discovery  
92 
 
Figure 3.5 Characterization of the A549.pr(IFN-β)GFP-HCV/NS3.4A(1b) reporter cell-
line (A) Western blot analysis shows expression of NS3.4A(1b). Expression of NS3.4A(1b) was 
detected with anti-V5 antibody and visualised with Advansta WesternBright ECL HRP 
substrate (Advansta). (B) GFP expression in the A549.pr(IFN-β)GFP-NS3/4A(1b). The cells 
were infected with the PIV5.VΔC virus (~MOI 7) for 24 hours and afterwards GFP expression 
was observed with fluorescent microscopy and quantified using the TECAN plate reader. The 
graph is presented as percentage (%) of GFP expression relative to A549.pr(IFN-β)GFP, which 
was set as 100% control. The bars show mean values (n=4) and error bars represent SD. 
Statistical analysis was performed using unpaired t-test, *p<0.05 (Prism/GraphPad). 
 
 
 
Prior to using the A549.pr(IFN-β)GFP-HCV/NS3.4A(1b) cell-line to generate 
proof-of-principle data, expression of NS3.4A(1b) was confirmed by western blot 
analysis (Figure 3.5/A). The V5 epitope tag that is fused to the C-terminus of 
NS3.4A(1b) was used for detection. Since the NS3.4A protease is a non-covalent 
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heterodimer, the anti-V5 antibody detected only the NS4A protein, which is a small 
protein around 6 kDa (Figure 3.5/A). In addition, we tested the level of GFP expression 
in the A549.pr(IFN-β)GFP-HCV/NS3.4A(1b) cell-line (Figure 3.5/B). Interestingly, 
only a few GFP positive cells were detected in the A549.pr(IFN-β)GFP-
HCV/NS3.4A(1b) cells after infection with PIV5.VΔC (Figure 3.5/B). In agreement 
with fluorescent microscopy, quantification of GFP fluorescent units showed that GFP 
expression was reduced to 18% in the A549.pr(IFN-β)GFP- HCV/NS3.4A(1b) cell-line 
compared to A549.pr(IFN-β)GFP (Figure 3.5/B). This data indicates that NS3/4A 
protease effectively antagonizes the IFN-induction pathway, mediating a significant 
reduction in the activity of the ΙFN-β promoter, and subsequenly blocking GFP 
expression in our reporter assay.  
To assess GFP restoration in A549.pr(IFN-β)GFP- HCV/NS3.4A(1b) cell-line, 
we utilized Danoprevir  (ITMN-191/RG7227), which is a genome-specific inhibitor of 
HCV NS3.4A. Danoprevir was serially diluted against the A549.pr(IFN-β)GFP- 
HCV/NS3.4A(1b) reporter cell-line and the level of GFP expression was measured 
following PIV5.VΔC infection (Figure 3.6). As observed previously, A549.pr(IFN-
β)GFP expressed high GFP expression after PIV5.VΔC infection, whereas GFP signal 
was considerably reduced in the A549.pr(IFN-β)GFP-HCV/NS3.4A(1b) cell-line, 
compared to A549.pr(IFN-β)GFP (Figure 3.6). Danoprevir had no effect on the level of 
GFP produced by the A549.pr(IFN-β)GFP cell-line after infection with PIV5.VΔC 
(Figure 3.6). In contrast, Danoprevir suppressed the ability of NS3.4A(1b) to antagonize 
the IFN-induction pathway, and increased GFP expression in the A549.pr(IFN-β)GFP-
HCV/NS3.4A(1b) cell-line, in a concentration-specific manner (Figure 3.6). In 
particular, Danoprevir concentrations above 50 nM (log10= 1.69) gradually blocked the 
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activity of the IFN antagonist, resulting in a dose-specific increase in GFP fluorescent 
signal. Drug concentrations above 5 μM  (log10= 3.69) caused up to 69.65% restoration 
of GFP expression, indicating that Danoprevir strongly inhibited the antagonistic 
function of NS3.4A(1b) against the IFN-induction pathway (Figure 3.6). Overall, we 
generated proof-of-principle data supporting our hypothesis that GFP restoration could 
provide the basis for the identification of small molecule inhibitors of targeted viral IFN 
antagonists. 
 
 
Figure 3.6 Proof-of-principle data showing that a HCV/NS3.4A inhibitor (Danoprevir ) 
restored GFP expression in A549.pr(IFN-β)GFP-HCV/NS3.4A(1b) reporter cell-line in a 
dose-response manner. Danoprevir or DMSO was serially diluted in the A549.pr(IFN-β)GFP 
and A549.pr(IFN-β)GFP-HCV/NS3/4A(1b) cell-lines and incubated for 2 hours at 37°C / 5% 
CO2. Then, reporter cells were infected with PIV5.VΔC (inducer of the IFN-β promoter) at a 
MOI of 7 for 24 hours and GFP expression was measured using TECAN plate reader. 
Danoprevir was serially diluted in concentrations ranging from 0.05 nM (log10= -1.3) to 5 μΜ 
(log10= 3.69). Equivalent volumes of DMSO were added. The graph is presented as percentage 
(%) of GFP expression based on the DMSO/-PIV5.VΔC A549.pr(IFN-β)GFP control which 
was set as the 100% control. The bars show mean values (n=4) and error bars represent SD. 
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3.3 Summary  
We successfully developed a cell-based reporter assay, which allows viral IFN 
antagonists to be subjected to HTS. Our assay is based on two validated A549 reporter 
cell-lines, the A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP cell-lines, which produce 
GFP under the control of the IFN-β promoter or ISRE element, respectively. Hence 
these reporter cell-lines represent a straightforward method to monitor inhibition or 
activation of the IFN-induction and IFN-signalling pathways. The IFN-β promoter can 
be activated following infection with PIV5.VΔC, which is a potent inducer of the IFN-
induction pathway; therefore the A549.pr(IFN-β)GFP reporter cell-line produces GFP 
(1.8 fold increase in GFP expression) in response to PIV5.VΔC infection. The ISRE 
element is activated following IFN-α treatment, which subsequenlty induces high GFP 
expression (3.4 fold increase) in the A549.pr(ISRE)GFP reporter cell-line. We also 
demonstrated that stable expression of BVDV Npro and PIV5 V reduced GFP 
expression to background levels in the A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP 
cell-lines. GFP expression was inhibited up to 95% and 100% in the A549.pr(IFN-
β)GFP-BVDV/Npro and A549.pr(ISRE)GFP-PIV5/V cell-lines, respectively, 
illustrating that the expression of viral IFN antagonists blocks the ability of the reporter 
cell-lines to produce GFP. Taken together, this data demonstrates that the A549.pr(IFN-
β)GFP and A549.pr(ISRE)GFP cell-lines could provide the basis for developing a 
modular screening platform, which would allow viral IFN antagonists to be subjected to 
HTS.  
In addition, we used a HCV NS3-4A PI to generated proof-of-principle data 
demonstrating that our cell-based assay is suitable for identifying small molecules that 
inhibit viral IFN antagonist function(s). Specifically, we utilized a A549.pr(IFN-β)GFP 
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derivative that constitutively expresses HCV NS3.4A(1b).  HCV/NS3.4A(1b) inhibited 
PIV5.VΔC-induced GFP expression (80% reduction) in the A549.pr(IFN-β)GFP-
NS3.4A(1b) reporter cell-line. When a HCV/ NS3.4A(1b) inhibitor (Danoprevir) was 
added to the A549.pr(IFN-β)GFP-NS3.4A(1b) reporter cell-line, GFP expression was 
increased in a dose-specific manner, indicating that the function of NS3.4A against 
MAVS/TRIF was effectively suppressed by the inhibitor. Overall, this data supports 
that restoration of GFP expression can be used as a measurable parameter to identify 
small molecules that inhibit the anti-IFN functions of targeted viral IFN antagonists in 
our reporter assay.  
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Chapter 4: Targeting RSV-encoded IFN 
antagonists NS1 and NS2 
 
4.1 Introduction  
 RSV is an important human pathogen with an unmet clinical need for new 
therapeutic strategies, which is highlighted by the lack of RSV vaccine and virus-
specific antivirals. Recombinant RSV viruses that lack NS1 and/or NS2 exhibited 
attenuated replication in animal models (Whitehead et al., 1999; Teng et al., 2000), 
emphasizing the importance of NS1 and NS2 for RSV replication, which makes NS1 
and NS2 potential attractive targets for drug discovery. RSV NS1 and NS2 suppress the 
cellular IFN response, by inhibiting multiple signalling factors of the IFN-induction 
and/or IFN-signalling pathway. Therefore, we sought to utilize our cell-based assay to 
target NS1 and NS2 for the identification of candidate small molecule inhibitors that 
suppress their function against the cellular IFN response. Small molecules that inhibit 
the function(s) of NS1 and/or NS2 could potentially represent good drug candidates, 
and they could also be used as novel chemical tools to address fundamental questions 
about RSV biology.  
 
4.2 Results  
4.2.1 Generation and characterization of reporter cell-line derivatives 
that constitutively express RSV IFN antagonists NS1 and NS2 
 
In order to target NS1 and NS2 using HTS, we generated derivatives of the 
A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP reporter cell-lines that expressed NS1 or 
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NS2. To achieve constitutive expression of NS1 and NS2, we used codon-optimized, 
‘humanized’ versions of NS1 and NS2 (hNS1 and hNS2), which have been previously 
shown to have improved expression in A549 cells compared to the wild type sequences 
(Lo et al., 2005). The hNS1 and hNS2 sequences were successfully cloned into our 
lentiviral system to generate two lentiviruses that encode hNS1 or hNS2. These 
lentiviruses were used to generate two derivatives of the IFN-induction reporter cell-
line, namely A549.pr(IFN-β)GFP-RSV/hNS1 and A549.pr(IFN-β)GFP-RSV/hNS2 and 
two derivatives of the IFN-signalling reporter cell-line, namely A549.pr(ISRE)GFP-
RSV/hNS1 and A549.pr(ISRE)GFP-RSV/hNS2.  
Given that NS1 and NS2 can form a heterodimer, which is essential for their 
joint roles in suppressing various steps of IFN-induction and IFN-signalling(Lo et al., 
2005; Swedan et al., 2011; Spann et al., 2004), we also generated derivatives that 
expressed hNS1 and hNS2 together, in order to determine whether better inhibition of 
the IFN system is achieved when both IFN antagonists are present. The hNS1- and 
hNS2-encoding lentiviruses had two different resistance markers (blasticidin and 
puromycin, respectively), which allowed us to select for both genes in a single cell-line. 
Hence, sequential transductions with both lentiviruses in A549.pr(IFN-β)GFP and 
A549.pr(ISRE)GFP led to the generation of the A549.pr(IFN-β)GFP-hNS1.hNS2 and 
A549.pr(ISRE)GFP-hNS1.hNS2 cell-line, respectively.   
The hNS1 and hNS2 proteins were tagged at their N-termini, which allowed us 
to detect hNS1 and hNS2 expression in the reporter cell-line derivatives. Specifically, 
hNS1 expression was higher in the A549.pr(IFN-β)GFP-RSN/hNS1 compared to the  
A549.pr(IFN-β)GFP-RSN/hNS1.hNS2 reporter cell-line, as indicated by western blot 
analysis (Figure 4.1/A). Although the western blot bands were not quantified, we could  
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Figure 4.1 Expression of RSV hNS1 and hNS2 in the A549.pr(IFN-β)GFP cell-line was 
determined by western blot analysis (A) and immunofluorescence microscopy (B). RSV 
hNS1 and RSV hNS2 expression was detected using an anti-V5 and anti-myc antibody, 
respectively. Enhanced chemiluminescence (ECL) with horseradish peroxidase (HRP) was used 
as detection method for western blotting.  
 
 
 
still detect a clear difference in hNS1 expression (Figure 4.1/A). Similarly, 
immunofluorescence microscopy against RSV/hNS1 showed less fluorescent signal in 
the A549.pr(IFN-β)GFP-RSN/hNS1 compared to the A549.pr(IFN-β)GFP-
RSN/hNS1.hNS2 cell-line (Figure 4.1/B). hNS1 expression also varied between the 
A549.pr(ISRE)GFP-RSN/hNS1 and the A549.pr(ISRE)GFP-RSN/hNS1.hNS2 reporter 
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cell-lines (Figure 4.2). Western blot analysis showed that hNS1 expression was almost 
three times higher in the A549.pr(ISRE)GFP-RSV/hNS1.hNS2 cell-line compared to 
the A549.pr(ISRE)GFP-RSV/hNS1 cell-line (Figure 4.2/A and 4.2/B). Likewise, 
immunofluorescence microscopy showed that hNS1 expression was slightly higher in 
the A549.pr(ISRE)GFP-RSN/hNS1.hNS2 cell-line compared to A549.pr(ISRE)GFP-
RSN/hNS1 (Figure 4.2/D). Overall, the generation of reporter cell-line derivatives that 
constitutively expressed hNS1 appeared to be challenging, since hNS1 expression 
showed cytotoxicity effect, which considerably reduced the cells’ growth rate. 
Interestingly, hNS1 expression appeared to be more sustainable in reporter cell-line 
derivatives that expressed both hNS1 and hNS2. Although hNS1.hNS2-expressing cell-
lines expressed two IFN antagonists, they were growing faster than the hNS1-
expressing cell-lines, suggesting that the functions of the hNS1-hNS2 heterodimer were 
perhaps less toxic to the reporter cells compared to hNS1 functions.   
Unlike hNS1, constitutive expression of hNS2 did not show cytotoxicity, hence 
generating reporter cell-line derivatives that stably expressed hNS2 was less 
problematic. In both A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP cell-lines, hNS2 
expression was lower when expressed together with hNS1 compared to the cell-lines 
that expressed only hNS2, as indicated by western blot analysis (Figure 4.1/A and 
4.2/A). Quantification of NS2 expression in the IFN-signalling cell-line showed that 
hNS2 expression was nearly five times higher in A549.pr(ISRE)GFP-RSV/hNS2 cell-
line compared to the A549.pr(ISRE)GFP RSV/hNS1.hNS2 (Figure 4.2/C). The 
differences in NS2 expression were also evident  by  immunofluorescence   microscopy 
in between  
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Figure 4.2 Expression of hNS1 and hNS2 in the A549.pr(ISRE)GFP reporter cell-
line. (A) Expression of hNS1 and hNS2 was observed using infrared fluorescent western 
blot analysis using Odyssey LI-COR. (B-C) Bands were quantified using the Image 
Studio
TM
 software. The hNS1 and hNS2 signal intensities were quantified to relatively 
measure the protein expression levels, which were normalised to the β-actin signal 
intensity. (D) Expression of hNS1 and hNS2 was observed using immunofluorescence 
microscopy. RSV hNS1 and RSV hNS2 were detected using an anti-V5 and anti-myc 
antibody, respectively. 
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the different hNS2-expressing cell-lines (Figure 4.1/B and 4.2/E). The observed 
differences in the hNS2 expression were probably due to the fact that the 
A549.pr(ISRE)GFP-RSV/hNS2 served as the basis for creating the A549.pr(ISRE)GFP-
RSV/hNS1.hNS2 cell-line, and perhaps the second round of antibiotic selection led to 
variation in hNS2 expression. Overall, regardless the differences in expression, we 
successfully generated derivatives of A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP cell-
lines that constitutively expressed hNS1 or/and hNS2, using lentivirus technology. 
It is worth mentioning that the reporter cell-line derivatives generated in this 
study were not sub-cloned due to time constrains. Although screening against a 
homogeneous cell-line is more preferable, selecting for single clones increases the risk 
of screening against a dysfunctional or damaged population of cells. Therefore, for 
future applications beyond this study, we generated a FACS-based method, which 
allows the generation of a homogeneous population of cells in regards to expression of 
viral IFN antagonists, without selecting for single cell clones. In this method, the 
expression of the viral IFN antagonist is directly linked to a reporter gene that encodes 
for mcherry protein, as they are both expressed from the same ORF. This was achieved 
by creating a lentivirus transfer vector that contained the Thosea asigna virus (TaV) 2A 
peptide, which can separate different protein coding sequences in a single ORF, through 
a mechanism known as ‘ribosomal-skipping’ (Donnelly et al., 2001). This method was 
tested using the RSV NS2 protein and successfully led to the development of a reporter 
cell-line derivative, A549.pr(ISRE)GFP-cherry-2A-RSV/hNS2, that expresses both 
mcherry and RSV hNS2 (Appendix 3). Using the 2A technology, we can generate 
reporter cell-line derivatives that express viral IFN antagonists and a fluorescent 
reporter protein, which allows FACS sorting based on fluorescent signal.  
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4.2.2/1 Testing the functionality of RSV hNS1 and hNS2 via ability to 
block GFP expression in the A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP 
reporter cell lines. 
 
GFP expression is directly linked to the activity of the IFN-β promoter and the 
ISRE/MxA element in our reporter assay. Hence, the ability of hNS1 and hNS2 to 
antagonize the IFN induction and signalling pathways was quantified by measuring the 
GFP expression in the derivative A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP reporter 
cell-lines. In order to determine if hNS1 and NS2 proteins were functional in the 
A549.pr(IFN-β)GFP derivative reporter cell-lines, the IFN-induction pathway was 
induced via infection with PIV5.VΔC and the capacity of the cell-lines to produce GFP 
was quantified (Figure 4.3). As expected, PIV5.VΔC infections in the naïve 
A549.pr(IFN-β)GFP reporter resulted in high GFP expression (Figure 4.3). 
Unexpectedly, however, PIV5.VΔC infection in the derivative A549.pr(IFN-β)GFP 
reporter cell-lines expressing hNS1 and/or hNS2 led to significant cell death, especially 
in the cell-line expressing hNS1 and hNS2 together (Figure 4.3). Specifically, 
fluorescent microscopy showed that, for all three cell-lines, the majority of the cells that 
survived the PIV5.VΔC infections produced high or at least some level of GFP, 
indicating that hNS1 and hNS2 did not completely inhibit the activation of the IFN-β 
promoter (Figure 4.3). Interestingly, although all of the cells were positive for GFP, the 
hNS1-expressing cells produced lower GFP signal compared to the hNS2-expressing 
cells (Figure 4.3), suggesting that hNS1 is possibly a better antagonist of the IFN-
induction pathway. Due to the differences observed in cell densities following 
PIV5.VΔC infections, quantification of GFP fluorescent units was misleading (data not 
shown). Overall, for undetermined reasons, PIV5.VΔC-induced CPE was dramatically 
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elevated in the hNS1- and hNS2-expressing A549.pr(IFN-β)GFP cell-lines. Although 
this is an interesting observation, it interfered with the validity of our assay and did not 
allow us proceed any further with these reporter cell-line derivatives.  
 
Figure 4.3 Induction of the IFN-β promoter in the RSV hNS1-, hNS2- and hNS1.hNS2-
expressing A549.pr(IFN-β)GFP cell-lines, as indicated by GFP expression. The IFN-
induction pathway was activated following 24-hour infections with PIV5.VΔC (~ MOI 7), 
before observing GFP expression with fluorescent microscopy.  
 
 
Likewise, in order to determine if hNS1 and NS2 proteins are functional in the 
A549.pr(ISRE)GFP derivative reporter cell-lines the IFN-signalling pathway was 
induced via treatment with IFN-α (Figure 4.4). Following induction, GFP expression 
was observed with fluorescent microscopy (Figure 4.4/A) and quantified using TECAN 
plate reader (Figure 4.4/B). As expected, IFN-α treatment led to the activation of the 
IFN-signalling, and therefore induced high GFP expression in the naive 
A549.pr(ISRE)GFP reporter cell-line (Figure 4.4/A). Expression of hNS1 had less 
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impact on GFP signal compared to hNS2, however hNS1 and hNS2 co-expression 
inhibited GFP expression to nearly background levels (Figure 4.4/A). Likewise, 
quantification of GFP fluorescent units indicated that hNS1 expression caused 51% 
reduction in GFP expression levels, whereas hNS2 expression led to 78% inhibition 
(Figure 4.4/B). Interestingly, co-expression of hNS1 and hNS2 almost completely 
blocked GFP signal mediating 91% inhibition (Figure 4.4/B).  Overall, this data shows 
that the activity of the ISRE element (as indicated by GFP expression) is more affected 
by the presence of hNS2 rather than hNS1 but it is mostly inhibited when both hNS1 
and hNS2 are present. 
In order to confirm the validity of our assay, we sought to demonstrate that the 
MxA expression corresponds to the GFP expression in these reporter cell-lines. 
Therefore, the A549.pr(ISRE)GFP cell-line and its derivatives were treated with IFN-α, 
and MxA levels were observed with western blot analysis (Figure 4.5). As expected, the 
MxA expression was highly upregulated by IFN-α in the naive A549.pr(ISRE)GFP cell-
line (Figure 4.5). Similar to GFP expression, hNS1 expression significantly reduced 
MxA levels (**, P<0.01) causing a 44% reduction compared to the naïve 
A549.pr(ISRE)GFP cell-line (Figure 4.5). hNS2 expression caused a more significant 
reduction in MxA levels (****, p<0.0001) compared to hNS1. Specifically, MxA levels 
were reduced to up to 19% after NS2 expression and were further reduced to 9% when 
NS2 was expressed together with hNS1 (Figure 4.5). The difference in MxA levels 
between the NS2- and NS1.hNS2-expressing cell-lines was not statistically significant 
(ns, P>0.05), indicating that NS2 expression has a more important role in inhibiting 
IFN-signalling pathway, which is in agreement with our previous observations based on 
GFP expression. 
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Figure 4.4 Induction of the ISRE promoter in the RSV hNS1-, hNS2- and hNS1.hNS2-
expressing A549.pr(ISRE)GFP cell-lines, as indicated by GFP expression. GFP expression 
was observed with fluorescent microscopy (A) and quantified using TECAN plate reader (B). 
The IFN-signalling pathway was activated following 48-hour treatment with purified IFN-α 
(10
4
 U/ml). Graph is presented as percentage (%) of GFP expression relative to naïve 
A549.pr(ISRE)GFP, which was set as 100% control. Statistical analysis was performed using 
one-way ANOVA test and Tukey’s multiple comparisons test (F(3,33)=619.0, ****p<0.0001) 
(Prism/GraphPad). Mean values (n=10), error bars=SD. 
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Figure 4.5 Effect of hNS1 and hNS2 on MxA expression upon activation of the IFN-
signalling pathway. Following 16-hour treatment with purified IFN-α (2000 U/ml), MxA 
expression was observed using Odyssey CLx imager and quantified using ImageStudio 
software. The MxA signal intensity was normalized to β-actin levels, and presented as a % 
relative to the naïve A549.pr(ISRE)GFP reporter cell-line, which was set as 100%. Statistical 
analysis was performed using one-way ANOVA test and Tukey’s multiple comparisons test 
(F(3,12)=29.86, p<0.0001), ****p<0.0001, **p<0.01, *p<0.05 (Prism/GraphPad). Mean values 
(n=4), error bars=SD 
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Overall, in agreement with published work (Lo et al., 2005; Swedan et al., 2011; 
Ramaswamy et al., 2006), our data demonstrated that RSV hNS2 counteracts type I 
IFN-signalling pathway more potently compared to RSV hNS1, whereas maximum 
inhibitory effect requires both hNS1 and hNS2. 
 
4.2.2/2 Evaluating hNS1 and hNS2 functionality via STAT2 degradation in 
the A549.pr(ISRE)GFP reporter cell-line. 
 
Previous studies have showed that RSV NS1 and NS2 cooperate to degrade 
STAT2 through the proteasome, nevertheless NS2 was found to be more important for 
this function (Lo et al., 2005; Swedan et al., 2009; Ramaswamy et al., 2004; Elliott et 
al., 2007). Therefore, in order to further assess the functionality of hNS1 and hNS2 in 
our reporter cell-lines, we measured STAT2 expression (Figure 4.6). In the naïve 
A549.pr(ISRE)GFP cell-line that does not express any viral IFN antagonists, we 
observed high levels of endogenous STAT2 (Figure 4.6). A 22% reduction in STAT2 
levels was observed in the A549.pr(ISRE)GFP-hNS1 cell-line, which was not 
significantly different from the naïve control cell-line (ns, p>0.05) (Figure 4.6). As 
anticipated, hNS2 expression had a greater effect on STAT2 levels and the reduction 
was significant compared to the naïve A549.pr(ISRE)GFP cell-line;  hNS2 mediated a 
73% decrease (**, p<0.01) when expressed on its own, and 87% decrease (***, 
p<0.001) when expressed together with hNS1 (Figure 4.6). This data is in agreement 
with other studies (Lo et al., 2005; Swedan et al., 2011; Goswami et al., 2013) and 
strongly suggests that the STAT2 degradation is mostly driven by hNS2, however the 
presence of hNS1 is essential for establishing a robust inhibitory effect.  
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Figure 4.6 Effect of hNS1 and hNS2 on STAT2 expression. STAT2 expression was observed 
with near-infrared fluorescent western blot analysis (Odyssey CLx imager) and quantified using 
the Image Studio
TM
 software. STAT2 quantification was carried out based on signal intensity, 
which was normalized to β-actin expression, and then presented as percentage (%), relative to 
naïve A549.pr(ISRE)GFP, which was set as 100%. Statistical analysis was performed using 
one-way ANOVA test and Tukey’s multiple comparisons test (F(3,4)=72.55, p=0.0006), 
***p<0.001, **p<0.01(Prism/GraphPad). Mean values (n=2), error bars=SD 
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4.2.3 Evaluating the role of NS1 and NS2 in STAT2 degradation in the 
context of RSV infection in vitro 
 
 Following these observations, we wanted to determine if our cell-lines reflect 
the function of NS1 and NS2 proteins in the context of viral infection, therefore we 
quantified STAT2 expression during in vitro RSV infection. To achieve this, A549 
naïve cells were infected with wild type or recombinant RSV viruses that lack the NS1 
or NS2 gene (RSV.ΔNS1 and RSV.ΔNS2, respectively) (Jin et al., 2000), and STAT2 
expression was measured in the absence or presence of IFN-α (Figure 4.7). Infection 
with wtRSV led to almost complete degradation of STAT2 (97% reduction) in the 
absence of IFN-α, and there was no increase in the STAT2 levels in the presence of 
IFN-α (Figure 4.7). In agreement with our previous data, the lack of NS1 did not affect 
RSV-mediated STAT2 degradation, as RSV.ΔNS1 infection significantly reduced 
STAT2 expression (86% reduction) almost to the same extent as wtRSV infection. In 
contrast, the RSV.ΔNS2 mutant mediated only a 30% reduction in STAT2 levels, 
indicating that the lack of NS2 had a significant effect (****, p<0.0001) on the STAT2 
degradation function of RSV (Figure 4.7). This data is in agreement with published 
work (Ramaswamy et al., 2006; Swedan et al., 2011) and demonstrates that NS2 is 
indispensable for the RSV-mediated STAT2 degradation, which corresponds to the 
observations made in our reporter assay.  
Despite wtRSV infection significantly reduced STAT2 expression levels 
compared to mock infected cells (****, p<0.0001), wtRSV upregulated MxA levels up 
to 50% in the absence of IFN-α, however no further increase was observed in the 
presence  of  IFN-α  (Figure 4.7). This  might  be due  to the  fact  that MxA  is highly  
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Figure 4.7 Effect of wtRSV and recombinant RSV, RSV.ΔNS1 and RSV.ΔNS2, on MxA 
and STAT2 expression. A549 naïve cells were infected with wtRSV (A2 strain), RSV.ΔNS1 
or RSV.ΔNS2 for 24 hours at a MOI of 5, and the following day they were treated with purified 
IFN-α (2000 U/ml) for 16 hours. MxA and STAT2 levels were observed using Odyssey CLx 
imager and quantified using ImageStudio software. The quantification of the western blot bands 
was carried out based on signal intensity, which was normalized to β-actin expression, and then 
presented as a percentage (%) relative to the mock infected/ (+) IFN cells, which was set as the 
100% control. Statistical analysis was performed using two-way ANOVA test and Tykey’s 
multiple comparisons test (F (3,8)=201.3, p<0.0001) ****p<0.0001, ***p<0.001 
(Prism/GraphPad). Mean values (n=2, 3), error bars=SD 
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upregulated by IFN-α, and leaky STAT2 expression might be enough to recruit  
transcription factors and trigger MxA expression. RSV.ΔNS1-induced MxA levels were 
very similar to wtRSV, however RSV.ΔNS2 induced higher MxA expression, similar to 
mock infected cells (Figure 4.7). Quantification of the MxA expression indicated 
considerable variation between different repeats, therefore the observed differences in 
MxA levels were not statistically significant (ns, p>0.05). However, the pattern of MxA 
expression pattern was consistent between different experiments; MxA was highly 
upregulated by RSV.ΔNS2 infections and less induced by RSV.ΔNS1 and wtRSV.  
 
4.2.4 Proof-of-principle data demonstrated restoration of GFP in the 
A549.pr(ISRE)GFP-RSV/NS2 cell-line upon NS2 siRNA knockdown 
 
 The hNS1- and/or hNS2-expressing A549.pr(ISRE)GFP reporter cell-line 
derivatives were generated to allow us target NS1 and NS2 using a HTS approach. Our 
previous data showed NS1 and NS2 act synergistically to mediate STAT2 degradation, 
a function that is mainly driven by NS2, and thereby hNS2 inhibited GFP expression 
more effectively than hNS1 in our reporter assay. Hence, A549.pr(ISRE)GFP-
RSV/hNS2 cell-line was further utilized for the identification of small molecules that 
inhibit NS2 function against the IFN-signalling pathway. Although the 
A549.pr(ISRE)GFP-hNS1.hNS2 cell-line had the lowest GFP expression, it was not 
considered for HTS, because screening against both NS1 and NS2 would complicate 
our assay and make the results inconclusive. For instance, an inhibitor would have to 
block the independent, as well as the joint functions of NS1 and NS2 to be selected as a 
candidate hit molecule.  
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 In order to validate our hypothesis that small molecule inhibitors of RSV NS2 
could be identified by conducting HTS using the A549.pr(ISRE)GFP-RSV/hNS2 cell-
line, we sought to show that inhibition of hNS2 could lead to GFP restoration. Due to 
the lack of small molecules inhibitors of NS2, we used hNS2 siRNA knockdown to 
demonstrate restoration of GFP in the A549.pr(ISRE)GFP-RSV/hNS2. The capability 
of sihNS2 to knockdown hNS2 expression in the A549.pr(ISRE)GFP-RSV/hNS2 
reporter cell-line was observed by western blot analysis (Figure 4.8). Our results 
showed that hNS2 expression was reduced to non-detectable levels, even after treatment 
with a low concentration of sihNS2 (10 nM) (Figure 4.8). Although sihNS2 treatment 
was effective, we observed that it had an effect on cells’ growth rate, as the sihNS2-
treated cells were growing slower than the control cells. The 96-well format of the GFP 
reporter assay is sensitive to cell densities, and in order to overcome this problem the 
cell seeding concentrations were adjusted accordingly for the next experiment. 
 
 
Figure 4.8 sihNS2 treatment knockdowns RSV NS2 expression in the A549.pr(ISRE)GFP-
RSV/hNS2 cell-line, as observed with western blot analysis. The cell-lines were treated with 
10 nM, 25 nM and 50 nM of sihNS2 for 24 hours. Three controls were used for this experiment; 
the -siRNA control contained only optiMEM, the RNAiMax control contained only the siRNA 
transfection reagent and the siNT control is a non-targeting siRNA, which was also used as a 
negative control (Dharmacon).  
 
Chapter 4:  
Targeting RSV-encoded IFN antagonists NS1 and NS2 
 
114 
 
Once hNS2 knockout was confirmed, we tested whether sihNS2 treatment could 
restore GFP expression (Figure 4.9). In particular, A549.pr(ISRE)GFP and 
A549.pr(ISRE)GFP-RSV/hNS2 were treated with 50 nM sihNS2 for 24 hours, and then 
treated with IFN-α for 48 hours, before measuring and observing GFP expression 
(Figure 4.9/A and 4.9/B). The ability of the A549.pr(ISRE)GFP cell-line to produce 
GFP was not affected by sihNS2, as the level of GFP expression was similar to the three 
negative controls (-siRNA, RNAiMax and siNT) (Figure 4.9/A and 4.9/B). As expected, 
low GFP signal was observed in the A549.pr(ISRE)GFP-RSV/hNS2 for the all three 
negative controls (Figure 4.9/A and /B). Interestingly, treatment with 50 nM sihNS2 
partially restored GFP expression in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line 
(Figure 4.9/A and /B). Quantification of GFP showed that the A549.pr(ISRE)GFP-
RSV/hNS2 produced 30% more GFP signal after sihNS2 treatment (Figure 4.9/A); the 
partially restored GFP expression was also confirmed by fluorescent microscopy 
(Figure 4.9/B).  
To further explore this observation, we tested the STAT2 expression after 
sihNS2 treatment. In the A549.pr(ISRE)GFP cell-line, sihNS2 treatment had no effect 
on STAT2 expression, whereas higher STAT2 expression was observed in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line, compared to the negative controls (Figure 
4.9/C). In conclusion, our data suggests that siRNA NS2 knockdown was sufficient 
enough to reduce hNS2-mediated STAT2 degradation and subsequently increase GFP 
expression in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line. 
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Figure 4.9 Proof-of-principle data showing that GFP expression is restored in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line following sihNS2 treatment. Cells were seeded in a 
96-well plate and transfected with 50 nM of siNT and sihNS2 for 24 hours, and then treated with 
IFN-α (10000 U/ml) for 48 hours. The -siRNA control contained optiMEM only, and a second 
control contained the siRNA transfection reagent only (RNAiMAx). (A) GFP expression was 
quantified using the TECAN plate reader. The graph is presented as percentage (%) of GFP 
expression relative to -siRNA/ +IFN A549.pr(ISRE)GFP control, which was set as 100%. 
Statistical analysis was performed using one-way ANOVA test and Tukey’s multiple 
comparisons test (F (3,16)=179.5, ****p<0.0001) (Prism/GraphPad). Mean values (n=5), error 
bars =SD (B) Flluorescent images were taken using the Incucyte imager. (C) STAT2 expression 
as observed by western blot analyis. Cells were lysed with disruption buffer and STAT2 
expression was observed with western blot analysis using Odyssey CLx imager.  
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4.3 Summary  
In order to target RSV NS1 and NS2 using HTS, we developed derivatives of 
the A549.pr(IFN-β)GFP and A549.pr(ISRE)GFP reporter cell-lines that constitutively  
expressed hNS1 and hNS2, either separately or together. The expression of the proteins 
was successfully confirmed with immunodetection based on their N-terminal epitope 
tags. Expression of hNS1 was found to be toxic, however no apparent cytotoxicity was 
observed in the hNS2-expressing cell-lines.  
NS1- and NS2-expressing reporter cell-lines were further characterized to 
determine the activity of the IFN-β promoter and ISRE element in these cell-lines by 
mesearing GFP expression. Infections with PIV5.VΔC were unexpectedly virulent in 
the NS-expressing A549.pr(IFN-β)GFP cell-lines, and therefore we were unable to draw 
conclucions about the functionality of NS1 and NS2 against the IFN-induction pathway. 
Hence, these reporter cell-lines were not taken any further, as they were not suitable for 
the development of a HTS approach. In contrast, expression of hNS1 or/and hNS2 in 
the A549.pr(ISRE)GFP reporter cell-lines allowed us to quantify the NS1 and NS2 
antagonism against the IFN-signalling pathway. Previous studies have shown that RSV 
hNS1 and hNS2 can act synergistically or independently against the cellular IFN 
signalling (Ramaswamy et al., 2004; Ramaswamy et al., 2006; Swedan et al., 2009; 
Swedan et al., 2011). Likewise, our data demonstrated that expression of hNS2 
inhibited GFP expression to a greater extent compared to hNS1, however maximal 
inhibitory effect was observed when hNS1 and hNS2 were co-expressed.  
The most well documented function of NS1 and NS2 against the IFN-signalling 
pathway is their ability to mediate STAT2 degradation through the proteasome (Lo et 
al., 2005; Swedan et al., 2011; Spann et al., 2004). Therefore, we quantified STAT2 
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expression, in order to assess the functionality of hNS1 and hNS2 in the reporter cell-
lines. Our data illustrated that the STAT2 degradation function is mainly attributed to 
NS2, however the presence of NS1 is essential for more effective degradation. This 
observation was also confirmed in the context of virus infection, during which NS2 was 
found to be indispensable for the RSV-mediated STAT2 degradation.  
In conclusion, A549.pr(ISRE)GFP reporter cell-line derivatives that stably 
express hNS1 and/or hNS2 were successfully generated to allow RSV NS1 and NS2 to 
be subjected to HTS. In particular, cell-line characterization showed that the 
A549.pr(ISRE)GFP-RSV/hNS2 reporter cell-line was more suitable for HTS, mainly 
because hNS2 expression was less toxic than hNS1, and also due to the fact that hNS2 
had a more prevailing function in regards to STAT2 antagonism. Furthermore, we 
demonstrated partial restoration of GFP expression in the A549.pr(ISRE)GFP-
RSV/NS2 cell-line upon NS2 siRNA knockdown, lending support to our hypothesis that 
small molecules inhibitors of NS2 could be identified based on GFP restoration in the 
A549.pr(ISRE)GFP-RSV/NS2 cell-line.  
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Chapter 5: Assay development and performance 
of a HTS targeting RSV NS2 
 
5.1 Introduction  
 
In order to utilize our cell-based reporter assay to conduct a HTS targeting RSV 
NS2, our assay had to be first adapted to a HTS format. Prior to this study, one of the 
parental reporter cell-lines, the A549.pr(IFN-β)GFP has been validated for HTS in 
collaboration with the Dundee Discovery Unit (DDU), as part of Mrs Zoe’s Gage PhD 
research project. The adaptation of A549.pr(IFN-β)GFP to a HTS setting was successful 
and was followed by a screen against 15,667 compounds, which led to the identification 
of small molecules that inhibit the IFN-induction pathway (unpublished Gage et al.,). In 
this study, we applied the statistical validation performed for the A549.pr(IFN-β)GFP 
reporter cell-line to our assay, in order to verify its quality and robustness. Once the 
quality of the assay’s performance was verified, a HTS approach was performed in-
house for the identification of small molecules that inhibit the function of RSV NS2 
against the IFN-signalling pathway.  
 
5.2 Results  
 
5.2.1 Development of a robust 96- and 384-well format cell-based HTS 
assay 
 
To adapt our assay to a HTS format, we first identified parameters in the assay 
procedure that acted as potential sources of variation. Key sources of variation were 
identified, such as (i) TECAN plate reader-induced artifacts, (ii) incubator related plate 
Chapter 5:  
Assay development and performance of a HTS targeting RSV NS2 
119 
 
patterns, (iii) edge effects attributed to evaporation or cell adhesion, and lastly (iv) 
liquid handling irregularities. Various practical steps were implemented to minimize 
exogenous sources of variation to adapt the assay to a HTS format, and further 
miniaturize it from a 96-well to a 384-well plate HTS format. The performance of the 
assay in both 96- and 384-well format has been validated according to the DDU quality 
control (QC) guidelines, based on which a GFP cell-based reporter assay is suitable for 
HTS when: (i) fold increase (S/B) > 2.5, (ii) % CV < 10 and (iii) Z’ factor > 0.5. Both 
% CV and Z’ factor are widely used for evaluation of assay quality; % CV measures the 
signal variation within a single treatment (e.g. high or low signal controls), whereas the 
Z’ factor is reflective of both assay signal dynamic range and the variation associated 
with high and low signal control measurements (Zhang 1999).  
We initially verified the parental reporter cell-line, A549.pr(ISRE)GFP reporter 
cell-line, because it produces high GFP signal in response to IFN-α, hence it allows a 
more thorough evaluation of signal variation compared to A549.pr(ISRE)GFP-
RSV/hNS2 cell-line. The robustness of the A549.pr(ISRE)GFP reporter cell-line has 
been successfully demonstrated though S/B, %CV and Z’ factor statistical analyses in a 
96- and 384-well format (Figure 5.1 and 5.2). These analyses were performed on ten 
separate plates to allow us assess the reproducibility and consistency of the assay. The 
statistical verification of the A549.pr(ISRE)GFP reporter cell-line is summarized on 
Table 5.1. Specifically, in a 96-well plate format, the A549.pr(ISRE)GFP reporter cell-
line had an average fold increase equal to 3.1, an average % CV for the high and low 
signal control equal to 3.74 and 3.70, respectively and an average Z’ factor equal to 0.77 
(Figure 5.1; Table 5.1). The quality of the assay was also validated in a 384-well format 
(Figure 5.2); our data indicated a robust 384-well format HTS assay, which had an 
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average fold increase of 2.5, an average % CV for the high and low signal control equal 
to 5.04 and 4.25, respectively and an average Z’ factor equal to 0.65 (Figure 5.2; Table 
5.1).  
 
Figure 5.1 Statistical validation of the A549.pr(ISRE)GFP cell-line in a 96-well plate 
format. (A) Fold increase in GFP signal (n=80, error bars=SD) and Z’ factor for ten separate 
plates. (B) %CV for the high (+ IFN) and low (-IFN) signal controls for the same plates.  
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Figure 5.2 Statistical validation of the A549.pr(ISRE)GFP cell-line in a 384-well plate 
format. (A) Fold increase in GFP signal (n=32, error bars=SD) and Z’ factor for ten separate 
plates and (B) %CV for the high (+ IFN) and low (-IFN) signal controls for the same plates.  
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Table 5.1 The robustness of our in-house HTS platform was statistically validated using 
the A549.pr(ISRE)GFP reporter cell-line. 
 
Statistical Parameter DDU QC 
requirements 
96-well format 384-well format 
Fold increase or S/B  ≥ 2.5 3.1 2.5 
% CV                 +IFN  
                      
                             -IFN 
 
< 10% 
3.70 % 5.04 % 
3.74 % 4.25 % 
Z’ factor (> 0.5) > 0.5 0.77 0.65 
 
  Although the quality of our HTS assay was successfully evaluated based on the 
statistical analyses performed in the A549.pr(ISRE)GFP reporter cell-line (Table 5.1), 
we also tested variation in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line (Figure 5.3). 
The statistical validation of the A549.pr(ISRE)GFP-RSV/hNS2 cell-line was limited to 
one  statistical parameter; %CV, in both a 96- and 384-well format (Figure 5.3). The 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line had an average %CV for the high (+IFN) and 
low (-IFN) signal control equal to 2.71 and 3.96, in a 96-well plate format (Figure 
5.3/A) and 4.76 and 4.06, in a 384-well plate format (Figure 5.3/B). The Z’ factor was 
not an applicable statistical parameter for the A549.pr(ISRE)GFP-RSV/hNS2 cell-line, 
as it depends on signal window (GFP signal+IFN - GFP signal-IFN). More specifically, 
hNS2 expression suppresses the IFN-induced ISRE activation, hence low GFP signal is 
produced by the A549.pr(ISRE)GFP-RSV/hNS2 cell-line, which makes the signal 
window narrow in this cell-line. Z’ factor would be a suitable statistical parameter only 
in the presence of a NS2 small molecule inhibitor, which could be used as a positive 
control to restore GFP expression in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line, and 
hence widen signal window. Due to the lack of NS2 small molecule inhibitors, signal 
variation and consistency in the A549.pr(ISRE)GFP-RSV/hNS2 was verified only 
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based on the %CV, which measures signal variation in high and low signal controls 
separately, without taking into consideration the signal window (Figure 5.3).  
Overall, this data shows that the tested statistical parameters met the DDU QC 
guidelines (S/B ratio ≥ 2.5, %CV < 10% and Z’ factor > 0.5), indicating successful 
development of a reproducible and robust assay that allows us to perform HTS in a 384-
well format using in-house liquid handling screening equipment.   
Figure 5.3 Statistical validation of the A549.pr(ISRE)GFP-RSV/hNS2 cell-line. % CV for 
the high (+ IFN) and low (-IFN) signal controls was measured in ten separate plates in a 96-well 
(A) and 384-well (B) plate HTS format (n=32).  
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5.2.2 Primary HTS to identify small molecules that inhibit RSV NS2 
function 
 
A primary HTS was conducted against the A549.pr(ISRE)GFP-RSV/hNS2 cell-
line to identify small molecules that suppress the NS2 function against the IFN-
signalling pathway via restoration of GFP expression. The library screened derived 
from the Maybridge
1
 screening collection, which was kindly provided by Professor 
Nicholas Westwood (University of St Andrews, UK). The library consists of 16,000 
small molecules with drug-like properties that obey the Lipinski’s ‘rule of 5’, according 
to which, a drug-like molecule should have; (i) no more than five hydrogen bond 
donors, (ii) no more than ten hydrogen bond acceptors, (iii) a partition of coefficient 
(logP) lower then 5 and (iv) a molecular mass not greater than 500 daltons (Lipinski et 
al., 2001). The compounds were arrayed in fifty 384-well plates as single compounds at 
10 mM in DMSO. In order to make it practicable and minimize handling errors, the 
screen was performed in five batches of ten 384-well plates. Once the primary screen 
was completed, we combined the data from all assay plates and calculated the 
percentage (%) effect of the 16,000 screened compounds to identify the compounds that 
restored GFP expression in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line (Figure 5.4). A 
normal distribution curve centred around zero point was formed when the frequencies 
of the 16,000 screened compounds were plotted against their percentage effect (% of 
inhibition), indicating that no systemic errors were accosiated with the screen 
performace (Figure 5.4). Selection of hit compounds is discussed in Section 5.2.3.  
The assay quality was monitored during the screen to ensure that no 
instrumental and/or biological factors were affecting the performance of our assay in the 
                                                 
1
 Supplementary information about the Maybridge library:  
http://www.maybridge.com/portal/alias__Rainbow/lang__en/tabID__146/DesktopDefault.aspx  
Chapter 5:  
Assay development and performance of a HTS targeting RSV NS2 
125 
 
HT setting. To determine if the data collected from each plate met the minimum quality 
requirements, and if any patterns existed before and after data normalization, the 
distribution of control and test sample data were examined at experiment-, plate- and 
well-level. The quality of screening data on each plate was assessed using heat maps, 
which allow the identification of abnormal patterns that are usually related to plate 
patterns (data not shown). For the quantitative assessment of the screen’s performance, 
we used two statistical parameters; the fold increase (S/B) and the %CV (Figure 5.5). 
The average fold increase (S/B) of all the assay plates (n=50) was equal to 1.37 (Figure 
5.5/A).  The average %CV was equal to 4.58 and 6.02 for +IFN controls and -IFN 
controls, respectively (Figure 5.5/B). Seven assay plates did not meet the QC 
requirements (%CV > 10%) (Figure 5.5/B). These plates were excluded from the 
statistical analyses that followed the primary screen for the identification of potential 
hits that inhibit the function(s) of NS2. Overall, the primary screen fulfilled the 
statistical requirements for a valid HTS assay, and therefore further statistical analyses 
followed for hit compound selection.  
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Figure 5.4 Primary HTS against A549.pr(ISRE)GFP-RSV/hNS2. Frequency distribution of 
the 16,000 screened compounds (Maybridge library) plotted against their percentage effect (% 
inhibition of GFP signal).  % Effect = 100 –[100 x (experimental value – AVG-IFN) / (AVG+IFN – 
AVG-IFN)], where AVG stands for average value of the +IFN controls (AVG+IFN) or  -IFN 
controls (AVG-IFN)  
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Figure 5.5 Statistical analysis of the primary screen. The A549.pr(ISRE)GFP-RSV/hNS2 
cell-line was subjected to HTS using a library of 16,000 compounds. The screen was 
conducted in 5 batches of ten plates (A) Fold Increase in GFP expression (n=32, error 
bars=SD). (B) %CV for the +IFN and -IFN controls. The statistical analysis was carried out 
separately for each assay plate (n=50).  
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5.2.3 Selection of compounds via restoration in GFP expression   
The hit selection process was carried out into two steps; hits were initially 
selected from the primary screen and then, a confirmatory screen analysis was 
performed to increase the likelihood of obtaining a set of small molecules that have a 
specific inhibitory activity against RSV NS2.  
 
5.2.3/1 Hit selection from the primary screen  
The first selection of potential hits was based on the % effect of the compounds. 
Specifically, compounds that restored GFP expression at 50% above the background 
levels (GFP signal of IFN-treated controls) were selected for further analysis (Figure 
5.6). Based on the percentage effect cut-off (-50% inhibition), the primary screen led to 
the identification of thirty-eight small molecules, which restored fluorescent signal in 
the A549.pr(ISRE)GFP-RSV/hNS2 cell-line (Figure 5.6). In addition to the % effect, 
hits were selected using the Z-Score parameter (also known as standard score), which 
indicates how many standard deviations (SD) a particular compound is above or below 
the signal mean of the plate (Goktug et al., 2013).  In our study, hits were designated as 
molecules that had Z-Score of 3, hence restored GFP expression ≥ three standard 
deviations above the sample signal mean (mean + 3SD). From the thirty-eight 
compounds that scored ≥ 50% GFP restoration (Figure 5.6), ten did not pass the ‘mean 
+ 3SD’ cut-off, and therefore they were excluded from further analyses (data not 
shown). This led to the identification of 28 potential hits, which increased fluorescent 
signal 50% above the IFN-treated control in the A549.pr(ISRE)GFP-RSV/hNS2 cell-
line, and had Z-Score equal to 3. 
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Figure 5.6 Hit compound selection from primary screen. Percentage (%) effect shows the 
level of restoration in GFP expression in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line.The % 
effect cut-off of our assay was 50% and 38 compounds had increased the GFP signal 50% 
above the high signal control (IFN-treated control).  
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  In order to analyze these hits further, we measured their fold increase in 
fluorescent signal (Figure 5.7). HIT-6 and HIT-13 had a fold increase equal to 5.5 and 
6.8, respectively, which is higher than the maximum fold increase in GFP expression 
ever observed in the parental GFP reporter cell line, A549.pr(ISRE)GFP (Figure 5.7). 
Therefore, these compounds were eliminated, as they were highly likely to be auto-
fluorescent compounds. The fold increase of the HIT-5 was at the borderline, and 
therefore it was not eliminated at this stage (Figure 5.7). Overall, the primary screen 
against RSV NS2 was successfully performed, leading to the identification of twenty-
six compounds, which significantly restored fluorescent signal in the 
A549.pr(ISRE)GFP-RSV/hNS2 reporter cell-line.   
Figure 5.7 Fold increase in fluorescent signal of the identified twenty-eight hits. The bottom 
line shows the fold increase in GFP expression after IFN treatment of the A549.pr(ISRE)GFP-
RSV/hNS2 cell-line, the average of which was equal to 1.37 during the primary screen. The top 
line marks the maximum fold increase of the A549.pr(ISRE)GFP cell-line, which is equal to 
3.4.  
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5.2.3/2 Hit selection from the confirmatory screen  
The twenty-six selected hits were further validated with a confirmatory screen, 
during which the activity of the compounds was tested more thoroughly and any other 
auto-fluorescent compounds were dismissed. The primary screen was conducted at a 
single concentration (11.42 μΜ), whereas during the confirmatory screen the selected 
compounds were tested at various concentrations ranging from 0.1 μΜ to 50 μΜ and 
plotted against their GFP signal to assess whether they form dose-response curves. 
Specifically, the compounds were cherry-picked from the library plates and tested 
against: (i) the A549.pr(ISRE)GFP-RSV/hNS2 to confirm their ability to restore GFP 
expression in our assay, and (ii) growth media to test whether the observed increase in 
GFP signal was due to auto-fluorescence (Figures 5.8 - 5.10). At this stage, the twenty-
six selected compounds were renamed using an AV prefix (AV-1 – AV-26).  
The confirmatory screen showed that fourteen of the identified hits produced 
fluorescent signal when serially diluted in A549.pr(ISRE)GFP-RSV/hNS2 reporter cell-
line and also in growth media (Figure 5.8). Most of the compounds were only slightly 
auto-fluorescent at concentrations around 10 μΜ (Log10=1) (Figure 5.8), explaining 
why we did not detect such a high increase in fluorescent signal during the primary 
screen. Hit compounds, including AV-5, AV-9 and AV-20, were highly auto-
fluorescent at concentrations above 10 μΜ (Log10=1), causing saturation of fluorescent 
signal in both conditions tested (Figure 5.8). Hit compounds AV-2, AV-7 and AV-15 
were less auto-fluorescent, as they produced less fluorescent signal and only at high 
concentrations (Figure 5.8). Regardless their differences in auto-fluorescence, all 
fourteen compounds that produced fluorescent signal in growth media were disregarded. 
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Overall, 57% of the hits were false-positives, since sixteen compounds (including HIT-6 
and HIT-13) were found to be auto-fluorescent.  
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Figure 5.8 Confirmatory Screen: Auto-fluorescent hit compounds. Graphs are presented as 
a fold increase in fluorescent signal. Compounds were serially diluted in A549.pr(ISRE)GFP-
RSV/hNS2 cell-line and growth media. The serial dilutions of the compounds range from 0.10 
μΜ (log10= -1) to 50 μΜ (log10= 1.69). The control values show the fluorescent signal in the + 
IFN (10
4 
U/ml), + DMSO control. The discontinued lines are due to ‘overflow’ values, which 
had fluroscent signal higher to the reading capacity of TECAN plate reader. 
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In addition to the auto-fluorescent compounds, another three hit compounds 
(AV-12, AV-21 and AV-22) were eliminated, as they had no activity during the 
confirmatory screen (Figure 5.9). These compounds produce no fluorescent signal in the 
A549.pr(ISRE)GFP-RSV/hNS2 reporter cell-line and neither did in growth media 
(Figure 5.9). Another hit, AV-25, was eliminated mainly due to toxicity. Although hit 
AV-25 restored GFP signal in the A549.pr(ISRE)GFP-RSV/hNS2 reporter cell-line 
without being auto-fluorescent, we observed that fluorescent signal was declining at 
concentrations higher than 10 μΜ (Log10=1), indicating that AV-25 was perhaps toxic 
at higher concentrations (Figure 5.9). Due to the nature of our assay, toxicity was not a 
major concern, because the compounds were selected based on GFP restoration. For 
instance, a toxic compound is less likely to be selected from our screen, because the 
reduction is cell numbers would also reduce GFP signal. Supporting our hypothesis, the 
identified toxic compound AV-25 showed toxicity only at concentrations higher than 
the screening concentration (11.42 μΜ) (Figure 5.9). Although toxicity could be simply 
identified by a decline in GFP signal, as observed for AV-25 (Figure 5.9), cell densities 
were also monitored during the primary and confirmatory screens by crystal violet 
staining (data not shown).  
Interestingly, eight compounds (AV-8, AV-10, AV-11, AV-13 AV-14, AV-16, 
AV-18, AV-19) increased fluorescent signal in the A549.pr(ISRE)GFP-RSV/hNS2 
without being auto-fluorescent, as they did not produce any signal in growth media 
(Figure 5.10). More precisely, the compounds AV-8, AV-14, AV-16, AV-18, AV-19 
caused higher GFP restoration than the AV-10, AV-11, AV-13 compounds; AV-8, AV-
14, AV-16, AV-18 and AV-19 had a maximum fold increase around 1.6, whereas AV-
10, AV-11 and AV-13 had a maximum fold increase ranging from 1.4 to 1.5 (Figure 
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5.10). Regardless their differences in fold increase, all of these compounds increased 
GFP signal in the A549.pr(ISRE)GFP-RSV/hNS2 reporter cell-line without being auto-
fluorescent, hence showing promising activity. 
 
 
Figure 5.9 Confirmatory screen: False-positives and a toxic compound. Graphs are 
presented as a fold increase in fluorescent signal. Compounds were serially diluted in 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line and growth media. The serial dilutions of the 
compounds range from 0.10 μΜ (log10= -1) to 50 μΜ (log10= 1.69). The compounds AV-12, 
AV-21 and AV-22 showed no activity, whereas compound AV-25 showed toxicity at higher 
concentrations. The control values show the fluorescent signal in the + IFN (10
4 
U/ml), + 
DMSO control.  
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Figure 5.10 Confirmatory screen: Hit compounds. Graphs are presented as a fold increase in 
fluorescent signal. Compounds were serially diluted in A549.pr(ISRE)GFP-RSV/hNS2 cell-line 
and growth media. The serial dilutions of the compounds range from 0.10 μΜ (log10= -1) to 50 
μΜ (log10= 1.69). Compounds with prosing activity did not fluorescent in growth media, and 
showed GFP restoration in the NS2-expressing cell-line. The control values show the 
fluorescent signal in the + IFN (10
4 
U/ml), + DMSO control.  
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These eight hit compounds did not produce fluorescent signal in growth media, 
however this does not exclude the possibly that they could produce fluorescent 
byproducts when metabolized in the cellular environment, hence increasing fluorescent 
signal in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line. To assess this possibility, the 
eight hit compounds were tested in naïve A549 cells and the A549.pr(ISRE)GFP-
RSV/hNS2 reporter cell-line in the absence or presence of IFN-α treatment and 
fluorescent signal was observed with fluorescent microscopy (Figure 5.11). 
Interestingly, none of the compounds produced fluorescent signal in the A549 cells in 
the absence or presence of IFN-α, confirming that the compounds are not auto-
fluorescent and do not produce fluorescent metabolic byproducts in cells (Figure 5.11). 
Likewise, no fluorescent signal was detected in the A549.pr(ISRE)GFP-RSV/hNS2 
following compound treatment in the absence of IFN-α (Figure 5.11). In agreement with 
our previous observations (Figure 5.10), all compounds restored GFP expresion in the 
A549.pr(ISRE)GFP-RSV/hNS2 in the presence of IFN-α (Figure 5.11). In conclusion, 
this data confirms that compounds AV-8, AV-10, AV-11, AV-13 AV-14, AV-16, AV-
18 and AV-19 are not auto-fluorescent and shows that the observed increase in 
fluorescent signal is due to restoration in GFP expression in the A549.pr(ISRE)GFP-
RSV/hNS2 cell-line.  
The identified compounds are minimally substituted heterocyclic building 
blocks, especially designed for drug discovery by Maybrigde (Table 5.2). As designated 
by Lipinski’s ‘Rule of 5’, all of these compounds have molecular weight less than 500 
Da (Table 5.2). Their minimal substitution allows easier interpretation of structure-
activity relationship (SAR), and subsequently more straightforward lead optimization. 
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Figure 5.11 The eight hit compounds restored GFP expression in A549.pr(ISRE)GFP-
RSV/hNS2 cell-line, without producing fluorescent signal in A549 naïve cells. Cells were 
treated with 25 μΜ of each compound for 2 hours and then treated with IFN-α (104 U/ml) for 48 
hours. Fluorescent images were taken with IncuCyte cell imager at 10X magnification.  
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Table 5.2 Compounds’ CAS number, molecular weight (MW), chemical name and 
chemical structures. The chemical structures were drawn using the ChemBioDraw software. 
  CAS Number 
Maybrigde   Code 
MW(Da) Chemical Structure 
AV-8 661475-55-4/  
CD06524 
 
 286.358 
 
N-[2-(1H-indol-3-yl)ethyl]-4-methyl- 
1,2,3-thiadiazole-5-carboxamide  
 
AV-10 2199-83-9/ 
BTB06399 
 
 295.13 
 
6-bromo-3-butyryl-2H-chromen-2-one 
 
 
AV-11 53266-94-7/ 
SB00646 
 
 186.234 
 
Ethyl 2-(2-amino-1,3-thiazol-4-yl)acetate 
 
 
AV-13 92635-79-5/ 
BTB05216 
 
 199.301 
 
Methyl N-(2-thienylmethylidene)- 
aminomethanehydrazonothioate 
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 GAS Number/ 
Maybrigde   Code 
MW (Da)    Chemical Name and Structure 
AV-14 15641-27-7/ 
ML00232 
 
 
 231.254 
 
Ethyl2-(1H-indol-3 ylmethylidene) 
hydrazine-1-carboxylate 
 
AV-16 883054-87-3/ 
SP01362 
 
 267.287 
 
N-(1H-indazol-3-yl)-3-methoxybenzamide 
 
AV-18 5541-89-9/ 
NRB02761 
 
 187.2407 
 
4-(1H-indol-3-yl)butan-2-one 
 
AV-19  4651-81-4/ 
GK02784 
 
 
 157.1923 
 
Methyl 2-aminothiophene-3-carboxylate 
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5.3 Summary 
The robustness and reproducibility of our 384-well format HTS assay was 
successfully demonstrated through statistical assessment. The assay fulfilled the DDU 
QC requirements, as it had a fold increase (S/B) = 2.5, %CV < 6 and Z’ factor > 0.65. 
Once the quality of the assay was shown to be suitable for HTS, a primary screen was 
conducted in-house for the identification of small molecule inhibitors of RSV NS2. The 
A549.pr(ISRE)GFP-RSV/hNS2 was subjected to HTS using a chemical library of 
16,000 small molecules. The primary screen was performed using in-house liquid 
handling equipment, and screen’s consistency and validity was demonstrated through 
statistical analysis (fold increase = 1.37, %CV < 7). The frequencies of the 16,000 
screened compounds were normally distributed against their percentage effect (% 
inhibition), and compounds were selected based on two criteria; compounds were 
classified as hits when GFP expression was 50% above the background levels and were 
characterized by a Z-Score of 3. This led to the selection of twenty-eight hits that 
significantly increased fluorescent signal in the A549.pr(ISRE)GFP-RSV/hNS2 cell-
line. Hence, the hit rate of our screen was 0.175% (28 hits out of 16,000), however hit 
rates typically observed in antagonist or inhibitor format assays are usually around 2-
3% (Hughes et al., 2011). This is due to the fact that although we are searching for NS2 
inhibitors, our assay is based on restoration in GFP signal and hit rates tend to be lower 
(<0.5%) in assays that compound selection is based on an increase in assay signal rather 
than a decrease in signal (Hughes et al., 2011). 
Following the primary screen, the twenty-eight selected hits were further 
characterized based on their ability to generate dose-response curves in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line. The confirmatory screen also allowed us to 
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eliminate false-positives. Overall, from the twenty-eight initially identified hits, 57% 
were auto-fluorescent (sixteen compounds), 11% were eliminated because they showed 
no activity (three compounds) and 3% due to toxicity (one compound), and lastly 29% 
of the selected hits showed promising activity (eight compounds). The eight hit 
compounds mediated a significant increase in GFP signal without being auto-
fluorescent, and particularly, the AV-8, AV-14, AV-16, AV-18, AV-19 compounds 
resulted into a higher fold increase in GFP expression than the AV-10, AV-11, AV-13 
compounds. The rest of this thesis will focus on the characterization and validation of 
these eight candidate compounds that significantly restored GFP expression in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line.     
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Chapter 6: Hit compound characterization to 
demonstrate their activity against RSV NS2 
function 
 
6.1 Introduction  
The primary HTS against RSV NS2 led to the identification of eight 
compounds namely AV-8, AV-10, AV-11, AV-13, AV-14, AV-16, AV-18 and AV-19 
that restored GFP expression in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line in a 
reproducible manner. These compounds were purchased from the Maybridge 
Company and further characterized, in order to (i) confirm their ability to restore GFP 
fluorescence signal in the NS2-expressing cell-line and determine their EC50 values, 
(ii) test the stability of their activity and their cytotoxicity, (iii) assess their specificity 
against NS2, (v) evaluate their mechanism of action with respect to inhibition of NS2-
mediated STAT2 degradation, and finally (v) test their ability to restrict RSV 
replication.  
 
6.2 Results  
 
6.2.1 Verification of hit compounds ability to restore GFP expression 
in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line 
 
The activity of the purchased compounds was reassessed with two-fold dose-
response curves ranging from 0.01 μM to 50 μM (Figure 6.1). In the absence of 
compounds, the A549.pr(ISRE)GFP-RSV/hNS2 cell-line had an average fold increase 
in GFP expression around 1.32, when treated with IFN-α (Figure 6.1). This is in 
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agreement with our previous data, as during primary screen the cell-line had a fold 
increase of 1.37. As anticipated, all compounds restored GFP expression but at 
different levels, with compounds AV-14, -16, -18 and -19 resulting in a higher fold 
increase in GFP expression (Figure 6.1). The fold increase was significantly increased, 
ranging from 1.83 to 1.96, in the presence of compounds AV-14, -16, -18 and -19 
(Figure 6.1; Table 6.1). The rest of the compounds, AV-8, -10, -11 and -13, were less 
effective, and led to a lower GFP restoration in the A549.pr(ISRE)GFP-RSV/hNS2 
cell-line, ranging from 1.44 to 1.69 (Figure 6.1;  Table 6.1). This data confirms the 
results of the primary screen (Figure 5.10), and indicates that hit compounds can be 
categorized into two groups based on their activity; group A composed of AV-14, -16, 
-18 and -19 compounds, which were more potent, and group B composed of AV-8, -
10, -11 and -13 compounds, which had a weaker activity (Table 6.1).  
In addition to the fold increase in GFP expression, the activity of the 
compounds was further characterized regarding their EC50 values, which determines 
the concentration of compound that provokes a response halfway between the lowest 
and higher response (Goktug et al., 2013). The identified compounds had different 
EC50 values; AV-10, -13, and -19 had EC50 values within a single μM range (1-2 μM), 
whereas the EC50 values of AV-8, -14, -16 and -18 lay within low μM range (0.2-0.8 
μM) (Figure 6.1; Table 6.1). AV-11 had the highest EC50 value (419.4 μM) of all the 
compounds (Figure 6.1). Although some of the compounds had good EC50, they had 
very weak activity, as indicated by their low fold increase (Table 6.1). Hence, the rest 
of this chapter will focus on the compounds of Group A, which had a fold increase in 
GFP expression above 1.8 and reproducible EC50 values in the single μM range or 
lower (Table 6.1).  
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Figure 6.1. Dose-response curves demonstrating restoration of GFP expression in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line, in the presence of selected compounds. Dose-
response curves range from 0.10 μM (log10= -1) to 50 μΜ (log10= 1.69). The control values 
show the fluorescent signal in the +IFN (10
4 
U/ml), +0.05% [v/v] DMSO control. The EC50  
(μΜ) values were calculated using Prism (GraphPad) software. Curves represent mean values 
(n=8), error bars=SD.  
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Table 6.1 Hit Ranking based on fold increase in GFP expression.  
  HIT Fold increase  EC50 (μΜ) 
Group A  1 AV-16 1.96 0.28 
2 AV-14 1.94 0.42 
3 AV-18 1.90 0.73 
4 AV-19 1.83 2.08 
Group B  5 AV-13 1.69 1.15 
6 AV-11 1.67 419.4 
7 AV-10 1.61 1.37 
8         AV-8 1.44 0.81 
 
 
6.2.2 Exploring the properties of hit compounds regarding stability, 
cytotoxicity and chemical structure   
 
6.2.2/1 Hit compounds activity remained stable over a six day period 
In order to evaluate compounds stability over time, compounds were incubated 
with A549 naïve cells or growth media for up to six days, and then tested for their 
ability to restore GFP expression in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line. 
Interestingly, the same level of GFP restoration was observed for all the samples 
tested, regardless of incubation time, with the exception of compound AV-14, which 
showed a small reduction in activity at later time points  (Figure 6.2). Specifically, 
AV-14 activity was 27% reduced, after a 6-day incubation with A549 cells. Incubating 
the compounds in the presence of A549 naïve cells or plain growth media had no 
effect on compounds’ activity, as restoration of GFP expression was the same between 
the samples taken from cells or growth media (Figure 6.2). Overall, this data suggests 
that the activity of all eight compounds was stable over a period of six days, with only 
exception being AV-14, which showed a slight reduction in activity at later time 
points.  
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Figure 6.2 Testing the stability of compounds activity. 10 μΜ of each compound was 
incubated over A549 naïve cells or growth media only, and a sample was collected from each 
flask for six days. At the end of the assay, samples were added to A549.pr(ISRE)GFP-
RSV/hNS2 cell-line, and compounds ability to restore GFP was measured and compared to 
fresh compound. The graphs are presented as percentage (%) of restoration in GFP expression 
relative to fresh compounds, which was set as 100%. Absorbance of crystal violet (A650 nm) 
was used for normalizing the GFP signal to cell density. Bars show mean values (n=3), error 
bars=SD.  
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6.2.2/2 Compounds showed no cytotoxicity in the A549.pr(ISRE)GFP-
RSV/hNS2 cell-line  
 
The compounds’ effect on cell viability was monitored throughout the primary 
and confirmatory screen using crystal violet staining. Crystal violet dye penetrates cell 
membranes and allows detection of cell density, however it does not show if the 
compounds have any effect on the cell’s metabolism. In contrast, AlamarBlueTM is a 
more sensitive assay, which assesses the viability of mammalian cells based on their 
ability to metabolically process the oxidized form of AlamarBlue reagent (resazurin) 
to the reduced form of AlamarBlue reagent, which is the highly red fluorescent 
resofurin (Hamid et al., 2004). Therefore, the level of AlamarBlue reagent reduction is 
a quantitative measure, which shows cell viability based on metabolic activity. Our 
results demonstrated that A549.pr(ISRE)GFP-RSV/hNS2 cell-line was capable of 
almost fully reducing (80% reduction) the AlamarBlue reagent (Figure 6.3). The 
ability of the cells to reduce AlamarBlue was not affected by the presence of hit 
compounds, indicating that none of the compounds is cytotoxic (Figure 6.3). In 
agreement with the crystal violet staining, this data confirms that the identified 
compounds do not induce toxicity effects.  
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Figure 6.3 Compounds showed no cytotoxicity by AlamarBlue cell viability assay. 
Compounds was serially diluted in concentrations ranging from 0.10 μM (log10= -1) to 50 μΜ 
(log10= 1.69) on A549.pr(ISRE)GFP-RSV/hNS2 cells for 48 hours. The level of AlamarBlue 
reduction was measured based on fluorescence using the TECAN plate reader. Graphs show 
mean values (n=6),  error bars=SD. 
 
 
 
6.2.2/3 Compounds AV-14, AV-16, AV-18 represent chemically related 
series with an indole structure 
 
Hit compounds belong to the Maybridge chemical library, which consists of 
heterocyclic compounds that are well-known for their good pharmacological 
properties (Biswal et al., 2012). The identified compounds represent minimally 
substituted building blocks for drug discovery, with ring structures that are 
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functionalized with a selection of synthetically useful reactive groups
2
 (Table 5.2). 
Interestingly, three of the compounds of Group A (AV-14, -16 and -18) shared 
structural similarity, as they contained an indole ring (Figure 6.4/A). Indole is an 
aromatic heterocyclic organic compound, which consists of a six-membered benzene 
ring fused to a five-membered nitrogen-containing pyrrole ring (Figure 6.4/A) (Biswal 
et al., 2012).  
To assess the importance of the indole ring in NS2 inhibition, the indole 
compound (Sigma) was tested against the A549.pr(ISRE)GFP-RSV/hNS2 cell-line, 
and GFP fluorescent signal was quantified (Figure 6.4/B). Our results showed that 
high concentration of indole (25 μΜ/ log10=1.39) slightly increased GFP levels in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line (Figure 6.4). Specifically, indole mediated a 
fold increase in GFP expression equal to 1.45, whereas the indole-containing 
compounds AV-14, -16 and -18 had a maximum fold increase of 2 (Figure 6.4). 
Overall, our results showed that the indole compound alone was not enough to 
sufficiently block NS2-mediated suppression of GFP in the A549.pr(ISRE)GFP-
RSV/hNS2 cell-line. This suggests that the indole ring might have a role in NS2 
inhibition, but the observed restoration of GFP expression is not strictly linked to this 
structure. Hence, structure-activity relationship (SAR) experiments are required to 
define the relative importance of the indole ring and molecules’ side chains in NS2 
inhibition. 
 
 
                                                 
2
 Supplementary information about the chemical structures of the Maybridge library:  
http://www.maybridge.com/portal/alias__Rainbow/lang__en/tabID__23/DesktopDefault.aspx 
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Figure 6.4 Effect of indole ring on restoration of GFP expression in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line. (A) Chemical structures of indole, AV-14, AV-16 
and AV-18 (from left to right). (B) Indole and indole-containing compounds AV-14, -16, -18 
were serially diluted against A549.pr(ISRE)GFP-RSV/hNS2 cell-line and incubated for 2 
hours, before adding IFN-α (104 U/ml). Dose-response curves range from 0.10 μM (log10= -1) 
to 50 μΜ (log10= 1.69). Graphs show mean values (n=6),  error bars=SD. 
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6.2.3 Demonstrating compounds specificity to RSV NS2  
6.2.3/1 Compounds activity is specific to cell-lines expressing RSV hNS2 
and not other viral IFN antagonists 
 
In order to demonstrate compounds specificity to RSV NS2, the compounds 
activity (restoration of GFP expression) was tested against a panel of cell-lines, some 
of which constitutively expressed other viral IFN antagonists. These were A549 naïve 
cells, the naïve A549.pr(ISRE)GFP reporter cell-line, and also A549.pr(ISRE)GFP 
derivatives that expressed: (i) RSV hNS1 protein (A549.pr(ISRE)GFP-RSV/hNS1), 
which is known to counteract the cellular IFN response using independent, as well as 
joint mechanisms with NS2 (Lo et al., 2005; Swedan et al., 2009; Swedan et al., 
2011), (ii) RSV hNS1 and hNS2 protein together (A549.pr(ISRE)GFP-
RSV/hNS1.hNS2) and (iii) PIV5 V protein (A549.pr(ISRE)GFP-PIV5/V), a very 
potent antagonist of the IFN-signalling pathway, which degrades STAT1 through the 
proteasome (Didcock et al., 1999). 
Compounds AV-14, AV-16, AV-18 and AV-19 were serially diluted two-fold 
from 0.10 μΜ to 50 μΜ in the five cell-lines mentioned above (Figure 6.5). As 
anticipated, none of the compounds produced fluorescent signal in the A549 naïve 
cells, which again excludes the possibility of auto-fluorescence (Figure 6.5). The 
compounds had no impact on the ability of the A549.pr(ISRE)GFP reporter cell-line to 
produce GFP at concentrations below 10 μΜ (log10=1), however at concentrations 
above 10 μM, a small reduction in GFP expresssion was observed (Figure 6.5). Crystal 
violet staining showed that GFP reduction at higher concentrations was not due to 
cytotoxicity (data not shown), which is also confirmed by our previous data obtained 
with AlamarBlue assay (Figure 6.3). Despite the reduction observed at high compound 
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concentrations, this observation shows that none of the compounds induced GFP 
expression in any unspecific way. 
In agreement with our previous data, all of the compounds induced GFP 
restoration in the A549.pr(ISRE)GFP-RSV/hNS2 reporter cell-line, mediating 
approximately a two fold increase in GFP expression (Figure 6.5). Interestingly, all the 
compounds also restored GFP expression in the NS1.NS2-expressing cell-line but only 
up to the GFP levels observed in the NS1-expressing cell-line (Figure 6.5). This 
demonstrates that compounds blocked NS2 function in the hNS1.hNS2-expressing 
cell-line without affecting NS1 function against the IFN-signalling pathway (Figure 
6.5). This agreed with the observation that the compounds had no effect on GFP 
expression in the A549.pr(ISRE)GFP-RSV/hNS1 cell-line (Figure 6.5). In the 
PIV5/V-expressing cell-line, GFP expression levels remained stable to background 
levels (fold increase = 1) after compound treatment (Figure 6.5), showing that hit 
compounds had no effect on the ability of PIV5 V to antagonize the IFN-signalling 
pathway. Overall, GFP restoration was only observed in NS2-expressing cell-lines, 
A549.pr(ISRE)GFP-RSV/hNS2 and A549.pr(ISRE)GFP-RSV/hNS1.hNS2, indicating 
that identified small molecules are highly likely to be acting specifically against the 
anti-IFN functions of RSV NS2.  
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Figure 6.5 Restoration of GFP expression was observed only in NS2-expressing cell-lines. 
Group A compounds diluted on A549 naïve cells (orange), A549.pr(ISRE)GFP reporter cell-
line (purple), A549.pr(ISRE)GFP derivatives that RSV/hNS1 (red), RSV/hNS2 (green) and 
RSV/hNS1.hNS2 (black), and PIV5/V (blue). Dose-response curves range from 0.10 μM 
(log10= -1) to 50 μΜ (log10= 1.69). Cells were treated with compound for 2 hours and then 
treated with IFN-α (104 U/ml) for 48 hours (n=3, error bars =SD).  
 
-1 0 1 2
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
Concentration log(µΜ)
F
o
ld
 I
n
c
re
a
s
e
 
AV-14
-1 0 1 2
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
Concentration log(µΜ)
F
o
ld
 I
n
c
re
a
s
e
 
AV-16
-1 0 1 2
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
Concentration log(µΜ)
F
o
ld
 I
n
c
re
a
s
e
 
AV-18
-1 0 1 2
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
3.0
3.2
3.4
Concentration log(µΜ)
F
o
ld
 I
n
c
re
a
s
e
 
AV-19
A549.naive
A549.pr(ISRE).GFP
A549.pr(ISRE).GFP-PIV5/V
A549.pr(ISRE).GFP-RSV/hNS2 
A549.pr(ISRE).GFP-RSV/hNS1
A549.pr(ISRE).GFP-RSV/hNS1.hNS2
Chapter 6:  
Hit compound characterisation to demonstrate their activity against RSV NS2 function 
155 
 
6.2.3/2 Biological activity of the compounds was demonstrated via their 
ability to block NS2-mediated STAT2 degradation.  
 
The most documented function of RSV NS2 against the IFN-signalling 
pathway is its ability to degrade STAT2 through the proteasome (Lo et al., 2005; 
Ramaswamy et al., 2004). As shown in Chapter 4, constitutive expression of RSV 
NS2 mediates STAT2 degradation in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line. In 
order to demonstrate biological activity of the selected compounds, we tested their 
ability to block the NS2-mediated STAT2 degradation, in the A549.pr(ISRE)GFP-
RSV/hNS2 cell-line (Figure 6.6). As expected, IFN-α treatment upregulated STAT2 in 
the A549.pr(ISRE)GFP cell-line and this was not affected by the presence of the hit 
compounds (Figure 6.6). In agreement with our previous observations, STAT2 
expression was considerably reduced in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line, 
even after IFN-α treatment (Figure 6.6). Specifically, quantification of STAT2 
expression showed an 88% reduction in STAT2 levels in the A549.pr(ISRE)GFP-
RSV/hNS2 cell-line after IFN-α treatment, compared to the naïve A549.pr(ISRE)GFP 
cell-line (Figure 6.6). Interestingly, STAT2 expression was increased in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line in the presence of the hit compounds (Figure 
6.6). All tested compounds caused approximately 30% increase in STAT2 expression, 
which is in agreement with our previous observations that demonstrated partial 
restoration of GFP expression by hit compounds.  
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Figure 6.6 STAT2 and MxA expression is increased after compound treatment in 
the A549.pr(ISRE)GFP-RSV/hNS2 reporter cell-lines. A549.pr(ISRE)GFP and 
A549.pr(ISRE)GFP-RSV/hNS2 cell-lines were treated with 10 μΜ of compound or 
0.05% [v/v] DMSO for 2 hours and then treated with IFN-α (2000 U/ml) for 24 hours, in 
the presence of the compound. STAT2 and MxA expression was observed with infrared 
fluorescent western blot analysis (Odyssey CLx imager) and quantified using the Image 
Studio
TM
 software. Control and test samples run on the same gel to allow quantification. 
Stable NS2 expression was confirmed in the A549.pr(ISRE)GFP-RSV/hNS2 reporter 
cell-line. Graphs are presented as percentage (%) of relative STAT2 and MxA expression 
relative to DMSO/+IFN A549.pr(ISRE)GFP control, which was set as 100%. Mean 
values (n=3), error bars=SD.  
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In addition to STAT2 expression, we also tested the effect of the compounds on 
MxA expression in the A549.pr(ISRE)GFP and A549.pr(ISRE)GFP-RSV/hNS2 cell-
lines (Figure 6.6). In the A549.pr(ISRE)GFP cell-line, MxA expression was highly 
upregulated after IFN-α treatment, in the absence or presence of hit compounds (Figure 
6.6). As observed previously, MxA expression is reduced in the A549.pr(ISRE)GFP-
RSV/hNS2 cell-lines due to the NS2 antagonism against the IFN-signalling pathway 
(Figure 6.6). Specifically, MxA expression was 87% reduced in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line compared to the A549.pr(ISRE)GFP cell-line. 
Similar to STAT2 expression, MxA levels were increased after treatment with hit 
compounds (Figure 6.6). Specifically, all compounds increased MxA expression more 
than 50% compared to the DMSO control in the A549.pr(ISRE)GFP-RSV/hNS2 cell-
line (Figure 6.6). Overall, this data demonstrates that hit compounds inhibited NS2-
mediated STAT2 degradation, and subsequently increased MxA expression in the 
A549.pr(ISRE)GFP-RSV/hNS2 cells, which correlates with the ability of the hit 
compounds to mediate restoration of GFP expression.  
To further explore compounds specificity, we tested whether the hit compounds 
are capable of blocking other viral IFN antagonists from degrading STAT2. To 
investigate this, the activity of compound AV-16 was tested against the PIV2 V protein. 
The PIV2 V protein circumvents the IFN-signalling pathway in a similar manner to 
RSV NS2 protein, as PIV2 V also mediates degradation of STAT2 and this proteolytic 
activity was found to be partially alleviated by proteasome inhibition (Parisien et al., 
2001). As anticipated, IFN-α treatment highly upregulated STAT2 in the 
A549.pr(ISRE)GFP cell-line and Hep2 naïve cells, whereas STAT2 expression was 
hardly detectable in their derivatives that expressed RSV hNS2 and PIV2 V, 
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respectively (Figure 6.7).  As observed previously, AV-16 partially blocked the 
RSV/hNS2-mediated STAT2 degradation, but interestingly, had no effect on the 
PIV2/V-mediated degradation of STAT2 (Figure 6.7). We could not test differences in 
MxA expression, because Hep2 cells are MxA-deficient. Overall, the ability of the hit 
compound to inhibit STAT2 degradation appears to be specific to RSV NS2 protein, as 
AV-16 had no effect on the PIV2/V-mediated STAT2 degradation. 
 
 
 
 
To further explore the biological activity of the compounds, we tested their 
ability to inhibit the NS2-mediated STAT2 degradation in the context of virus infection 
in vitro. To achieve this, A549 naïve cells were infected with wtRSV, and then treated 
with AV-16, in the absence or presence of IFN-α (Figure 6.8). In agreement with 
published work (Ramaswamy et al., 2006), our data showed that RSV infection 
Figure 6.7 Compound AV-16 had no effect on PIV5/V-mediated STAT2 degradation. 
STAT2 levels were tested in cell-lines expressing the RSV/hNS2 and PIV2/V IFN 
antagonists, namely A549.pr(ISRE)GFP-RSV/hNS2 and Hep2-PIV2/V, respectively. Cells 
were treated with 10 μΜ of compound AV-16 for 2 hours and then treated with IFN (1000 
U/ml) for 16 hours, in the presence of the compound. RSV.NS2 (anti-myc) and PIV2.V (anti-
V5) proteins are also shown on the gel to confirm stable expression of the proteins.  
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effectively blocked most of IFN response, which was activated in response to virus 
stimulus, as STAT2 levels were marginally increased (18% increase) following RSV 
infections compared to the mock control (Figure 6.8). Interestingly, when AV-16 
compound was added following RSV infection, STAT2 expression was 30% higher, 
indicating that compound AV-16 partially inhibited the RSV-mediated STAT2 decrease 
(Figure 6.8).  In addition, the virus suppressed STAT2 levels up to 50% in the presence 
of IFN-α treatment, when compared the -RSV/ +IFN control (Figure 6.8). The ability of 
the virus to reduce the IFN-mediated STAT2 upregulation was blocked by compound 
AV-16, leading to a 40% increase in STAT2 levels compared to +RSV/ +IFN control 
(Figure 6.8). In conclusion, this data indicates that the AV-16 partially inhibits the 
STAT2 degradation function of RSV, which is in agreement with observations made in 
our reporter assay. 
In order to determine if the increase in STAT2 levels was enough to augment 
activation of the ISRE element, we tested MxA expression, which represents an end 
point of the IFN-signalling pathway. Consistent with previous obervations, RSV 
infection only partially blocked MxA expression, causing a 60% increase in MxA levels 
in the absence or precence of IFN-α treatment (Figure 6.8). Addition of compound AV-
16 increased MxA levels; MxA levels were increased up to 80% in the absence of IFN-
α and up to 95% in the presence of IFN-α (Figure 6.8). Taken together, the AV-16-
mediated partial inhibition of RSV function against STAT2 increased MxA expression 
in reponse to RSV infection, demonstrating that the activity of the ISRE element is 
restored after compound treatment in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line. 
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Figure 6.8 Compound AV-16 partially inhibited STAT2 degradation during RSV 
infection in vitro. A549 naïve cells were infected with RSV A2 strain (MOI of 5) for 1 hour 
and then, without removing the inoculum, AV-16 compound (10 μΜ) was added for 24 hours. 
The next day, the cells were treated with IFN-α (1000 U/ml) for 16 hours. STAT2 and MxA 
levels were observed using Odyssey CLx imager and quantified using ImageStudio software. 
Lanes 1-4 show STAT2 expression in mock infected cells; -/+ IFN treatment and -/+ compound 
AV-16. Lanes 5-8 show STAT2 expression in RSV infected cells; -/+ IFN treatment and -/+ 
compound AV-16. Control and test samples run on the same gel to allow quantification. Signal 
intensity is a relative measure of STAT2 and MxA expression, which was normalised to β-actin 
expression, and then presented as a % in relation to STAT2/MxA expression in the  (-) RSV/ 
(+) IFN control (lane 3), which was set as 100%. Mean values (n=3), error bars=SD.  
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6.2.4 Hit compounds did not inhibit RSV replication in vitro 
Our previous observations strongly suggest that our HTS approach successfully 
led to the identification of compounds that have specific inhibitory activity against the 
RSV NS2 protein, as they were shown to specifically inhibit the NS2-mediated STAT2 
degradation. In order to determine whether inhibiting NS2-mediated STAT2 
degradation is enough to restrict RSV growth, we tested the effect of the hit compounds 
on RSV replication kinetics on A549 naïve cells (Figure 6.9 and 6.10). In particular, the 
ability of the hit compounds (AV-14, -16, -18, -19) to restrict RSV replication was 
tested against two RSV strains (A2 and the Long strain), and the virus titers were 
quantified at various times points post infection. In the absence of AV-14 and AV-18, 
RSV/A2 peaked 48 hours post infection, reaching its maximum titer, which was 
approximately 3x10
4
 Pfu/ml (Figure 6.9/A), whereas RSV/Long peaked 72 hours post 
infection, reaching a maximum titer of 9x10
5
 Pfu/ml (Figure 6.9/B). The presence of 
compounds AV-14 and AV-18 had no effect on the titer of either RSV/A2 or 
RSV/Long, as viruses reached same titers in the presence of the compounds (Figure 
6.10). Likewise, in the absence of AV-16 and AV-19, RSV/A2 peaked at 48 hours post 
infection, whereas RSV/Long peaked at 72 hours post infection, reaching maximum 
titers of 3x10
5
 Pfu/ml and 1x10
7
 Pfu/ml, respectively (Figure 6.10). Similar to 
compounds AV-14 and AV-18, neither AV-16 nor AV-19 had any inhibitory effect 
against RSV growth, as both RSV strains grew up to the same titers in the absence or 
presence of the compounds (Figure 6.10).  
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Figure 6.9 Effect of the AV-14 and AV-18 compounds on RSV growth on A549 naive 
cells. The growth of RSV A2 (A) and RSV Long (B) was monitored in the presence of the 
AV-16 and AV-19 compounds or 0.05% [v/v] DMSO. A549 cells were infected with RSV 
viruses at a low MOI (0.01) for 3 hours, and then the inoculum was replaced by fresh media 
containing 10 μΜ of compounds or the equivalent volume of DMSO. The virus titers were 
tested at various time points, as indicated on the growth curves.  
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Figure 6.10 Effect of the AV-16 and AV-19 compounds on RSV growth on A549 
naive cells. The growth of RSV A2 (A) and RSV Long (B) was monitored in the 
presence of the AV-16 and AV-19 compounds, as described previously. A549 cells were 
infected with an MOI (0.01) for 3 hours, and then the inoculum was replaced by fresh 
media containing 10 μΜ of compounds or the equivalent volume of DMSO. Virus 
samples were collected and titrated at various time points, as indicated on the growth 
curves.  
Chapter 6:  
Hit compound characterisation to demonstrate their activity against RSV NS2 function 
164 
 
Although hit compounds had no effect on RSV replication kinetics, we also 
tested whether they have an impact on RSV plaque number and size. RSV plaques were 
studied on human dermal fibroblasts (Hambleton et al., 2013) and Hep2 cells. 
Specifically, RSV plaques were observed in the presence of hit compounds or DMSO at 
4 days post infection in both cell-lines (Figure 6.11). Although RSV can form plaques 
on human fibroblasts, plaques are very small and better visualised under the 
microscope, therefore only virus titers are presented here. According to RSV titration, 
the virus titre was equal to 1.9x10
6
 Pfu/ml in the absence or presence of the hit 
compounds, indicating that none of them had an effect on RSV replication on human 
fibroblasts (Figure 6.11/A).  RSV plaque formation was also observed on Hep-2 naïve 
cells, as RSV forms bigger plaques on this cell-line and it was easier to determine if hit 
compounds have any effect on virus plaque size. In agreement with the previous 
observation, RSV titer was estimated to be approximately 3x10
6
 Pfu/ml, both in the 
absence or presence of the compounds (Figure 6.11). In addition, no obvious difference 
was observed on RSV plaque size when AV-16 and AV-18 were added (Figure 6.11/B). 
Overall, RSV replication was quantified after monitoring RSV growth on A549 naïve 
cells and also observed with plaque assays on human fibroblasts and Hep2 naïve cells. 
Unfortunately, both approaches indicated that the hit compounds had no apparent effect 
on RSV replication. 
Given that hit compounds work by inhibiting RSV NS2 protein from 
antagonizing STAT2, we hypothesized that the compounds might have an effect on 
RSV replication in the presence of IFN-α. To address this, A549 naïve cells were pre-
treated with IFN-α, and then infected with RSV/Long before adding AV-16 compound. 
The virus growth was monitored for two days post infection (Figure 6.12). 
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Figure 6.11 Hit compounds had no effect on RSV plaque size and number.                   
(A) wtRSV(Long) was added to human fibroblasts at MOI of 0.01 for 1 hour and after 
removing the inoculum, 10 μΜ of compounds or 0.05% [v/v] DMSO was added to the 
0.5 % methylcellulose overlay. (B) wtRSV(A2) was added to Hep2 naive cells, as 
described above and then 10 μΜ of AV-16 and AV-18 or DMSO was added to the 
overlay. In both experiments plaques were fixed four days post-infection and visualized 
after immunostaining using an anti-RSV/F antibody. Mean values (n=3), error bars=SD.   
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In the absence of IFN-α treatment and 24 hours post infection, RSV/Long reached a 
titer of 3x10
4
 Pfu/ml, whereas in the presence of IFN the virus titer was 7x10
2
 Pfu/ml 
(Figure 6.12). At 48 hours post infection, the IFN’s effect on virus replication was less 
intense, as the virus-IFN balance started shifting in the favor of the virus, resulting into 
a smaller difference in titers. In particular, the virus reached a titer of 5x10
5
 Pfu/ml in 
the absence of IFN-α, and had a titer of 5x104 Pfu/ml in the presence of IFN (Figure 
6.12). Unfortunately, treatment with AV-16 had no impact on RSV growth neither in 
the presence nor in the absence of IFN-α (Figure 6.12). This result negated our 
hypothesis, as it shows that the inhibitory effect of AV-16 is not sufficient enough to 
restrict RSV replication, not even in the presence of IFN.  
Considering that RSV encodes for two IFN antagonists (NS1 and NS2) that are 
known to work synergistically or independently to antagonize the cellular IFN response 
(Lo et al., 2005; Swedan et al., 2011; Swedan et al., 2009), we reasoned that the 
compounds had no effect on RSV replication, perhaps because NS1 compensates for the 
lost of NS2 function against STAT2. To test this hypothesis, we measured the effect of 
AV-16 on RSV.ΔNS1 replication, which is a recombinant RSV virus that lacks the ORF 
that encodes for NS1 protein (Figure 6.13). The replication of RSV.ΔNS1 peaked at 3 
days post infection, and had a titer of 3x10
5
 Pfu/ml (Figure 6.13). Virus replication was 
monitored for 5 days, and no changes observed in regards to virus titer at latter time 
points (Figure 6.13). In contrast to our hypothesis, treatment with AV-16 had no effect 
on the replication RSV.ΔNS1, as the virus reached same titers in the presence of the 
compound (Figure 6.13). Taken together, compound AV-16 had no impact on 
RSV.ΔNS1 replication; therefore the incapability of the compound to restrict wtRSV 
replication cannot be attributed to NS1 compensation.  
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Figure 6.12 AV-16 had no effect on RSV growth in the presence of IFN-α treatment. A549 
naïve cells were pre-treated with IFN-α (2000 U/ml) for 16 hours and then infected with RSV 
(Long) at an MOI of 0.01 for 3 hours. Then, the inoculum was removed and replaced by fresh 
media containing either 10 μΜ of AV-16 compound or the equivalent volume of DMSO. The 
virus titers were tested at various time points, as indicated on the growth curve.  
 
 
Figure 6.13 AV-16 had no effect on the replication of RSV.ΔNS1. Hep2 naïve cells were 
infected with RSV.ΔNS1 virus at a low MOI (0.01) for 3 hours, and then the inoculum was 
replaced by fresh media containing 10 μΜ of AV-16 or the equivalent volume of DMSO. The 
virus titer were tested at various time points, as indicated on the growth curves.  
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6.3 Summary 
 A primary HTS targeting RSV NS2 led to the identification of eight compounds, 
which were further characterized to demonstrate their specificity against RSV NS2 and 
also determine their biological activity. Hit compound characterization showed that 
compounds fall into two groups based on their ability to restore GFP expression in the 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line. The compounds of Group A (AV-14, -16, -18 
and -19) had more promising activity, as they mediated a higher fold increase in GFP 
expression (up to 1.96), compared to the compounds of Group B (AV-8, -10, -11 and -
13). Hence, further hit characterization focused primarily on compounds AV-14, AV-
16, AV-18 and AV-19. Hit compounds appeared to act specifically against RSV NS2, 
as they restored GFP expression only in NS2-expresssing reporter cell-lines. Our data 
demonstrated that the biological activity of the compounds is related to inhibition of 
NS2-mediated STAT2 degradation. Interestingly, all compounds partially suppressed 
NS2-mediated STAT2 degradation in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line and 
also in the context of RSV infection in vitro. Supporting compounds specificity to NS2, 
our data showed that AV-16 did not inhibit STAT2 proteasomal degradation when 
mediated by another viral IFN antagonist, the PIV2 V protein. Unfortunately, although 
the compounds showed sufficient inhibition of the NS2-mediated STAT2 degradation, 
none of the compounds affected RSV replication in vitro. The inhibitory effect of the 
compounds was not enough to restrict RSV replication neither in the presence or 
absence of IFN-α, as the compounds did not block RSV growth any further than IFN-α. 
In addition, our data showed that AV-16 had no effect on RSV.ΔNS1 replication. This 
observation ruled out the possibility that NS1 might compensate for the loss of NS2 
Chapter 6:  
Hit compound characterisation to demonstrate their activity against RSV NS2 function 
169 
 
functions during wtRSV infection, suggesting that our NS2 inhibitors are not potent 
enough to restrict RSV growth.  
In conclusion, we successfully identified eight compounds, four of which (AV-
14, -16, -18 and -19) are certainly more efficient in inhibiting the NS2 degradation 
function against STAT2. To date, these are the only known small molecules that impose 
an inhibitory effect against RSV NS2, which underlines the novelty of these 
compounds. These inhibitors could be used in primary research to improve our 
understanding in regards to the role of NS2 in IFN antagonism, and dissect its multiple 
functions during RSV replication. Although at the current time our NS2 inhibitors do 
not restrict RSV growth, the activity of the hit compounds will be optimized by 
medicinal chemistry to potentially improve their potency and efficacy against RSV 
infection.  
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Chapter 7: Discussion  
 
Type I IFNs form the first line of defense against virus infections that dampen 
initial virus replication and ensure survival of the host until specialized adaptive 
immune responses are developed. However, viruses have evolved a great number of 
intricate strategies to circumvent the cellular IFN response, including the expression of 
viral IFN antagonists. The expanding understanding of viral IFN antagonism illustrates 
that viral interactions with the IFN system form a central host-pathogen interface in 
determining the outcome of viral infections. Several studies have demonstrated that 
viruses lacking a fully functional viral IFN antagonist experience attenuated replication 
in vivo due to a potent IFN response, which successively contributes to the 
establishment of long-lasting immune memory. For instance, Influenza A/B virus NS1 
deletion mutants were found to induce IFN and, as a consequence, were attenuated in 
vitro and in vivo, while conferring protection against challenge with wild type virus 
(Donelan et al., 2003; Hai et al., 2008). Moreover, severe acute respiratory 
syndrome (SARS)-coronavirus nsp1, human PIV1 P/C and Japanese encephalitis virus 
(JEV) E deletion mutants were also greatly attenuated in vivo, while retaining 
immunogenicity, and therefore are considered good vaccine candidates (Züst et al., 
2007; Liang et al., 2009). Since viruses unable to counteract the cellular IFN response 
are highly attenuated, targeting viral IFN antagonists represents a promising antiviral 
strategy. Our interest is to investigate whether a novel class of virus-specific drugs that 
work by inhibiting viral interferon antagonist function could be developed. 
 This study led to the development of a modular cell-based HTS approach that 
allows viral IFN antagonists of clinically important viruses to be subjected to HTS for 
the identification of candidate antiviral molecules, which would allow us to validate 
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viral IFN antagonists as drug targets. Our cell-based HTS assay is based on two A549 
reporter cell-lines, namely A549.pr(IFN-β)GFP (Chen et al., 2010) and 
A549.pr(ISRE)GFP, which provide a straightforward method for monitoring IFN-
induction and IFN-signalling pathways by GFP expression under the control of the IFN-
β promoter or the ISRE element. We successfully utilized these validated reporter cell-
lines to underpin a novel screening platform for targeting viral IFN antagonists. This 
screening approach allows small molecule inhibitors of viral IFN antagonists to be 
identified via GFP restoration, in reporter cell-line derivatives that express viral IFN 
antagonists. We adapted this assay to a 384-well format and its robustness has been 
demonstrated though statistical analyses, which validated the assay as being suitable for 
HTS by consistently achieving Z’-factor scores of 0.65 to 0.77 (Figure 5.2). 
 
7.1 Identification of small molecules that suppress RSV NS2 
function against STAT2 
 
To the best of our knowledge, this is the first time small molecule inhibitors of 
RSV NS2 have been identified. RSV is the most frequent viral pathogen causing ALRI, 
the leading cause of global child mortality (Nair et al., 2010). Despite decades of 
research and antiviral drug endeavor, no efficacious RSV treatment or vaccine is 
available, highlighting the urgent need for novel therapeutic approaches. Therefore, 
there is a compelling case for research to further understand RSV biology and explore 
novel therapeutic targets. Although a number of small molecule anti-RSV compounds 
have been described, the majority of them target the F protein (Cianci et al., 2004; 
Roymans et al., 2010; DeVincenzo et al., 2014), some of them target N or L (Sudo et 
al., 2005; Chapman et al., 2007), but no small molecules have been previously 
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identified against either NS2 or NS1. The importance of NS1 and NS2 for viral 
replication and virulence have been demonstrated through genetic analyses in cell 
culture and animal studies (Spann et al., 2003; Spann et al., 2004; Teng et al., 2000; Jin 
et al., 2000; Whitehead et al., 1999). Hence, recombinant viruses lacking NS1 and/or 
NS2 have been extensively studied as potential RSV vaccine candidates, as their 
deletion results in highly attenuated RSV replication and diminished pathogenicity in 
vivo (Teng et al., 2000; Whitehead et al., 1999; Wright et al., 2006; Luongo et al., 
2013). Since RSV mutants lacking IFN antagonists are severely attenuated, we reasoned 
that inhibitors of RSV NS1 and NS2 could represent promising direct-acting antiviral 
drugs.  
The use of RSV NS1 and NS2 inhibitors represents a promising strategy for 
inhibiting RSV, especially in combination with other antiviral agents, such as fusion or 
polymerase inhibitors. The current RSV antiviral research leans towards F inhibitors; 
Targeting viral entry has always been a promising therapeutic approach, however 
another reason for this prevalence may be that F inhibitors do not need to cross the 
membrane barrier as fusion of the viral and cellular membranes occurs outside the cell. 
This negates limitations such as lipophilicity and molecular weight, allowing more 
flexibility in drug design. The most promising antiviral compound currently in clinical 
trials is the recently discovered F inhibitor, GS-5809 (Mackman et al., 2015; 
DeVincenzo et al., 2014). Although current evidence suggests that it is possible to 
restrict RSV replication in vivo via small-molecule antiviral agents, treatment with a 
single antiviral agent would increase the likelihood of the emergence of resistance. As 
with other viruses (e.g. HIV and HCV), combination therapies with drugs targeted to 
other RSV proteins, such as NS1 and NS2, should avoid selection of resistant viruses.  
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One obstacle to the therapeutic use of antivirals against RSV is the narrow 
window for intervention. Similar to influenza viruses, RSV causes acute respiratory 
infections with symptoms occurring in the upper respiratory tract before reaching the 
lungs (Collins & Graham 2008). Therefore, there is a delay of approximately four days 
between the first symptoms and hospitalization, which emphasizes the need for rapid 
diagnostics, in order to increase the efficacy of future antiviral treatments (Collins & 
Melero 2011). Nonetheless, the current use of neuraminidase inhibitors (e.g. 
Oseltamivir) as a prophylaxis against influenza viruses could serve as a model for an 
RSV antiviral (Aoki et al., 2013). Although the narrow treatment window is limiting the 
effectiveness of an antiviral therapy, RSV antiviral drugs represent a promising 
therapeutic approach, especially given the challenges encountered during the clinical 
trials of the FI-RSV vaccine. 
Although this is the first HTS assay to identify small molecule inhibitors of RSV 
NS2, small molecules that inhibit other viral IFN antagonists, such as NS1 of Influenza 
A viruses and Ebola virus VP35, have been previously identified by other screening 
approaches. A small molecule that inhibited the NS1 function against IFN mRNA 
expression recently showed potent antiviral activity in vitro, however the potential of 
such a compound to inhibit virus replication in vivo remains undetermined (Patnaik et 
al., 2013). Furthermore, a targeted screening approach has demonstrated that small 
molecules that target the IFN inhibitory domain of Ebola VP35 also block its 
polymerase cofactor ability, resulting to reduced virus replication in vitro (Brown et al., 
2014). Similar to NS1 inhibitors, the efficacy of these compounds in vivo remains to be 
demonstrated. 
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To date, HCV NS3.4A PIs are the only clinically approved antivirals that 
function against a viral IFN antagonist. Following the discovery of NS3.4A PIs, great 
advances have been made in HCV antiviral therapy, as Telaprevir and Boceprevir were 
the first direct-acting antiviral agents introduced for treatment of genotype 1 HCV in 
2011 (Gentile et al., 2009; Hézode et al., 2014). Simeprevir is a more recently approved 
NS3/4A inhibitor, which has improved pharmacological properties, compared to 
Telaprevir and Boceprevir (Nagino et al., 2015). In 2013, the U.S. Food and Drug 
Administration (FDA) approved Simeprevir in combination with Sofosbuvir 
(polymerase inhibitor) as the first IFN- and ribavirin-free treatment option for genotype 
1 chronic hepatitis C infection (Gogela et al., 2015). The advances made in HCV 
antiviral therapy provide a sense of optimism that inhibitors of viral IFN antagonists 
could be effective virus-specific antiviral agents, which can improve the effectiveness 
of combinational antiviral therapies.    
 
7.1.1 Potential mechanisms of action of RSV NS2 inhibitors  
To be able to screen for small molecules that target RSV NS2, we first created a 
reporter cell-line derivative that constitutively expressed RSV hNS2, namely 
A549.pr(ISRE)GFP-RSV/hNS2. Using this cell-line, we screened a library of 16,000 
small compounds, among which we found four molecules (AV-14, AV-16, AV-18 and 
AV-19) capable of inhibiting the NS2 function against the IFN-signalling pathway. 
Excitingly, we demonstrated that hit compounds specifically inhibited the NS2-
mediated STAT2 degradation in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line and also 
in the context of RSV infections in vitro (Figure 6.6 and 6.8). Indeed, none of the 
compounds inhibited the ability of other viral IFN antagonists, such as RSV NS1, PIV5 
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V and PIV2 V, to circumvent the cellular IFN-signalling pathway (Figure 6.5), 
emphasizing the specificity of these compounds towards RSV NS2.  
Understanding the compounds mechanism of action could improve our 
understanding regarding RSV antagonism against STAT2. Published work has shown 
that RSV modulates the JAK/STAT signalling pathway through proteasome-dependent 
degradation of STAT2 (Spann et al., 2004; Lo et al., 2005; Goswami et al., 2013). 
However, the relative importance of NS1 and NS2 in suppressing the cellular IFN 
response and the precise mechanism by which STAT2 degradation occurs during RSV 
infections remains undetermined. In agreement with previous studies (Lo et al., 2005; 
Spann et al., 2004; Ramaswamy et al., 2006; Goswami et al., 2013), our data 
demonstrates that RSV hNS2 can independently mediate STAT2 degradation and block 
the IFN-signalling pathway, however NS1 and NS2 co-expression leads to a maximal 
inhibitory effect (Figure 4.6). In contrast, independent NS1 had little to no effect on 
STAT2 degradation but does impose a moderate block to IFN-signalling (Figure 4.5). 
To date, only one study proposed a STAT2 degradation mechanism that does not 
support a NS2-independent function against STAT2. This study showed that 
components of the Cul2-RING E3 ligase (CRL2) complex mediate STAT2 degradation 
via a direct interaction with NS1 but not NS2 (Elliott et al., 2007). However, mutation 
of the putative NS1 Cul2 binding motif (BC box) did not inhibit STAT2 degradation or 
any other NS1 function, therefore the ability of NS1 to interact with Cul2 is still 
questionable (Swedan et al., 2011). Consequently, the role of NS1 and NS2 in RSV-
mediated STAT2 antagonism remains inconclusive and controversial; hence, the 
identified NS2 inhibitors could be used as research tools to improve our understanding 
about RSV-mediated STAT2 degradation.  
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One possible mechanism of action could be that hit compounds suppress NS2 
function against STAT2 by binding directly to NS2. This could subsequently block 
essential interactions of NS2 with cellular factors, such as ubiquitin factors or cellular 
proteases, which are important for the formation of the NS-degradasome. Swedan et al., 
(2011) have showed that NS2 C-terminal tetrapeptide DNLP is important for the ability 
of NS2 to bind the MAP1B, and this interaction was shown to be indispensable for the 
NS2 degradation function against STAT2. While the mechanistic role of MAP1B is 
unrevealed, it is possible that MAP1B serves as an adaptor that recruits other host 
proteins that are essential for STAT2 degradation. Therefore, it is tempting to speculate 
that hit compounds could inhibit STAT2 antagonism by binding to the NS2 DNLP 
peptide, hence blocking its interaction with the host factor MAP1B. Moreover, the 
compounds could bind elsewhere in NS2, and still prevent MAP1B from binding to 
NS2 DNLP. It is also possible that the compounds do not interfere with NS2-MAP1B 
interaction but instead block NS2-mediated STAT2 degradation by impeding NS2 from 
interacting with another cellular factor(s), which is also crucial for this NS2 function. In 
collaboration with Dr Uli Schwarz-Linek (University of St Andrews, UK), we 
endeavored to purify RSV NS2 to enable us perform drug-protein binding studies using 
nuclear magnetic resonance (NMR). Unfortunately, consistent with previous work 
(Evans et al., 1996), the highly unstable nature of the RSV NS2 protein  did not allow 
us to proceed any further with the structural studies and hindered our attempt to 
investigate the hypothesis of direct binding. 
It is also probable that the hit compounds inhibit STAT2 degradation by 
blocking the interaction of the NS-degradasome with mitochondria. A recent study has 
proposed that a stable NS-degradasome requires recruitment of mitochondrial MAVS, 
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suggesting that mitochondria and MAVS facilitate the function(s) of NS-degradasome, 
and consecutively assist RSV suppression of innate immunity (Goswami et al., 2013). 
Supporting the association of NS-degradasome with mitochondria, another study has 
recently shown that NS1 co-localizes with mitochondria during RSV infection and co-
immunoprecipitates with MAVS in NS1 transfected A549 cells (Boyapalle et al., 2012). 
However, NS2 is capable of degrading STAT2 in the absence of NS1 (Ramaswamy et 
al., 2006; Lo et al., 2005), therefore if mitochondrial localization is crucial for the 
STAT2 degradation function, other interactions must be responsible for locating NS2 to 
mitochondria. In fact, NS2 was found to co-localize with mitochondria when 
constitutively expressed in A549 cells, however there is no evidence yet to suggest that 
it directly interacts with MAVS or any other mitochondrial protein (Swedan et al., 
2011). Knowing that RIG-I CARD domain binds to MAVS CARD domain during 
RLR-mediated activation IFN-induction pathway (Seth et al., 2005; Kawai et al., 2005), 
and given that NS2 was found to interact with RIG-I by direct binding to its CARD 
domain (Ling et al., 2009), it is conceivable that tethering of RIG-I might facilitate the 
translocation of NS2 to mitochondria. The effect of hit compounds on NS2 localization 
can be demonstrated by cellular localization studies in the context of RSV infection. If 
hit compounds inhibit NS2 by obstructing its localization to mitochondria, it would be 
also noteworthy to explore whether NS2 ability to bind RIG-I diminishes in the 
presence of the compounds. It is also feasible that our NS2 inhibitors do not affect NS2 
localization, but instead act by blocking NS2 interaction with other mitochondrial 
factors, which are involved in RSV-mediated STAT2 antagonism, hence interfering 
with the assemblage of the NS degradation complex. In conclusion, several studies 
support the association of NS1 and NS2 with mitochondria and mitochondrial MAVS, 
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however their role in STAT2 degradation needs to be further investigated. If the 
association with mitochondria is crucial for stabilizing the NS degradation complex, it 
is possible that our NS2 inhibitors interfere with this process.   
The mechanism of action of NS2 inhibitors might not involve direct binding to 
NS2, but instead these molecules could inhibit host factors involved in RSV-mediated 
STAT2 degradation. Our results showed that hit compounds were capable of inhibiting 
NS2-medated STAT2 degradation but they did not block STAT2 degradation when 
mediated by PIV2 V, and also had no impact on PIV5/V-mediated STAT1 degradation. 
This data demonstrates that these molecules act specifically against the STAT2 
degradation function of NS2, and suggests that these viruses perhaps utilize different 
host factors to mediate degradation of STATs. Similar to RSV, PIV2 and PIV5 mediate 
STAT2 or STAT1 degradation, respectively, through the proteasome (Parisien et al., 
2001; Didcock et al., 1999). Although these viruses utilize a proteasome-dependent 
mechanism, they recruit different ubiquitin factors to achieve this. Specifically, the 
PIV2- and PIV5-mediated STAT degradation requires the formation of a V-dependent 
degradation complex, which comprises of STAT1 and STAT2 and also involves host-
encoded factors like DDB1 (a UV-damage DNA binding protein), and members of the 
cullin family like Cul4A (Andrejeva et al., 2002; Ulane & Horvath 2002; Precious et 
al., 2007). Although the mechanism for RSV-mediated STAT2 degradation remains 
unknown, a previous study suggested that it requires Cul2 and Rbx1 ubiquitin factors 
(Elliott et al., 2007), which are not known to be related to PIV2 or PIV5 degradation 
activity. For instance, if the hit compounds do not inhibit NS2 function by direct 
binding to NS2, they could bind and hence inhibit the function of ubiquitin ligases, 
which are essential for NS2-mediated degradation but are not involved in the V-
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dependent degradation complex. This could explain why our inhibitors suppressed NS2 
function against STAT2 but had no effect against PIV2 V or PIV5 V degradation 
function against STATs. Since Elliot et al., (2007) demonstrated that RSV-mediated 
STAT2 degradation requires Cul2, we tested whether hit compounds interfere with Cul2 
in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line. However, none of the compounds had 
an effect on Cul2 expression levels in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line 
(Appendix 4). Furthermore, the compounds are not likely to inhibit STAT2 degradation 
by blocking Cul2 activation. Specifically, the cullin-RING ubiquitin ligases are 
activated by NEDD8, a process known as neddylation (Merlet et al., 2009). Both 
neddylated and uneddylated forms of Cul2 were detected in NS2-expressing cells in the 
presence of the hit compounds (Appendix 4), suggesting the compounds are not likely 
to suppress Cul2 activation to inhibit NS2-mediated STAT2 degradation. However, 
these observations do not exclude the possibility that the compounds could interact with 
Cul2 in a different manner. On the other hand, it is possible that Cul2 activity is only 
related to RSV NS1 degradation functions and it is not important for the NS2-mediated 
STAT2 degradation function. Hence, other members of the cullin-RING ubiquitin ligase 
family might associate with NS2 and are possibly targeted by the hit compounds. 
Exploring this hypothesis will allow us gain more insight into the degradation activity 
of RSV NS2, and perhaps NS1.   
Another possibility is that compounds might interact with host factors that bring 
STAT2 into close proximity to the NS degradation complex. There is no evidence to 
suggest that NS1 or NS2 directly bind to STAT2, therefore it remains undermined 
which cellular or viral factors are involved in this process. Furthermore, although NS1 
has been reporter to degrade other host factors, such as RIG-I and IRF7 (Goswami et 
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al., 2013), it still remains unknown whether NS2 degrades other cellular factor(s) except 
from STAT2. It is possible that NS2 targets additional factors for degradation; these 
might be either innate immune proteins or host factors involved in other signalling 
cascades, such as apoptosis. If more proteins were targeted by NS2 for proteasomal 
degradation, we could investigate whether our NS2 inhibitors are also capable of 
blocking this function. This would allow us to assess whether our NS2 inhibitors can 
block multiple interactions of NS2 with the host cell.  
Our results exclude the possibility that hit compounds interfere with the 
proteolytic activity of the 20S core subunit of the 26S proteasome. In brief, the 26S 
proteasome is a multi-protein complex, which comprises of one or two 19S regulatory 
particles, which are capable of binding the polyubiquitin chain and cleaving it from the 
protein substrate, and a core 20S core particle, which proteolytically processes the 
denatured proteins (Da Fonseca et al., 2012). Previously described proteasome 
inhibitors, such as MG132 and TMC-95A interfere directly with the active sites in the 
core particle and block its proteolytic activity (Adams et al., 1998; Koguchi et al., 2000; 
Goldberg 2012). The identified small molecules do not impose a similar function 
against the proteasome, because they did not block STATs degradation when mediated 
by PIV2 or PIV5. Furthermore, the compound-mediated increase in STAT2 levels in the 
NS2-expressing cell-line is less likely to be due to STAT2 stabilization, because no 
STAT2 increase was observed in the PIV2/V-expressing cell-line. Undoubtedly, further 
investigations are required to provide mechanistic insight into the compound-mediated 
NS2 inhibition. 
In summary, our NS2 inhibitors are likely to counteract the STAT2 degradation 
function of NS2 through a number of possible mechanisms (Figure 7.1). First, they 
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could possibly bind NS2 to block its interaction with cellular host factors, such as 
MAP1B or other host proteins, including mitochondrial factors, ubiquitin factors or 
cellular proteases that might be essential for STAT2 degradation. Second, hit 
compounds might not bind NS2 but instead bind to host factors involved in STAT2 
degradation. For instance, they might sequester host factors that bring STAT2 into close 
proximity to NS-degradasome. Third, they could interfere with the activation of 
ubiquitin factors,   which are  crucial  for  the  assembly of the NS degradation complex.  
 
 
 
Figure 7.1 Potential mechanisms of action of hit compounds against NS2 STAT2 
degradation function. According to Goswami et al., (2013), the metastable NS-degradasome 
comprises of NS1, NS2 and other cellular factors, which loosely interact with each other. NS-
degradasome is stabilized by recruitment to MAVS on motile mitochondria, perhaps allowing 
recruitment of other host factors, such as chaperones and ubiquitination pathway proteins. NS2 
inhibitors (I) could block STAT2 degradation function by interacting with the formation of the 
metastable NS degradasome by either binding to NS2 or cellular factors, such as proteasome 
components or proteases essential for STAT2 degradation. Furthermore, the small molecules 
might inhibit NS2 by blocking its interaction with mitochondria, hence disrupting stabilization 
of the degradation complex. It could be also possible that the compounds interfere with cellular 
factors that bring STAT2 in close proximity to the degradation complex. Modified by Goswami 
et al., (2013) 
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To investigate their mechanism of action, the compounds can be used in 
immunoprecipitation studies to reveal specific protein-protein interactions involved in 
the NS-degradasome formation. Biotinylation of hit compounds could facilitate such 
studies and could also allow the development of fluorescent assays using biotin 
conjugates. The limited knowledge about RSV-mediated STAT2 degradation function 
makes it difficult to explore the compounds mechanism of action. However, 
understanding how the compounds inhibit NS2 will enable us to gain more insight into 
the proteasome-mediated degradation of STAT2.  
 
 
7.1.2 The impact of our NS2 inhibitors on RSV growth 
 
Unfortunately, although hit compounds had an inhibitory effect against NS2 
function, none of the compounds restricted RSV replication in vitro. The inhibitory 
effect of compound AV-16 was not strong enough to inhibit RSV growth either in the 
presence or absence of IFN-α, suggesting that the compound did not block the anti-IFN 
properties of RSV, which facilitate virus replication in the presence of IFN. Our first 
speculation was that hit compounds did not have an effect against RSV replication in 
vitro, because RSV also encodes for NS1 that also antagonizes the cellular IFN 
response (Lo et al., 2005; J Ren et al., 2011; Goswami et al., 2013; Swedan et al., 2009; 
Swedan et al., 2011). Negating our hypothesis, compound AV-16 had no effect against 
a mutant RSV that lacks NS1, therefore the idea that NS1 compensates for the NS2 lost 
cannot explain the incapability of hit compounds to inhibit RSV.  
Consequently, another possible reason for the compounds’ ineffectiveness 
against RSV could be that the compounds are not potent enough to restrict virus 
replication. Indeed, none of the compounds restored GFP expression up to 100%, as the 
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maximum fold increase observed was 1.96 as opposed to 3.4, which was previously 
obtained in the A549.pr(ISRE)GFP reporter cell-line when no viral IFN antagonist is 
expressed. Consistent with this observation, hit compounds partially inhibited STAT2 
degradation in the A549.pr(ISRE)GFP-RSV/hNS2 cell-line and also during RSV 
infection on A549 cells, causing a 30% increase in STAT2 levels (Figure 6.6 and 6.8). 
Using the hit compounds in combination or extending incubation time did not increase 
compounds’ inhibitory effect against NS2 function (Appendices 5 and 6). Hence, a 
reasonable explanation could be that this level of inhibition is not sufficient enough to 
restrict virus replication in vitro.  
To improve the compounds potency and perhaps their ability to restrict virus 
growth, structure-activity relationship (SAR) studies are required. Interestingly, three of 
the hit compounds AV-14, AV-16, AV-18 share structural similarity as they all contain 
an indole ring (Table 5.3). Although indole moiety is very small, it is an interesting 
chemical structure, because of its diverse biological activities, which are imposed not 
only by indole but its various substituted derivatives as well. Indole ring containing 
marketed drugs show various biological activities, including anticancer, antimicrobial, 
anti-diabetic, antidepressant and also antiviral activity (Biswal et al., 2012). 
Specifically, Arbidol (Umifemovir) is an indole-containing small molecule that blocks 
virus fusion, and therefore has an antiviral activity against many viruses, including 
influenza A viruses (Liu et al., 2013). Our results demonstrated that indole weakly 
restored GFP expression in the A549.pr(ISRE)GFP-RSV/hNS2 reporter cell-line 
(Figure 6.4), indicating that the indole ring on its own does not account for the ability of 
the hit compounds to mediate NS2 inhibition. Furthermore, all the identified molecules 
have different side chains, however they share structural similarity with other molecules 
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of the screened library, which did not appear to have an inhibitory effect against NS2. 
This observation suggests that both functionalities (indole ring and side chains) are 
important for compounds activity. Hence, the relative importance of these moieties in 
NS2 inhibition needs to be further explored using more thorough SAR investigations. 
The incapability of the NS2 inhibitors to counteract RSV replication could also 
indicate that targeting the STAT2 degradation function of NS2 may not be enough to 
restrict RSV. It was previously shown that the C-terminal NS2 tetrapeptide DNLP is 
indispensable for the STAT2 degradation function of NS2 (Swedan et al., 2011), though 
the effect of NS2 DNLP on RSV replication has not been studied. Therefore, studying 
the replication kinetics of a RSV mutant that lacks NS2 DNLP would allow us to 
determine if targeting STAT2 degradation function is a promising antiviral strategy. 
Another factor that could contribute to the compounds’ inability to inhibit RSV 
growth is perhaps the multifunctional nature of NS2. For instance, hit compounds are 
inhibiting the NS2 function against STAT2, however a few studies suggested that NS2 
has other functions important for IFN antagonism and virus pathogenicity that might not 
be inhibited by our hit compounds (Spann et al., 2005; Swedan et al., 2009; Ling et al., 
2009; Liesman et al., 2014). It remains unknown whether these functions are related to 
the same or different molecular mechanisms. Due to their multifunctional nature of 
NS2, our NS2 inhibitors could possibly work as a double-edged sword. For example, if 
NS2 was operating as an E3 ligase to degrade STAT2 and used the same activity to 
degrade other cellular factors, then a molecule that inhibited NS2 ability to degrade 
STAT2 could possibly inhibit other degradation functions of this protein. This is 
essentially the reason behind the effectiveness of the PIs of HCV NS3.4A. More 
precisely, HCV NS3/4A protease has a crucial role for virus replication, which is the 
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processing of viral polypeptide. In addition, HCV NS3/4A protease is a potent 
antagonist of the type I IFN-induction pathway, as it interferes with the pathogen 
recognition RLR- and TLR3-mediated signalling pathways by cleaving TRIF and 
MAVS signalling adaptors (Li et al., 2005; Meylan et al., 2005; Horner et al., 2011). 
NS3/4A protease inhibitors suppress HCV replication by simultaneously disrupting two 
processes critical to the survival of the virus; the enzymatic cleavage of HCV C-
terminal polyprotein into discrete nonstructural proteins and evasion of early innate 
immunity (Gogela et al., 2015). The fact that no other NS2 function is as well defined 
as the STAT2 degradation function prevented us from determining if hit compounds 
target any other NS2 function.  
It is also tempting to speculate that NS2 inhibitors are more likely to have a 
significant impact on RSV replication in vivo, since RSV NS2 seems to be a virulence 
factor that is more important for the establishment of lower respiratory tract infections, 
which are associated with severe respiratory disease. Evidence suggests that RSV NS2 
is an important virulence determinant of RSV infections in humans, as deletion of the 
NS2 gene severely attenuated RSV in children and adults (Wright et al., 2006). A recent 
study have also shown that RSV NS2 could be a contributing factor for enhanced 
propensity of RSV to cause severe airway disease in young children (Liesman et al., 
2014). Specifically, using a human cartilaginous airway epithelium (HAE) and a 
hamster model, they have shown NS2 promotes epithelial cell shedding, which 
accelerates viral clearance but also contributes to acute obstruction of the distal airways 
(Liesman et al., 2014). Moreover, a chimpanzee model showed RSV/ΔNS2 replication 
was moderately attenuated in the upper respiratory tract, however 10,000-fold reduction 
was observed in the lower respiratory tract (Whitehead et al., 1999). Hence in vivo 
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studies might be more appropriate for testing the impact of the identified compounds 
against RSV replication. Several animal species are used for experimental modeling of 
RSV disease, including chimpanzees, cattle, sheep, cotton rats and mice, however none 
of them completely reproduces all the characteristic features of RSV disease in humans 
(Simões et al., 2015; Bem et al., 2011). The newborn lamb RSV model is an attractive 
model for testing the efficacy of NS2 inhibitors in vivo, mainly because (i) airway 
structure and function of newborn lambs are more similar to those in infants compared 
to mice and (ii) RSV pathology, including anti-viral and anti-inflammatory responses 
observed in new-born lambs was similar to humans (Sow et al., 2011; Scheerlinck et 
al., 2008). Due to the ethical and economic constrains related to such animal models, 
BALB/c mice are extensively used for studying RSV infections in vivo, clearly because 
of their relatively low cost and the extensive experience and molecular tools available 
(Prince et al., 1979). Although the efficacy of this animal model is limited due to 
important genetic and structural differences with humans, neonatal mice represent a 
more suitable animal model than adult mice for testing the antiviral effect of NS2 
inhibitors, because they can develop asthma-like disease, including increased airway 
hypersensitivity (Cormier et al., 2010). Hence, it would be interesting to investigate 
whether hit compounds impose an inhibitory effect against RSV disease in these animal 
models.  
In order to target the majority of RSV functions against the cellular IFN 
response, the ideal scenario would be to target both RSV NS1 and NS2, since they are 
the two primary IFN antagonists encoded by RSV. RSV NS1 represents a promising 
target for drug discovery, as in addition to its primary role as an IFN antagonist, it also 
performs other important functions for virus replication, which are unrelated to IFN 
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modification (Evans et al., 1996; Hengst & Kiefer 2000; Atreya et al., 1998; Bitko et 
al., 2008; Wu et al., 2012). Although we developed reporter cell-line derivatives that 
constitutively expressed NS1, we noted that constitutive expression of NS1 was toxic to 
the cells hence slowing down their growth rate. It is possible that NS1 had only a 
moderate effect on the activation of the IFN-β promoter and ISRE element due to the 
fact that cells perhaps cannot sustain high NS1 expression. This limitation could be 
overcome by the development of an inducible expression system. Specifically, a 
tetracycline-dependent induction (Tet-on) system has been previously validated using 
human cytomegalovirus (CMV) immediate-early 1 (IE1) protein and it represents a 
powerful system for inducible protein expression (Knoblach et al., 2011). Future work 
will be to incorporate this inducible system into our A549 reporter assay and determine 
if an inducible HTS assay can be developed. If successful, this would allow us to target 
RSV NS1 for the identification for small molecules that inhibit NS1 function against the 
IFN-induction and/or IFN-signalling pathway and test whether a combination of NS1 
and NS2 small molecule inhibitors could restrict RSV replication. Antiviral drugs that 
target NS1 and NS2 could potentially restrict RSV infection due to impair replication 
and virulence but also due to increased IFN responses and enhanced immunogenicity 
against the virus.  
A major concern for targeting RSV IFN antagonists is the fact that evidence 
suggests that host immune responses could contribute to viral disease. Hence targeting 
IFN antagonists could increase the risk of developing more potent immune responses to 
RSV infections, which could subsequently lead to disease exacerbation. For instance, 
RSV-mediated bronchiolitis in children was shown to be associated with a Th2-
predominant immune response and a number of other cytokines (e.g. IFN-γ, TNF-α) 
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and chemokines (e.g. CXC) that are related to innate and adaptive immunity (Bermejo-
Martin et al., 2007). However, RSV NS1 protein is thought to enhance RSV disease by 
promoting proliferation and activation of Th2 cells, emphasizing the fact that targeting 
RSV IFN antagonists is more likely to restrain RSV virulence rather than enhancing 
RSV disease (Munir et al., 2011). In addition, a recent study has shown that RSV NS1 
and NS2 suppress the activation of glucocorticoids, one of the most powerful anti-
inflammatory agents, by suppressing the transactivation of the glucocorticoid receptor 
(Webster Marketon et al., 2014). Hence, inhibitors of RSV NS1 and NS2 could enhance 
glucocorticoid responsiveness, and subsequently limit RSV pathogenicity by preventing 
inflammatory responses, which worsen the outcome of RSV infections.   
Despite that immune and inflammatory responses to RSV can contribute to 
disease exacerbation, early innate immunity is crucial for controlling RSV infection. 
Hence, small molecules that inhibit RSV IFN antagonists and restore early innate 
immunity against RSV are more likely to contribute towards RSV control rather than 
supplementing RSV virulence. Specifically, effector molecules of the cellular IFN 
system such as STAT1 and STAT2 were shown to be important for preventing severe 
RSV infection in vivo. RSV infection in STAT1-/- or STAT2-/- mice was 100-fold 
higher in the lower respiratory tract, indicating that STATs are required for RSV control 
in vivo (Cline et al., 2009). In agreement with these findings, an earlier study have 
shown that RSV infection in STAT1 knockout mice was characterized by airway 
dysfunction, airway mucus and airway hyperresponsiveness, related to augmented IL-17 
levels (Hashimoto et al., 2005). Notably, it was also shown that activation of STAT1 by 
both type I and type II IFNs plays an important role in establishing a protective Th1-
biased immune response to RSV, supporting the role early innate immunity in 
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controlling RSV infection (Durbin et al., 2002). In vitro studies have demonstrated that 
RSV NS2 and NS1 target STAT2 for degradation, which successively interferes with 
the type I IFN-mediated activation of STAT1 (Ramaswamy et al., 2004; Goswami et 
al., 2013). Therefore, small molecules that suppress RSV NS1 and NS2 function against 
STATs could allow the establishment of enhanced innate immunity against RSV 
infection and prevent the development of ALRI. Taken together, although immune and 
inflammatory responses to RSV contribute to virus pathogenicity, evidence suggests 
that early innate immunity, especially the JAK/STAT signalling cascade, plays a crucial 
role in controlling the outcome of RSV infection, supporting that NS1 and NS2 could 
represent promising therapeutic targets. Hence, a therapy that combines antiviral and 
anti-inflammatory drugs, which are more specific and less toxic, is likely to represent a 
promising strategy for RSV prevention and control. 
 
7.2 The advantages of our HTS approach and future 
applications  
 
This study led to the development of a cell-based HTS assay, which allows the 
identification of small molecules that inhibit targeted viral IFN antagonists. This HTS 
assay offers several advantages over other drug discovery approaches. First, it negates 
challenging downstream target identification required for non-targeted phenotypic 
approaches. For example, a recent study has used a phenotypic cell-based reporter 
assay, where the expression of firefly luciferase was under the control of IFN-β 
promoter and identified molecules that inhibited the ability of Dengue virus to replicate 
and hence induce activation of the IFN-β promoter (Guo et al., 2014). Although this 
study successfully identified small molecules that inhibit the replication of several 
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viruses of the family Flaviviridae, further investigations were required to reveal the 
antiviral mechanism of these compounds, which seems to be related to viral entry (Guo 
et al., 2014). In contrast, our assay allows direct selection of compounds that inhibit 
targeted viral IFN antagonists.  
Second, our HTS assay avoids lengthy de novo assay development required by 
traditional targeted approaches, as it allows the identification of small molecules that 
inhibit viral IFN antagonists from screened chemical libraries. In addition, targeted 
approaches are applicable only when structural information is available for the targeted 
protein. In this context, another advantage of this HTS approach is that it allows us to 
target viral IFN antagonists, which might not be completely characterized, and therefore 
cannot be used in a biochemical or structure-based assays. For instance, although the 
molecular structure of HCV NS5A protein is yet not fully elucidated, cell-based HTS 
assays led to the discovery of small molecules that inhibit the function(s) of this viral 
protein (Gao et al., 2010; Lemm et al., 2010). One of these inhibitors, Daclatasvir 
(BMS-790052) is currently in advanced stages of clinical trials and expected to get 
approval soon (Belema et al., 2014). Previous work supports that cell-based HTS assays 
could outcompete limitations imposed by the lack of molecular structure and allow the 
discovery of inhibitors of not fully characterized viral proteins.  
Targeting individual viral proteins also represents a promising screening 
approach for viruses that cause intense cytopathology in cell culture, such as RSV. 
Previous HTS screening efforts for identification of RSV inhibitors using CPE as 
endpoint have been hampered due to the inherent virus instability. More specifically, 
RSV causes cell-cell fusion and death in cell culture, which interferes with the 
consistency and robustness of cell-based HTS approaches against RSV. To overcome 
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the virus instability problem, a recent study has proposed the use of cryopreserved 
RSV-infected cells as the source of infectious material, and developed a cell-based HTS 
assay that allows identification of inhibitors of RSV-induced CPE (Rasmussen et al., 
2011). Additional studies have demonstrated that cryopreserved RSV-replicon-infected 
cells are a more promising alternative to RSV CPE assays for HTS (Plant et al., 2015; 
Tiong-Yip et al., 2014). In particular, RSV replicon HTS assays are more consistent 
than RSV CPE assays, as RSV replicon lacks all three glycoproteins (F, G, SH), and 
hence cannot cause syncytia cytopathology or virus spread, which are key sources of 
assay variation (Malykhina et al., 2011). In conclusion, although virus replicon or virus 
CPE-based HTS assays require target identification, one major advantage these assays 
have is the capability to simultaneously target several virus mechanisms. On the other 
hand, targeting isolated viral proteins allows the development of screening approaches 
that (i) are not affected by RSV cytotoxicity and instability, (ii) are readily amendable to 
scale and (iii) do not pose biological safety hazards associated with live viral assays.  
In addition to virus instability and cytotoxicity, virus pathogenicity is also a 
major obstacle for HTS approaches. Indeed, drug discovery for highly pathogenic 
viruses (e.g. Ebola and Nipah viruses) is hindered due to requirement for biosafety level 
4 containment facilities. Overcoming this limitation, this screening platform allows the 
discovery of direct-acting antiviral agents by targeting their viral IFN antagonists in 
lower containment facilities. Screening at lower containment level provides more 
flexibility in experimental design, allowing for a more effective HTS method, and 
considerably reduces the screening costs. Overall, the suitability and effectiveness of a 
HTS approach depends on the virus itself, the current knowledge about virus replication 
and the available information regarding the biochemistry of viral proteins. 
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7.2.1 A global strategy for targeting viral IFN antagonists  
 
The conservation of IFN antagonism within certain virus families and its 
importance in viral replication makes viral IFN antagonists attractive targets for drug 
discovery. As most viruses express at least one viral IFN antagonist, this provides a 
wide variety of targets for the discovery of novel antiviral drugs. The effectiveness of 
this screening platform has been validated after the successful identification of RSV 
NS2 inhibitors. This technology can be expanded to a number of different viral IFN 
antagonists expressed by other clinically important viruses, which cause different type 
of infections such as chronic, zoonotic or emerging infections.   
One of the viral IFN antagonists that we are interested in targeting is the rabies 
virus (RABV) phosphoprotein (P) protein. Although there is an effective rabies vaccine, 
rabies still remains a devastating zoonotic disease as it causes 40,000 to 70,000 human 
deaths per year worldwide and has a case-fatality rate of almost 100% in non-vaccinated 
individuals (Schnell et al., 2010). The primary focus in rabies therapeutics is to reduce 
cost and complexity, and also improve effectiveness of postexposure prophylaxis (PEP). 
The only available PEP treatment for individuals with category III exposures to rabies 
(bites, scratches, and mucosal contacts) is active immunization with multiple doses of 
rabies vaccine, and passive immunization with human rabies immune globulin (Smith et 
al., 2011; WHO 2015). The objective of PEP is to prevent rabies from gaining access to 
the nervous system, hence PEP’s eficacy is limited once clinical signs of rabies 
develop. Antiviral molecules are highly likely to increase the effectiveness of the 
current PEP therapy, as they could more rapidly restrict virus replication; however 
penetration through the blood-brain barrier is essential for their therapeutic efficacy in 
the central nervous system (Appolinario & Jackson 2015).  
Chapter 7: 
Discussion  
193 
 
RABV is a poor inducer of type I IFNs, indicating the existence of viral 
mechanisms preventing the cellular IFN response to virus infection. The ability of 
rabies virusto escape the antiviral response induced by IFNs is attributed to its P 
protein, which is considered the major IFN antagonist of lyssaviruses (Rieder & 
Conzelmann 2011). Similar to all the viruses in the order Mononegavirales, RABV P 
protein is also critical for virus replication, as together with nucleoprotein (N) and RNA 
polymerase (L) forms the viral ribonucleoprotein, which is essential for transcription 
and replication of the viral RNA genome (Conzelmann 1998).  
Targeting RABV P represents a promising target for drug discovery, especially 
due to the well-defined interaction of P protein with the IFN-signalling pathway. 
Previous studies have shown that RABV P prevents IFNα/β- and IFNγ-stimulated 
JAK/STAT signalling as it binds to tyrosine-phosphoryalted STATs in the cytoplasm, 
and thereby blocks ISGF3 formation and the subsequent activation of the ISRE 
elements (Brzózka et al., 2006; Lieu et al., 2013). Specifically, a hydrophobic pocket in 
the P protein CTD was found to be critical for STAT antagonism (Wiltzer et al., 2014; 
Brzózka et al., 2006). The interaction of Rabies P with STATs is critical to lethal rabies 
disease, as mutant rabies viruses that lacked STAT-antagonism function were highly 
attenuated in mice (Wiltzer et al., 2014). Notably, the unique mechanism of selective 
targeting of IFN-activated STAT proteins by RABV P protein is conserved between the 
most distantly related lyssaviruses, indicating a conserved immune evasion strategy 
between the Lyssavirus genus (Wiltzer et al., 2012). Hence the current insights into the 
conserved mechanisms by which lyssaviruses coordinate distinct functions in IFN 
antagonism, highlight the potential of targeting P for the development of virus-specific 
antivirals with broad activity against the lyssaviruses.  
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In order to target RABV P using HTS, we developed an A549.pr(ISRE)GFP 
derivative that constitutively expresses RABV P (Figure 7.2/A). Once RABV 
expression was confirmed, the functionality of RABV P in the A549.pr(ISRE)GFP-
RABV/P cell-line was tested by measuring the effect of P expression on the IFN-
signalling pathway (Figure 7.2/B). In agreement with previous work (Brzózka et al.,  
2005; Brzózka et al.,  2006; Lieu et al.,  2013), RABV P completely blocked the IFN-
induced activation of the ISRE  element,  hence  no  GFP  positive  cells  were detected  
in the P-expressing A549.pr(ISRE)GFP reporter cell-line (Figure 7.2/B). Likewise, GFP 
quantification showed that GFP expression was reduced to background levels in the 
A549.pr(ISRE)GFP-RABV/P reporter cell-line (Figure 7.2/B). The clear cut reduction 
in MxA expression also confirmed the inhibitory effect of RABV P against the IFN-
signalling  pathway (Figure 7.2/C). Overall, our data shows that we successfully 
generated a derivate of the A549.pr(ISRE)GFP reporter cell-line that constitutively 
expresses RABV P protein, which completely blocks activation of the IFN-signalling, 
hence no GFP expression was observed in the A549.pr(ISRE)GFP-RABV/P reporter 
cell-line.  
Future work will be to perform HTS using the A549.pr(ISRE)GFP-RABV/P to 
identify small molecules that inhibit RABV P function against the IFN-signalling 
pathway. Evidence suggests that the hydrophobic pocket in the P CTD is indispensable 
for STATs antagonism and virus replication; hence it signifies a promising therapeutic 
target. 
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Figure 7.2 Generation of a cell-based reporter assay for targeting RABV P. (A) Expression 
of RABV P in the A549.pr(ISRE)GFP cell-line, as determined by western blot analysis. RABV 
P expression was detected using an anti-V5 antibody, which recognizes the V5 peptide tag that 
is fused to the N-terminus of the protein. (B-C) The effect of RABV P against the IFN-α 
activation of the ISRE element was monitored by measuring GFP expression (B) and MxA 
expression (C). GFP expression was observed with fluorescent microscopy and quantified using 
TECAN plate reader. Graph is presented as percentage (%) of GFP expression relative to naïve 
A549.pr(ISRE)GFP, which was set as 100% control. Bars present mean values (n=12) and error 
bars show SD. MxA expression levels were observed at 16h and 48h post IFN-α (2000 U/ml) 
treatment using Odyssey CLx imager.  
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7.3 Conclusion 
 This study led to the development of a modular cell-based screening platform, 
which could enable the discovery of novel direct-acting antivirals by the identification 
of small molecules that inhibit targeted viral IFN antagonists of clinically important 
viruses. Our HTS approach has been validated and its effectiveness has been 
demonstrated though the successful identification of four small molecules that 
specifically inhibit the STAT2 degradation function of RSV NS2, a crucial function for 
RSV antagonism against type I IFNs. The compounds’ activity will be further 
optimized using medicinal chemistry and subsequently, these compounds will be used 
as chemical tools to determine the unknown mechanism by which NS2 mediates 
STAT2 degradation and also to determine if NS2 is a suitable drug target. Future work 
will target IFN antagonists from other viruses for which there is a clinical need for new 
antiviral drugs, such as Rabies P, PIV3 C and Dengue NS5 proteins.  In conclusion, this 
HTS approach provides a global strategy for the identification of virus-specific antiviral 
compounds that inhibit viral IFN antagonists. This allows us to validate viral IFN 
antagonists as drug targets and determine whether inhibitors of viral IFN antagonist 
could represent a novel class of virus specific antivirals. 
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Appendices 
Appendix 1: DNA and amino-acid sequences  
A) RSV/hNS1 DNA and amino-acid sequence: Codon-optimized, ‘humanized’ 
version of the RSV genes for NS1 (GenBank accession no. AY904040.1). The 
RSV/hNS1 sequence derived from RSV Long strain, and had a V5-tag fused to its N-
terminus. In order to clone to the gene into the pdl.SV5V’IB vector, the BamH1 and 
NdeI restriction sites were added to the 5’ and 3’ end of the DNA sequence, 
respectively.  
 
 
 
Appendices 
226 
 
B) RSV/hNS2 DNA and amino-acid sequence: Codon-optimized, ‘humanized’ 
version of the RSV genes for NS2 (GenBank accession no. AY904041.1): The 
RSV/hNS2 sequence derived from RSV Long strain, had a myc-tag fused to its N-
terminus. In order to clone to the gene into the pdl.Not’I.IRES.puro vector, the BamH1 
and NotI restriction sites were added to the 5’ and 3’ end of the DNA sequence, 
respectively.  
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C) Rabies virus P (RV/P) DNA and amino-acid sequence: The RV/P sequence 
derived from challenge virus standard (CVS)- 11 strain (GenBank accession no. 
ADJ29909.1) and had a V5-tag fused to its N-terminus. In order to clone to the gene 
into the pdl.Not’I.IRES.puro vector, the BamH1 and NotI restriction sites were added to 
the 5’ and 3’ end of the DNA sequence, respectively. 
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Note: 
V5-tag: GGAAAGCCGATCCCAAACCCTCTATTAGGTCTGGACTCCACC  
myc-tag: GAACAGAAACTGATCTCTGAAGAAGACCTG 
ggatcc: BamH1 restriction site 
gcggccgc: NotI restriction site 
catatg: NdeI restriction site 
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Appendix 2: Lentiviral Vectors  
The pdl.SV5V’IB vector contains the gene for blasticidin-S deaminase confers 
blasticidin resistance The pdl.Not’I.IRES.puro vector contains the Pac gene encoding a 
puromycin N-acetyl-transferase (PAC), which confers resistance to puromycin. Both 
vectors were previously made by Dr Hsiang Chen. 
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Appendix 3: A549.pr(ISRE)GFP-2A-RSV/hNS2 reporter cell-line  
Generation of a A549.pr(ISRE)GFP derivative that expresses mcherry and RSV NS2 
protein from a single ORF, using 2A technology.RSV hNS2 expression was observed 
with immunofluorescence using a mouse anti-myc primary antibody and an anti-mouse 
FITC secondary antibody 
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Appendix 4: Cullin-2 expression in A549.pr(ISRE)GFP-RSV/hNS2 
reporter cell-line in the presence of compounds AV-8, -14, -16, -18 and -19  
 
A549.pr(ISRE)GFP and A549.pr(ISRE)GFP-RSV/hNS2 cell-lines were treated with 10 
μΜ of compound or 0.05% [v/v] DMSO for 24 hours, and STAT2 and Cullin-2 (Cul2) 
expression was observed with near-infrared fluorescent western blot analysis (Odyssey 
CLx imager). Cul2 was detected using rabbit anti-Cullin 2 monoclonal antibody (1:1000 
dilution; Life Technology). This antibody detects two Cul2 species; the top band 
presents the neddylated form (addition of NEDD8) of Cul2, whereas the lower band is 
the uneddylated form of Cull2.  
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Appendix 5: Addition of different compound combinations did not increase 
fold increase in GFP expression in  A549.pr(ISRE)GFP-RSV/hNS2 cell-
line  
 
(A) A549.pr(ISRE)GFP-RSV/hNS2 cell-line was treated with 10 μΜ of compound AV-
18, AV-14, AV-16, AV-18 or all compounds together for 2 hours and then treated with 
10
4 (
Units/ml)
 
IFN-α for 48 hours. (B) A549.pr(ISRE)GFP-RSV/hNS2 cell-line was 
treated with 10 μΜ of compound AV-10, AV-16, AV-18, AV-19, AV-16 and AV-19 
together or all compounds together for 2 hours and then treated with 10
4 
IFN-α for 48 
hours. GFP expression (fold increase) was measured using TECAN plate reader. Crystal 
violet staining (A650 nm) was also measured with TECAN and shows cell density after 
treatment with different compounds.   
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Appendix 6: Increasing the incubation period of compound AV-14, -16, -
18 and -19 decreases the fold increase in GFP expression in 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line  
 
A549.pr(ISRE)GFP-RSV/hNS2 cell-line was treated with 10 μΜ of compound AV-14, 
-16, -18 and -19 or 0.05% [v/v] DMSO for 2, 8, 18 or 26 hours and then treated with 
10
4 (
Units/ml)
 
IFN-α for 48 hours. GFP expression was measured using TECAN plate 
reader.  
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